10-K 1 form10k.htm BOVIE MEDICAL CORPORATION 10K 12-31-2011

U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2011
Commission file number 0-12183
BOVIE MEDICAL CORPORATION

(Exact name of registrant as specified in its charter)

Delaware No. |  | 11-2644611
(State or other jurisdiction of incorporation or organization) |  | (IRS Employer Identification No.)

734 Walt Whitman Rd., Melville, New York 11747
(Address of principal executive offices)
(631) 421-5452
(Issuer's telephone number)
Securities registered pursuant to Section 12(b) of the Act:

Title of each Class |  | Name of each Exchange on which registered
Common Stock, $.001 Par Value |  | NYSE Amex Market

Securities registered under Section 12(g) of the Exchange Act
None
Indicate by check mark if the Company is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes: o No x
Indicate by check mark if the Company is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes: o No x
Indicate by check mark whether the registrant (I) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes: x No o
Indicate by check mark whether the registrant submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (para 232.405 of this chapter) during the preceding 12 months ( or for such shorter period that the registrant was required to submit and post such files).
Yes: x No o
Indicate by checkmark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer”, “accelerated filer” and “small reporting company” in Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer o | Accelerated filer o | Non-accelerated filer o | Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes: o No x
The aggregate market value of the voting stock held by non-affiliates computed by reference to the price at which the stock was sold, or the average bid and asked prices of such stock, as of June 30, 2011, the registrant’s most recently completed second fiscal quarter, was approximately $46,300,000.
The number of shares of the registrant's $.001 par value common stock outstanding on the NYSE Amex exchange as of March 1, 2012 was 17,765,630
Company Symbol-BVX
Company SIC (Standard Industrial Code)-3841
DOCUMENTS INCORPORATED BY REFERENCE
None.

Bovie Medical Corporation
2011 Form 10-K Annual Report
Table of Contents

Part I |  | Page
Item 1 | Business | 1
Item 1A | Risk Factors | 6
Item 1B | Unresolved Staff Comments | 14
Item 2 | Properties | 14
Item 3 | Legal Proceedings | 15
Item 4. | Mine Safety Disclosures | 17
Part II |  |
Item 5. | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 17
Item 6. | Selected Financial Data | 18
Item 7 | Management's Discussion and Analysis of Financial Condition and Results of Operations | 19
Item 7A | Quantitative and Qualitative Disclosures about Market Risk | 30
Item 8 | Financial Statements and Supplementary Data | 30
Item 9 | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | 30
Item 9A | Controls and Procedures | 31
Item 9B | Other Information | 32
Part III |  |
Item 10 | Directors, Executive Officers, and Corporate Governance | 32
Item 11 | Executive Compensation | 37
Item 12 | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 43
Item 13. | Certain Relationships and Related Transactions and Director Independence | 45
Item 14 | Principal Accounting Fees and Services | 46
| Signatures | 47
Part IV |  |
Item 15 | Exhibits Index |

Table of Contents
BOVIE MEDICAL CORPORATION
Cautionary Notes Regarding “Forward-Looking” Statements
This report contains statements that we believe to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give our current expectations or forecasts of future events. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project,” or “continue,” or similar words or the negative thereof. From time to time, we also may provide oral or written forward-looking statements in other materials we release to the public. Any or all of our forward-looking statements in this report and in any public statements we make could be materially different from actual results. They can be affected by assumptions we might make or by known or unknown risks or uncertainties. Consequently, we cannot guarantee any forward-looking statements. Investors are cautioned not to place undue reliance on any forward-looking statements. Investors should also understand that it is not possible to predict or identify all such factors and should not consider the risk factors discussed in Item 1A below to be a complete statement of all potential risks and uncertainties. Past performance is no guaranty of future results.
Part I

ITEM 1. | Business

General
Bovie Medical Corporation (“Company”, “Bovie”, “we”, “us”, or “our” ) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 734 Walt Whitman Road, Melville, New York 11747.
We are actively engaged in the business of developing, manufacturing, and marketing medical products and devices with a strong emphasis in electrosurgical generators and electrosurgical disposables. We sell a broad range of products designed for doctor’s offices, surgery centers and hospitals.
Significant Subsidiaries
Aaron Medical Industries, Inc. is a wholly-owned Florida corporation based in Clearwater, Florida. It is principally engaged in the business of marketing our medical products.
Bovie Canada ulc (a wholly-owned subsidiary) is an Alberta, Canada Corporation which, prior to June 2010, operated a facility in Windsor, Ontario. This facility was consolidated into our U.S. operations. There was no activity in this entity during 2011.
Industry
Although the medical device industry can be challenging and very competitive, we believe it will continue to have a positive long term growth outlook with the number of surgical procedures performed increasing annually as a result of the aging “baby boomer” population. Additionally, we also anticipate a continued increase in minimally invasive surgical procedures due to ongoing advancements in technology coupled with continued overall pressure to reduce healthcare costs via a reduction in patient trauma and recovery time. Expanding global markets will also continue to provide growth opportunities for the medical device industry.
Business Strategy
We manufacture and market various medical products, both under private label and the Bovie brands (Bovie®, Aaron®, IDS™, and ICON™), to distributors worldwide. Additionally, Bovie has original equipment manufacturing (OEM) agreements with other medical device manufacturers. These OEM and private label arrangements and our use of the Bovie brands allow us to gain greater market share for the distribution of our products.
1

Table of Contents
Among our goals is that we strive to be a leader in advanced electrosurgical generators which can be used in the different niche markets with minimally invasive surgical instruments as well as a pioneer in plasma technology and its various medical applications. In 2011 we continued the development of our new products Seal-N-Cut™, A1450™ generator, and our J-Plasma™ handpiece. We received 510K clearance from the FDA for our J-Plasma™ handpiece in February 2012.
In the past couple of years the medical supply industry has experienced a trend of longer timeframes related to new products moving through the FDA clearance process. This trend, when coupled with the increasing complexity of our new products and our high product standards have resulted in development times longer than initially anticipated. However, during 2011 we continued to make substantial progress in the development of all of our new products along with further discovery of potential new applications, benefits, and uses for our J-Plasma™ product line.
Overall sales increased by approximately 4.9% from 2010 to 2011.
Our electrosurgery sales saw an approximate 5.3% upward trend in our generator sales in 2011 over 2010. We also experienced an upward trend in our electrosurgery disposables of approximately 30% due mainly to increased sales of our coated electrodes line in 2011 over 2010.
We have seen an upward trend in 2011 in third party product sales which we have introduced to our distributors as part of our strategic plan to maximize our distribution channels. During 2011, we introduced a product line of medical room lighting products manufactured by Medical Illuminations International, Inc., a California based corporation. We will continue to identify and offer additional new third party products that fit our portfolio of products throughout 2012.
Company Products
We group our products into three main categories: electrosurgery, cauteries, and other products. Information regarding sales by product categories and related percentages is included in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section of this report and is incorporated by reference herein.
Electrosurgery Products
Electrosurgery is our largest product line and includes desiccators, generators, electrodes, electrosurgical pencils and various ancillary disposable products. These electrosurgical products are used during surgical procedures in gynecology, urology, plastic surgery, dermatology, veterinary, and other surgical markets for the cutting and coagulation of tissue. It is estimated that 80% of all surgical procedures performed worldwide are accomplished by electrosurgery. Our electrosurgery products fall under two categories, monopolar or bipolar. Monopolar products require the use of a grounding pad attached to the patient for the return of the electrical current, while bipolar products consist of two electrodes; one for the inbound current and one for the return current and therefore do not require the use of a grounding pad.
Aaron® 900 and Aaron® 940
These products are low powered (30 and 40 watt) high frequency desiccators. These units were designed primarily for dermatology and family practice physicians. The units are used mainly for removing small skin lesions and growths as well as for office based coagulation.
Aaron® 950
Bovie has developed a high frequency desiccator with cut capacity for outpatient surgical procedures. These generators allow physicians to change the power settings with one action. They were designed mainly for use in doctors’ offices and are utilized in a variety of specialties including dermatology, gynecology, family practice, urology, plastic surgery and ophthalmology.
2

Table of Contents
Aaron ®1250U
We have also developed a 120-watt multipurpose electrosurgery generator. The unit features monopolar and bipolar functions with pad sensing. This generator was recently redesigned to allow one unit to work with a line voltage ranging from 100 – 240 VAC whereas previously there was a need for three different versions.
Aaron ®2250 / 3250 and IDS™ 200 / 300 / 400
Given the market interest in more powerful electrosurgical generators, we have developed 200, 300 and 400-watt multipurpose digital electrosurgery generators designed for the rapidly expanding surgi-center market and the hospital market. The digital hardware allows very high parallel data processing throughout the operation. All data is sampled and processed digitally. For the first time in electrosurgery, through digital technology, we are able to measure tissue impedance in real time (5,000 times a second). These units have been designed based on a digital feedback system. Bovie is using dedicated digital hardware instead of a general purpose controller for processing data. As the impedance varies, the power is adjusted to deliver a consistent clinical effect. The IDS™ 200 / Aaron® 2250 have the capability to do most procedures performed today in the surgi-center or outpatient settings and were introduced in 2003. Although 200 watts is more than enough power to do most procedures in the operating room, 300 watts is considered the standard and believed to be what most hospitals and surgi-centers will require. Therefore, we developed the IDS™ 300/ Aaron® 3250. The Bovie® IDS™ 400 is a 400 watt generator designed primarily for sale in the overseas markets. These units feature both monopolar and bipolar functions, have pad and tissue sensing, plus nine blended cutting settings.
ICON™ GI and ICON™ GP
The ICON™ product lines are innovative, custom designed specialty electrosurgical generators that incorporate an easy to use touch-screen interface which provides the user flexibility in achieving a desired effect through different digitally built-in modes. In addition, the ICON™ product line was designed to improve safety and convenience by requiring the use of only split pads with digital technology to protect against pad burns. It features specialized error messaging to prevent misinterpretation and allows for quicker troubleshooting, and has specialized audible alerts to indicate improper cable connections. The ICON™ line represents a new foundation platform that can be readily expanded thereby reducing the development time and cost for future new specialized generators and also allowing the user to easily upgrade existing units. The ICON™ GI is designed for the gastrointestinal (“GI”) niche market, while the ICON™ GP is designed for a more general purpose market like hospital operating rooms, surgery centers, etc.
ICON™ VS
This generator expands further on our ICON™ platform which incorporates a flexible and simple user interface and allows for customization of the output modes for a variety of electrosurgical applications. This product, like the ICON™ GI and GP, its predecessor generators, is designed and being developed to add safety features and improve convenience in performing general purpose procedures and includes a vessel sealing component. This generator will also be used with our Seal-N-Cut handle and accessories. We have received 510K FDA clearance to market the ICON™ VS.
Resistick™ II
Resistick™ II is a coating that is applied to stainless steel which resists eschar (scab or scar tissue caused by burning) during surgery. The coated electrodes continue the expansion of the Bovie® line of electrosurgical disposables.
Disposable laparoscopic instruments
Disposable laparoscopic instruments that are available in over thirty different jaw patterns and lengths, including ratcheted and non-ratcheted and offer the physician the quality of a reusable instrument with the convenience of a disposable. These instruments are used by physicians from a diverse group of specialties such as gynecology, general surgery and urology.
3

Table of Contents
ICON™ GS (J-Plasma)
Our J-Plasma™ technology is the foundation for the ICON™ GS plasma system, which utilizes a gas ionization process producing a stable thin focused beam of ionized gas that can be controlled in a wide range of temperatures and intensities, providing the surgeon greater precision, minimal invasiveness and an absence of conductive currents during surgery. The development of this new gas system generator also includes the design of a new proprietary handpiece. We have received 510K clearance from the FDA to market the ICON™ GS and as of February 2012, 510K clearance to market the J-Plasma™ handpiece.
Prior to our acquiring the J-Plasma™ technology, a German-based company, had licensed the same technology. The license agreement was terminated but the German company has filed its own patent possibly using the J-Plasma™ technology as its basis. Although we have filed for additional patent applications on enhancements outside of the original licensed technology, our management believes this German company may be infringing on our original patent and as a result, there is no assurance that there will not be future litigation or the possible loss of our competitive advantage.
Cauteries
Battery Operated Cauteries
Battery operated cauteries constitute our second largest product line. Cauteries were originally designed for precise hemostasis (to stop bleeding) in ophthalmology. The current use of cauteries has been substantially expanded to include sculpting woven grafts in bypass surgery, vasectomies, evacuation of subungual hematoma (bleeding from a smashed fingernail) and for arresting bleeding in many types of surgery. Battery operated cauteries are primarily sterile one-time use products. We manufacture one of the broadest lines of cauteries in the world, including but not limited to, a line of replaceable battery and tip cauteries, which are popular in overseas markets.
Other Products
Battery Operated Medical Lights
We manufacture a variety of specialty lighting instruments for use in ophthalmology as well as specialty lighting instruments for general surgery, hip replacement surgery and for the placement of endotracheal tubes in emergency and surgical procedures. We also manufacture and market physicians’ office use penlights.
Nerve Locator Stimulator
Bovie manufactures a nerve locator stimulator primarily used for identifying motor nerves in hand and facial reconstructive surgery. This instrument is a self-contained, battery-operated unit, individually packaged sterile, for one time use.
Research and Development and New Products
Our research and development activities are an essential component of our efforts to develop new innovative products for introduction in the marketplace. New and improved products play a critical role in our sales growth. We continue to place emphasis on the development of proprietary products and product improvements to complement and expand our existing product lines. We maintain close working relationships with physicians and medical personnel in hospitals and universities who assist in product research and areas of development. Our research and development activities are primarily carried out internally.
4

Table of Contents
Aaron® 1450
The Aaron® 1450-RF is a high frequency generator designed for surgery in the doctor office setting. This unit operates at 4 MHz, eight times higher frequency than a standard electrosurgical generator which operates at approximately 500 KHz. This unit is intended to be the first in a family of 4MHz generators initially designed for several office based specialties. The 1450-RF has been designed to include universal power control which allows the unit to be used in any power setting world wide. In March 2011, the FDA identified deficiencies in the original 510k submission and outlined several unresolved issues that needed to be addressed. We continue to perform additional testing and evaluations to resolve the issues that were raised during the review. We plan to include this information in a new 510k submission.
Seal-N-Cut™ Handle and Accessories
The Seal-N-Cut™ is a disposable endoscopic surgical handle that supports a plurality of electrical and mechanical modes. This technologically advanced endoscopic device will target the growing vessel and tissue sealing and cutting market. Although we have experienced significant delays in the development of this product for market due to modifications and improvements related to the product design, we anticipate that we will re-submit our application for 510k approval during 2012.
Sales & Marketing
The majority of our products are marketed through medical distributors, which distribute to more than 6,000 hospitals and to doctors and other health-care facilities. New distributors are contacted through responses to our advertising in international and domestic medical journals and domestic or international trade shows. International sales represented approximately 21% of total revenues in both 2011 and 2010 and 16% in 2009. Our products are sold in more than 150 countries through local dealers which are coordinated by sales and marketing personnel at the Clearwater, Florida facility.
Recently, in anticipation for the launch of our new surgical suite product lines, we have established a network of approximately 50 commission-based direct sales contractors to market and sell these products.
Our business is generally not seasonal in nature.
Competition
We compete with numerous manufacturers and distributors of medical supplies and devices, many of which are large and well established. In addition, our products are sold in various ways including private labeling some of our products for major distributors under their label, and selling the majority of our other products through distributors. Private labeling allows us to increase our position in the marketplace and thereby compete from two different approaches, our Aaron® or Bovie® label, and our customers’ private label. Our private label customers distribute our products under their name through their internal sales force. Selling the majority of our other products through distribution increases our sales potential and helps level the playing field in regards to our larger competitors as most of the companies we compete with sell direct. Domestically, we believe, we have a substantial market share in the field of electrosurgical generator manufacturing which consists of our Company label and OEM units.
Our main competitors are Valleylab (a division of Covidien), Conmed and Erbe Electromedizine, in the electrosurgery market, Xomed, in the battery operated cautery market, and Ethicon and U.S. Surgical in the endoscopic instrumentation market. We believe our competitive position did not change in 2011.
Intellectual Property
We rely on our intellectual property that we have developed or acquired over the years including patents, trade secrets, technical innovations, and various licensing agreements to provide our future growth and build our competitive position. We own 12 patents and 16 trademarks in the U.S. Some of our early patents are nearing the end of their patent term. We also have filed a number of U.S. and international patent applications for various new products. As we continue to expand our intellectual property portfolio we believe it is critical for us to continue to invest in filing patent applications to protect our technology, inventions, and improvements however, we can give no assurance that competitors will not infringe on our patent rights or otherwise create similar or non-infringing competing products that are technically patentable in their own right.
5

Table of Contents
Manufacturing and Suppliers
We are committed to producing products of the highest quality and technical advancements. We manufacture the majority of our products on our premises in Clearwater, Florida which is certified under the ISO international quality standards and may be subject to continuing regulation and routine inspections by the FDA to determine compliance with regulations in our quality system, medical device reporting, and FDA restrictions on promoting products for unapproved or off-label uses. In addition, we are also subject to regulations under the Occupational Safety and Health Act, the Environmental Protection Act and other federal, state and local regulations. In addition, a significant portion of our manufactured parts are purchased from vendors located in China and Korea, as well as from a key supplier in Bulgaria which supplies most of our generator electronic parts.
Customers
We sell the majority of our current products through major distributors which include Cardinal Health, Independent Medical Co-Op Inc. (IMCO), McKesson Medical Surgical, Inc., Medline, National Distribution and Contracting Inc. (NDC) (Abco, Cida and Starline), Owens & Minor, and Physician Sales & Service (PSS) and have manufacturing agreements for private label of certain products with Arthrex and others. In 2011, Arthrex orders represented approximately 5% of our total revenues which was down from 11% in 2010. If we continue to experience additional reductions in OEM generator sales, our business may be adversely affected.
Backlog
The dollar value of unshipped factory orders is not material.
Employees
At December 31, 2011, we had 139 full-time employees consisting of 4 executive officers, 21 supervisory personnel, 9 sales personnel, and 105 technical support, administrative, and production employees. None of our current employees are covered by any collective bargaining agreement and we have never experienced a work stoppage. We consider our employee relations to be good.

ITEM 1A. | Risk factors

In addition to risks and uncertainties in the ordinary course of business, important risk factors that may affect us are discussed below. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations.
Risks Relating to Our Business
Current challenges in the credit and capital markets may adversely affect our business and financial condition.
The economic conditions described below should also be considered when reviewing each of the subsequent paragraphs setting forth the various aspects of our business, operations, and products.
The continued global economic uncertainty and previous disruptions in credit markets, among other things, may materially limit credit availability in the credit and capital markets, lower levels of liquidity, cause increases in the rates of default and bankruptcy, and lower consumer and business spending. Although the ultimate outcome of these events cannot be predicted, they may have a material adverse effect on the Company and our ability to raise capital or borrow money in the credit markets and potentially to draw on our revolving credit facility or otherwise obtain financing. Similarly, current or potential customers and suppliers may no longer be in business, may be unable to fund purchases or may decide to reduce purchases, all of which could lead to reduced demand for our products, reduced gross margins, and increased customer payment delays or defaults. Further, suppliers may not be able to supply us with needed raw materials on a timely basis, may increase prices or go out of business, which could result in our inability to meet customer demand in a timely manner or affect our gross margins. We are also limited in our ability to reduce costs to offset the results of a prolonged or severe economic downturn given certain fixed costs associated with our operations.
6

Table of Contents
We do a substantial amount of business with certain original equipment manufacturers (“OEM”) which as a group have produced substantial revenues for our Company. Loss of business from a major OEM customer will likely adversely affect our business.
We manufacture the majority of our products on our premises in Clearwater, Florida. Labor-intensive sub-assemblies and labor-intensive products may be out-sourced to our specification. Although we sell through distributors, we market our products through national trade journal advertising, direct mail, distributor sales representatives and trade shows, under the Bovie name, the Bovie/Aaron name and private label. Major distributors include Cardinal Health, IMCO, McKesson Medical Surgical, Inc., Medline, NDC (Abco, Cida and Starline), Owens & Minor, and Physician Sales & Service. If any of these distributor relationships are terminated or not replaced, our revenue from the territories served by these distributors could be adversely affected.
We have a major OEM customer, Arthrex, Inc., for which we manufacture products on a private label basis for generators. In 2011, Arthrex orders represented approximately 5% of our total revenues which was down from 11% in 2010. If we continue to experience additional reductions in OEM generator sales, our business may be adversely affected.
We are also dependent on other OEM customers who have no legal obligation to purchase products from us. Should such customers fail to give us purchase orders for the product after development, our future business and value of related assets could be negatively affected. Furthermore, no assurance can be given that such customers will give sufficient high priority to our products. Finally, disagreements or disputes may arise between Bovie and its customers, which could adversely affect production and sales of our products.
We rely on certain suppliers and manufacturers for raw materials and other products and are vulnerable to fluctuations in the availability and price of such products and services.
Fluctuations in the price, availability, and quality of the raw materials we use in our manufacturing could have a negative effect on our cost of sales and our ability to meet the demands of our customers. Inability to meet the demands of our customers could result in the loss of future sales. In addition, the costs to manufacture our products depend in part on the market prices of the raw materials used to produce them. We may not be able to pass along to our customers all or a portion of our higher costs of raw materials due to competitive and marketing pressures, which could decrease our earnings and profitability.
We also have informal collaborative arrangements with three foreign suppliers under which we request the development of certain items and components and we purchase them pursuant to purchase orders. Our purchase order commitments are never more than one year in duration and are supported by orders from our customers.
If we are unable to protect our patents or other proprietary rights, or if we infringe on the patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged.
We own 12 U.S. patents and 16 registered U.S. trademarks with some of our early patents nearing the expiration of their patent term. We also have several U.S. and international patent applications pending for various new products. We intend to continue to seek legal protection, primarily through patents, for our proprietary technology. Seeking patent protection is a lengthy and costly process, and there can be no assurance that patents will be issued from any pending applications, or that any claims allowed from existing or pending patents will be sufficiently broad or strong to protect our proprietary technology. There is also no guarantee that any patents we hold will not be challenged, invalidated or circumvented, or that the patent rights granted will provide competitive advantages to us. Our competitors have developed and may continue to develop and obtain patents for technologies that are similar or superior to our technologies. In addition, the laws of foreign jurisdictions in which we develop, manufacture or sell our products may not protect our intellectual property rights to the same extent as do the laws of the United States.
7

Table of Contents
Adverse outcomes in current or future legal disputes regarding patent and other intellectual property rights could result in the loss of our intellectual property rights, subject us to significant liabilities to third parties, require us to seek licenses from third parties on terms that may not be reasonable or favorable to us, prevent us from manufacturing, importing or selling our products, or compel us to redesign our products to avoid infringing third parties’ intellectual property. As a result, our product offerings may be delayed, and we may be unable to meet customers’ requirements in a timely manner. Regardless of the merit of any related legal proceeding, we have incurred in the past and may be required to incur in the future substantial costs to prosecute, enforce or defend our intellectual property rights. Even in the absence of infringement by our products of third parties’ intellectual property rights, or litigation related to trade secrets, we have elected in the past and may in the future elect to enter into settlements to avoid the costs and risks of protracted litigation and the diversion of resources and management’s attention. However, if the terms of settlements entered into with certain of our competitors are not observed or enforced, we may suffer further costs and risks. Any of these circumstances could have a material adverse effect on our business, financial condition and resources or results of operations. (See ITEM 3. Legal Proceedings)
Our ability to develop intellectual property depends in large part on hiring, retaining and motivating highly qualified design and engineering staff with the knowledge and technical competence to advance our technology and productivity goals. To protect our trade secrets and proprietary information, generally we have entered into confidentiality agreements with our employees, as well as with consultants and other parties. If these agreements prove inadequate or are breached, our remedies may not be sufficient to cover our losses.
Divestitures of some of our operations or product lines may materially and adversely affect our business and results of operations.
We periodically evaluate the performance of our entire operations and we may sell, consolidate, or close a portion of our business or product lines. Any divestitures may result in significant write-offs, including those related to goodwill and other intangible assets, which could have a material adverse effect on our business and results of operations. Divestitures could involve additional risks, including difficulties in the separation of operations, services, products and personnel, the diversion of management’s attention from other business concerns, the disruption of our business and the potential loss of key employees. We may not be successful in managing these or any other significant risks that we encounter in divesting a business or product line.
We are subject to litigation proceedings that could adversely affect our business.
Intellectual Property Litigation or Trade Secrets
We have experienced certain allegations of infringement of intellectual property rights and use of trade secrets in the past and may receive other such claims, with or without merit, in the future. Previously, claims of infringement of intellectual property rights have sometimes evolved into litigation against us, and they may continue to do so in the future. It is inherently difficult to assess the outcome of litigation. Although we believe we have adequate defenses to these claims and that the outcome of the litigation will not have a material adverse impact on our business, financial condition, or results of operations, there can be no assurances that we will prevail. Any such litigation could result in substantial cost to us, significantly reduce our cash resources, and create a diversion of the efforts of our technical and management personnel, which could have an adverse effect on our business, financial condition and operating results. If we are unable to successfully defend against such claims, we could be prohibited from future sales of the allegedly infringing product or products, which could materially and adversely affect our future growth.
8

Table of Contents
Product Liability Litigation
Although we carry liability insurance, due to the nature of our products and their use by professionals, we may, from time to time, be subject to litigation from persons who sustain injury during medical procedures in hospitals, physician’s offices or in clinics and defending such litigation is expensive, disruptive, time consuming and could adversely affect our business. Bovie currently maintains product liability insurance with combined coverage limits of $10 million on a claims-made basis. There is no assurance that this coverage will be adequate to protect us from any possible liabilities (individually or in the aggregate) we might incur in connection with the sale or testing of our products. In addition, we may need increased product liability coverage as additional products are commercialized. This insurance is expensive and in the future may not be available on acceptable terms, if at all (see ITEM 3. Legal Proceedings).
Other Litigation
In addition to the litigation risks and proceedings mentioned above, we are currently involved or may become subject to legal claims or proceedings related to securities, employment, customer or third party contracts, environmental regulations, product liability or other matters. If we are required to defend against a legal claim or deem it necessary or advisable to initiate a legal proceeding to protect our rights, the expense and distraction of such a claim or proceeding, whether or not resolved in our favor, could materially and adversely affect our business, financial condition and operating results. Further, if a claim or proceeding were resolved against us or if we were to settle any such dispute, we could be required to pay damages and costs or refrain from certain activities, which could have a material adverse impact on our business, financial condition and operating results.
Our business is subject to the potential for defects or failures associated with our products which could lead to recalls or safety alerts and negative publicity.
Manufacturing flaws, component failures, design defects, off-label uses or inadequate disclosure of product-related information could result in an unsafe condition or the injury or death of a patient. These problems could lead to a recall of, or issuance of a safety alert relating to, our products and result in significant costs and negative publicity. Due to the strong name recognition of our brands, an adverse event involving one of our products could result in reduced market acceptance and demand for all products within that brand, and could harm our reputation and our ability to market our products in the future. In some circumstances, adverse events arising from or associated with the design, manufacture or marketing of our products could result in the suspension or delay of our current regulatory reviews of our applications for new product approvals. We also may undertake voluntarily to recall products or temporarily shut down certain production lines based on internal safety and quality monitoring and testing data. Any of the foregoing problems could disrupt our business and have a material adverse effect on our business, results of operations, financial condition and cash flows.
We have incurred and may in the future incur impairments to goodwill or long-lived assets.
We review our long-lived assets, including goodwill and other intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. Additionally, if in any period our stock price decreases to the point where our fair value, as determined by our market capitalization, is less than the book value of our assets, this could also indicate a potential impairment and we may be required to record an impairment charge in that period, which would adversely affect our results of operations.
Our valuation methodology for assessing impairment requires management to make judgments and assumptions based on historical experience and to rely heavily on projections of future operating performance. We operate in highly competitive environments and projections of future operating results and cash flows may vary significantly from actual results. Additionally, if our analysis indicates potential impairment to goodwill or any other long-lived intangible asset, we may be required to record additional charges to earnings in our financial statements, which could negatively impact our results of operations.
9

Table of Contents
Risks Related to Our Industry
The medical device industry is highly competitive and we may be unable to compete effectively.
The medical device industry is highly competitive. Many competitors in this industry are well-established, do a substantially greater amount of business, and have greater financial resources and facilities than we do.
Domestically, we believe we rank third in the number of units sold in the field of electrosurgical generator manufacturing and we sell our products and compete with other manufacturers in various ways. In addition to advertising, attending trade shows and supporting our distribution channels, we strive to enhance product quality, improve user friendliness and expand product exposure.
We also compete by private labeling our products for major distributors under their label. This allows us to increase our position in the marketplace and thereby compete from two different approaches, our Aaron® or Bovie® label, and our customers’ private label. Our private label customers distribute our products under their name through their internal sales force. We believe our main competitors do not private label their products.
Lastly, at this time we sell the majority of our products through distributors. Many of the companies we compete with sell direct, thus competing directly with distributors they sometimes use.
Our main competitors are Valleylab (a division of Covidien), Conmed and Erbe Electromedizine, in the electrosurgery market, Xomed, in the battery operated cautery market, and Ethicon and U.S. Surgical in the endoscopic instrumentation market. We believe our competitive position did not materially change in 2011.
Our industry is highly regulated by the U.S. Food and Drug Administration and internationally including other governmental, state and federal agencies which have substantial authority to establish criteria which must be complied with in order for us to continue in operation.
United States
The Company’s products and research and development activities are subject to regulation by the FDA and other regulatory bodies. FDA regulations govern, among other things, the following activities:

● | Product development.

● | Product testing.

● | Product labeling.

● | Product storage.

● | Pre-market clearance or approval.

● | Advertising and promotion.

● | Product traceability, and

● | Product indications.

In the United States, medical devices are classified on the basis of control deemed necessary to reasonably ensure the safety and effectiveness of the device. Class I devices are subject to general controls. These controls include registration and listing, labeling, pre-market notification and adherence to the FDA Quality System Regulation. Class II devices are subject to general and special controls. Special controls include performance standards, post market surveillance, patient registries and FDA guidelines. Class III devices are those which must receive pre-market approval by the FDA to ensure their safety and effectiveness. Currently, we only manufacture Class I and Class II devices. Pre-market notification clearance must be obtained for some Class I and most Class II devices when the FDA does not require pre-market approval. All Bovie products have been cleared by the pre-market notification process. To date, the FDA has not failed to clear any devices we have submitted.
A pre-market approval application is required for most Class III devices. A pre-market approval application must be supported by valid scientific evidence to demonstrate the safety and effectiveness of the device. The pre-market approval application typically includes:

● | Results of bench and laboratory tests, animal studies, and clinical studies

10

Table of Contents

● | A complete description of the device and its components; and

● | A detailed description of the methods, facilities and controls used to manufacture the device, and proposed labeling.

The pre-market approval process can be expensive, uncertain and lengthy. A number of devices for which pre-market approval has been sought by other companies have never been approved for marketing.
International Regulation
To market products in the European Union, our products must bear the “CE” mark. Manufacturers of medical devices bearing the CE mark have gone through a conformity assessment process that assures that products are manufactured in compliance with a recognized quality system and to comply with the European Medical Devices Directive.
Each device that bears a CE mark has an associated technical file that includes a description of the following:

● | Description of the device and its components,

● | A summary of how the device complies with the essential requirements of the medical devices directive, Safety (risk assessment) and performance of the device,

● | Clinical evaluations with respect to the device,

● | Methods, facilities and quality controls used to manufacture the device, and

● | Proposed labeling for the device.

Manufacturing and distribution of a device is subject to ongoing surveillance by the appropriate regulatory body to ensure continued compliance with quality system and reporting requirements.
We began CE marking of devices for sale in the European Union in 1999. In addition to the requirement to CE mark, each member country of the European Union maintains the right to impose additional regulatory requirements.
Outside of the European Union, regulations vary significantly from country to country. The time required to obtain approval to market products may be longer or shorter than that required in the United States or the European Union. Certain European countries outside of the European Union do recognize and give effect to the CE mark certification. We are permitted to market and sell our products in those countries.
If we are unable to successfully introduce new products or fail to keep pace with competitive advances in technology, our business, financial condition and results of operations could be adversely affected. In addition, our research and development efforts rely upon investments and alliances, and we cannot guarantee that any previous or future investments or alliances will be successful.
Our research and development activities are an essential component of our efforts to develop new and innovative products for introduction in the marketplace. New and improved products play a critical role in our sales growth. We continue to place emphasis on the development of proprietary products and product improvements to complement and expand our existing product lines. We maintain close working relationships with physicians and medical personnel in hospitals and universities who assist in product research and areas of development. Our research and development activities are primarily conducted internally and are expensed as incurred. These expenses include direct expenses for wages, materials and services associated with the development of our products net of any reimbursements from customers. Research and development expenses do not include any portion of general and administrative expenses. Our Clearwater, Florida facility has been our flagship research and design location. We expect to continue making future investments to enable us to develop new technologies and products to further our strategic objectives and strengthen our existing business. However, we cannot guarantee that any of our previous or future investments will be successful.
The amount expended by us on research and development of our products during the years 2011, 2010 and 2009, totaled approximately $1.2, $1.9, and $2.1 million respectively. During the past three years, we invested in our J-Plasma™ technology, including the ICON™ GS plasma system, Endoscopic Modular Instruments and accompanying new generators, and the Aaron 1450 generator. We have not incurred any direct costs relating to environmental regulations or requirements. For 2012, we expect the amount of our expenditures for research and development activities to remain around the same level as 2011.
11

Table of Contents
Even if we are successful in developing and obtaining approval for our new product candidates, there are various circumstances that could prevent the successful commercialization of the products.
Our ability to successfully commercialize our products will depend on a number of factors, any of which could delay or prevent commercialization, including:

| ● | the regulatory approvals of our new products are delayed or we are required to conduct further research and development of our products prior to receiving regulatory approval;

| ● | we are unable to build a sales and marketing group to successfully launch and sell our new products;

| ● | we are unable to raise the additional funds needed to successfully develop and commercialize our products or acquire additional products for growth;

| ● | we are required to allocate available funds to litigation matters;

| ● | we are unable to manufacture the quantity of product needed in accordance with current good manufacturing practices to meet market demand, or at all;

| ● | our product is determined to be ineffective or unsafe following approval and is removed from the market or we are required to perform additional research and development to further prove the safety and effectiveness of the product before re-entry into the market;

| ● | competition from other products or technologies prevents or reduces market acceptance of our products;

| ● | we do not have and cannot obtain the intellectual property rights needed to manufacture or market our products without infringing on another company’s patents; or

| ● | we are unsuccessful in defending against patent infringement or other intellectual property rights, claims that could be brought against us, our products or technologies;

The failure to successfully acquire or develop and commercialize new products will adversely affect the future growth of our business, financial condition and results of operations.
Our international operations subject us to foreign currency fluctuations and other risks associated with operating in foreign countries.
We operate internationally and enter into transactions denominated in foreign currencies. To date, we have not hedged our exposure to changes in foreign currency exchange rates, and as a result, we are subject to foreign currency transaction and translation gains and losses. We purchase goods and services in U.S. dollars and Euros. Foreign exchange risk is managed primarily by satisfying foreign denominated expenditures with cash flows or assets denominated in the same currency therefore we are subject to some foreign currency fluctuation risk. Our currency value fluctuations were not material for 2011.
Our operations and cash flows may be adversely impacted by future healthcare reform legislation.
The Patient Protection and Affordable Care Act and Health Care and Education Affordability Reconciliation Act were enacted into law in the U.S. in March 2010. Among other initiatives, this legislation imposes a 2.3% excise tax on domestic sales of class I, II, and III medical devices beginning in 2013. Substantially all of our products are class I or class II medical devices. We believe we are able to raise prices or otherwise pass through this enacted excise tax to our customers, however, we do not anticipate that this tax on medical devices will materially affect our results of operations and cash flows. However, since approximately 80% of our 2011 sales were derived in the U.S. we cannot predict if any additional regulations will be implemented at the federal or state level, or the effect of any future legislation or regulation in the U.S. or internationally.
12

Table of Contents
Our operations may experience higher costs to produce our products as a result of changes in prices for oil, gas and other commodities.
We use some plastics and other petroleum-based materials along with precious metals contained in electronic components as raw materials in many of our products. Prices of oil and gas also significantly affect our costs for freight and utilities. Oil, gas and precious metal prices are volatile and may increase, resulting in higher costs to produce and distribute our products. Due to the highly competitive nature of the healthcare industry and the cost-containment efforts of our customers we may be unable to pass along cost increases through higher prices. If we are unable to fully recover these costs through price increases or offset through other cost reductions, our results of operations could be materially and adversely affected.
Our manufacturing facilities are located in Clearwater, Florida and could be affected due to multiple risks from fire, hurricanes, physical changes in the planet due to climate change, and similar phenomena.
Our manufacturing facilities are located in Clearwater, Florida and could be affected by multiple weather risks, most notably hurricanes. Although we carry property and casualty insurance and business interruption insurance, future possible disruptions of operations or damage to property, plant and equipment due to hurricanes or other weather risks could result in impaired production and affect our ability to meet our commitments to our customers and impair important business relationships, the loss of which could adversely affect our operations and profitability. We do however maintain a backup generator at our Clearwater facility and a disaster recovery plan is in place to help mitigate this risk.
We do not produce hazardous materials or emissions that would adversely impact the environment. We do however, have air conditioning units and consume electricity which could be impacted by climate change in the form of increased rates. We do not however believe the increase in expense from the rate increases, as a percentage of sales, would be material in the near term.
Risks related to global natural disasters (whether or not caused by climate change), unusual weather conditions, pandemic outbreaks, terrorist acts, and global political events
The occurrence of one or more natural disasters, such as hurricanes, tsunamis, fires, floods, and earthquakes (whether or not caused by climate change), unusual weather conditions, pandemic outbreaks, terrorist acts or disruptive global political events, such as civil unrest in countries in which our suppliers are located, or similar disruptions could impair our ability to purchase, receive, or replenish inventory which could result in lost sales and otherwise adversely and materially affect our operations and financial performance. These events also can have indirect consequences such as increases in fuel (or other energy) prices or a fuel shortage, or increases in the costs of insurance if they result in significant loss of property or other insurable damage.
Risks Related to Our Stock
The market price of our stock has been and may continue to be highly volatile.
Our common stock is listed on the NYSE Amex Market under the ticker symbol “BVX.” The market price of our stock has been and may continue to be highly volatile, and announcements by us or by third parties may have a significant impact on our stock price. These announcements may include:

| ● | our listing status on the NYSE Amex Market;

| ● | our operating results or operating results below the expectations of public market analysts and investors;

| ● | developments in our relationships with or developments affecting our major customers;

| ● | negative regulatory action or regulatory non-approval with respect to our new products;

| ● | government regulation, governmental investigations, or audits related to us or to our products;

| ● | developments related to our patents or other proprietary rights or those of our competitors; and

| ● | changes in the position of securities analysts with respect to our stock.

13

Table of Contents
The stock market has from time to time experienced extreme price and volume fluctuations, which have particularly affected the market prices for the medical technology sector companies, and which have often been unrelated to their operating performance. These broad market fluctuations may adversely affect the market price of our common stock.
Historically, when the market price of a stock has been volatile, holders of that stock have often instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit. The lawsuit could also divert the time and attention of our management.
In addition, future sales by existing stockholders or any new stockholders receiving our shares in any financing transaction may lower the price of our common stock, which could result in losses to our stockholders. Future sales of substantial amounts of common stock in the public market, or the possibility of such sales occurring, could adversely affect prevailing market prices for our common stock or our future ability to raise capital through an offering of equity securities. Substantially all of our common stock is freely tradable in the public market without restriction under the Securities Act, unless these shares are held by our “affiliates”, as that term is defined in Rule 144 under the Securities Act.
Exercise of warrants and options issued by us will dilute the ownership interest of existing stockholders.
As of December 31, 2011, the warrants issued by us in April 2010 were exercisable for up to approximately 339,000 shares of our common stock, representing approximately 2% of our then outstanding common stock.
As of December 31, 2011, our outstanding stock options to our employees, officers, directors and consultants were exercisable for up to 1.5 million shares of our common stock, representing approximately an additional 9% of our then outstanding common stock. (See Note 14)
The exercise of some or all of our warrants and stock options will dilute the ownership interests of existing stockholders. Any sales in the public market of the common stock issuable upon such conversion or exercise could adversely affect prevailing market prices of our common stock.

ITEM 1B. | Unresolved Staff Comments

There are no outstanding unresolved comments from the staff of the Securities and Exchange Commission.

ITEM 2. | Properties

Bovie currently maintains the following locations:

| ● | Our executive office at 734 Walt Whitman Road, Melville, New York, which is leased for approximately $1,500 per month.

| ● | A 60,000 square foot facility which consists of office, warehousing, manufacturing and research space located at 5115 Ulmerton Rd., Clearwater, Florida Monthly principal and interest payments are approximately $29,000 per month.

| ● | A research and manufacturing facility at 3200 Tyrone Blvd., St. Petersburg, Florida which is leased for approximately $14,000 per month under a lease that expires in October 2013.

| ● | A separate warehouse facility in Clearwater, Florida that we lease for approximately $1,600 per month.

14

Table of Contents

ITEM 3. | Legal Proceedings

Medtronic Settlement
On March 3, 2011, we entered into a settlement agreement related to the legal action with Salient Surgical Technologies, Inc. and Medtronic, Inc. The settlement called for us and related parties to immediately exit and not enter into the monopolar and bipolar saline-enhanced RF device business (including SEER™ and BOSS™) worldwide through February 2015. In exchange, Salient made a one-time payment to us of $750,000. As a condition, we will not be able to sell certain finished products, which as of the settlement date amounted to approximately $100,000 of our inventory. We reserved approximately $87,000 of our inventory related to the products in this settlement in the first quarter of 2011. The terms also include a provision outlining a possible OEM contract manufacturing relationship between Salient and our Company. We currently have a longstanding OEM contract manufacturing agreement with Medtronic for advanced electrosurgical generators. We have given Medtronic notice that the agreement terminated as of December 31, 2011, with final deliveries occurring in 2012. We will continue to service the generators sold during this contract for the next five years. We anticipate sales of accessories and spare parts to continue into the future.
Livneh/Lican Development Settlement
On July 9, 2010, we filed a complaint in the United States District for the Middle District of Florida (Tampa division) naming Steven Livneh, (“Livneh”) who at the time was a director of the Company, and two of his related entities as defendants. In our complaint, we were seeking, among other things, a declaratory judgment from the Court concerning our rights under certain agreements entered into with the defendants in 2006 in connection with our acquisition of certain assets and technology, including intellectual property relating to our Seal-N-Cut™ product. We were also seeking damages for breach of contract, breach of fiduciary duty by Livneh relating to his service as an officer and director of the Company, tortious interference with contractual relations, defamation, slander of title and injunctive relief. Livneh filed a motion seeking to (a) dismiss the complaint or, in the alternative, to (b) transfer venue. On December 20, 2010, the court issued an order dismissing without prejudice five of our fifteen claims, due to New York being defined in the forum selection clauses in two of the underlying contracts with Livneh. The Company re-filed these five claims in federal court in New York. Livneh’s motion to dismiss the remaining claims in Florida was denied and the venue was not transferred.
On January 10, 2011, defendant Livneh filed a counter-complaint/third party complaint against us, our CEO, and our COO, alleging fraud, fraud in the inducement, fraudulent misrepresentation, breach of fiduciary duty, negligent misrepresentation, innocent misrepresentation, breach of contract, tortuous interference, shareholder derivative, defamation, breach of good faith and fair dealing, violation of the Uniform Trade Secrets Act, and violation of the Florida Whistleblower’s Act, and seeking rescission and a declaratory judgment. In addition to the foregoing relief, defendant also sought reinstatement of Mr. Livneh to the Company’s board of directors, issuance of certain shares of unrestricted stock, compensatory, actual and/or special damages, punitive and/or exemplary damages, and attorney’s fees and costs.
In December 2011, a settlement related to the above Livneh litigation was structured and subsequently entered into on February 22, 2012. Under the terms of the Settlement Agreement (the “Settlement Agreement”), the Company will, among other things, perform the following: (i) make a $250,000 lump sum payment to Livneh ($50,000 of which was previously recorded and expensed), (ii) make 18 installment payments to Livneh in the amount of $23,222.22 per month, (iii) reimburse Livneh for all unpaid expenses that Livneh incurred on behalf of the Company during the period of his employment and/or consultancy (from October 1, 2006 through August 11, 2010), (iv) pay Livneh $14,700, which represents the balance of the amounts due to Henvil Corp. Ltd. under a certain bill of sale, dated April 12, 2010, (v) transfer to Livneh the title of a certain automobile, (vi) transfer to Livneh all of the Company’s right and interest in certain Intellectual Property (as defined in the Settlement Agreement) pertaining to the Modular Ergonomic Grip (“MEG”), Modullion, RF Skin Resurfacing, Scannula, Double Jaw Forceps and Tip-On-Tube designs and trade name (collectively, the “Assigned Patents”), (vi) transfer to Livneh certain parts for the MEG device, (vii) grant Livneh an exclusive license to produce, market and sell the Seal-N-Cut device in the People’s Republic of China, (viii) pay to Livneh royalty payments of 3% on the Company’s Net Sales (as defined in the Settlement Agreement) of the Seal-N-Cut device outside the People’s Republic of China, and (ix) pay to Livneh a one-time royalty payment of 5% upon the closing of any sale by the Company of its right or interest in any Intellectual Property pertaining to the Seal-N-Cut device. To secure the Company’s obligations, the Company granted Livneh a security interest in all of its rights and interest of the Company in the Seal-N-Cut device, including all Intellectual Property pertaining thereto. Since the loss was quantifiable and known in December 2011, we recognized this settlement loss in 2011 and all payments hereunder were accrued during the fourth quarter.
15

Table of Contents
In exchange, Livneh will, among other things, perform the following: (i) pay us royalty payments of 3% on Livneh’s Net Sales of the Assigned Patents, excluding any Net Sales of the RF Skin Resurfacing or Tip-On-Tube, (ii) pay us a one-time royalty payment of 5% upon the closing of any sale by Livneh, Henvil or Lican Development Ltd. of their right or interest in any Intellectual Property pertaining to the Assigned Patents, and (iii) pay us royalty payments of 3% on Livneh’s Net Sales of the Seal-N-Cut device in the People’s Republic of China.
As a result of the Settlement Agreement, we have recorded an expense in the fourth quarter of 2011 of approximately $737,000 for the transfer of the MEG and the Modullion intellectual property. We have also accrued expenses in approximate amounts for the transfer of related inventory and molds of $194,000 and an additional $27,000 for other various expenses.
The Settlement Agreement contains no admission of liability or wrongdoing by us, Mr. Andrew Makrides, the Company’s Chief Executive Officer, Mr. Moshe Citronowicz, the Company’s Director of Strategic Development, Livneh, Henvil or Lican. Pursuant to the Settlement Agreement, we, along with Mr. Makrides, Mr. Citronowicz, Livneh, Henvil and Lican agreed to dismiss the litigations with prejudice and they fully and finally released all claims known and unknown, foreseen and unforeseen, which they had against each other through the date of the Settlement Agreement.
Eisenstein Settlement
On June 10, 2011, we signed a settlement agreement related to the legal action involving Dr. David Eisenstein, MD under which we paid $53,500 to Dr. Eisenstein and an additional $20,000 directly to his legal counsel for legal fees. In exchange, Dr. Eisenstein surrendered his 5,000 stock options and both parties signed a general release and dismissal.
Stockholder Derivative Action
In September 2011, we were served in a purported stockholder derivative action that was filed in the United State District Court for the Middle District of Florida against the Company and certain of its present and former officers and directors. The complaint asserts, among other things, breach of fiduciary duties and bad faith in relation to the management of the Company. The complaint seeks, among other things, unspecified compensatory damages and various forms of equitable relief. The allegations in the derivative action appear to be based largely on the January 10, 2011 Livneh counterclaim described above. We are reviewing the allegations in the complaint and investigating whether there is a collusive connection between the derivative action and the subsequently settled lawsuit with Livneh. We believe the allegations to be frivolous and without merit and we intend to defend the action vigorously. The outcome of this matter is uncertain, no range of potential loss can be estimated and accordingly no effect has been given to any loss that may result from the resolution of this matter in the accompanying consolidated financial statements.
Keen Action
In February 2012 we received notice that an action had been commenced against us in United States District Court for the Middle District of Florida, by Leonard Keen our former Vice President and General Counsel, related to his termination on December 9, 2011 and associated employment contract. Mr. Keen is demanding amounts outlined under his employment contract which provided for the payment of a base annual salary of not less than $187,500 as well as certain other payments and benefits. The employment agreement also provided for the payment, under certain circumstances, of a lump sum severance payment equal to three times base compensation plus certain other payments and benefits as set forth in the employment agreement under severance payment. Mr. Keen also asserts a claim concerning an alleged violation of Florida’s “Whistle Blower’s Act” and seeks specific performance of certain indemnification rights under his employment agreement. We believe we have meritorious defenses against Mr. Keen’s claims and will vigorously defend this action. The outcome of this matter is uncertain and accordingly no effect has been given to any loss that may result from the resolution of this matter in the accompanying consolidated financial statements, however the range of potential loss is zero to approximately $600,000 plus possible attorney fees which are not determinable at this time.
16

Table of Contents
In addition to the above, in the normal course of business, we are subject, from time to time, to legal proceedings, lawsuits and claims. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. Consequently, we are unable to ascertain the ultimate aggregate amount of monetary liability or financial impact with respect to these matters as of December 31, 2011. These matters could affect the operating results of any one or more quarter when resolved in future periods.

ITEM 4. | Mine Safety Disclosures

Not Applicable.
PART II

ITEM 5. | Market for Registrant’s Common Equity and Related Stockholder Matters

Bovie’s common stock currently is traded on the NYSE Amex. The table shows the reported high and low bid prices for the common stock during each quarter of the last eight respective quarters. These prices do not represent actual transactions and do not include retail markups, markdowns or commissions.

2011 |  | High |  |  | Low |
4th Quarter |  | $ | 3.06 |  |  | $ | 1.90 |
3rd Quarter |  |  | 3.66 |  |  |  | 2.02 |
2nd Quarter |  |  | 3.35 |  |  |  | 2.55 |
1st Quarter |  |  | 3.62 |  |  |  | 2.45 |

2010 |  | High |  |  | Low |
4th Quarter |  | $ | 5.00 |  |  | $ | 1.67 |
3rd Quarter |  |  | 3.28 |  |  |  | 2.03 |
2nd Quarter |  |  | 6.56 |  |  |  | 2.62 |
1st Quarter |  |  | 8.12 |  |  |  | 5.51 |

On March 1, 2012, the closing bid for Bovie’s Common Stock as reported by the NYSE Amex exchange was $2.83 per share. As of March 1, 2012, the total number of Stockholders of Bovie’s Common Stock was approximately 3,500, of which approximately 2,800 are estimated to be Stockholders whose shares are held in the name of their broker, stock depository or the escrow agent holding shares for the benefit of Bovie Medical Corporation Stockholders and the balance are Stockholders who keep their shares registered in their own name.
Recent Sales of Unregistered Equity Securities
On April 18, 2010, we entered into a securities purchase agreement with purchasers named therein to raise in the aggregate approximately $3 million in a private placement of common stock and warrants pursuant to Section 4(2) of the Securities Act of 1933, as amended, and/or Regulation D promulgated thereunder. Upon closing of the transaction, we entered into a registration rights agreement with the purchasers and issued to the purchasers an aggregate of 571,429 shares of common stock at a per share price of $5.25, and warrants to acquire additional shares of common stock of up to fifty percent of the common shares acquired by each respective purchaser at an exercise price of $6.00 per share.
The warrants are immediately exercisable and will terminate on the fifth anniversary of the issuance date. The exercise price of the warrants is subject to adjustment so that, among other things, if we issue any shares of common stock (including options and warrants, with standard exceptions), at a price that is lower than the exercise price then in effect, the exercise price then in effect will be reduced to such lower price.
17

Table of Contents
In connection with the private placement, we paid certain cash fees and issued a warrant to the placement agent, Rodman & Renshaw, LLC, for the purchase of 42,857 shares of Common Stock at an exercise price of $6.00 per share for its activity engaged on behalf of the Company. In addition, the Company paid certain cash fees and issued a warrant to Gilford Securities Incorporated for the purchase of 10,000 shares of Common Stock at an exercise price of $6.00 per share for its activity engaged on behalf of the Company.
The warrants contain provisions for a net cash settlement in the event that there is a fundamental transaction (contractually defined as a merger, sale of substantially all assets, tender offer or share exchange). Due to this contingent redemption provision, the warrants require liability classification and must be adjusted to fair value each reporting period.

|  | Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights (a) |  |  | Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights (b) |  |  | Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (excluding securities reflected in column (a)) (c) |
Equity compensation plans approved by security holders |  |  | 1,468,560 |  |  | $ | 3.87 |  |  |  | 46,140 |
Equity compensation plans not approved by security holders |  |  | 64,286 | (1) |  |  | 6.61 |  |  |  | — |
Warrants |  |  | 338,571 |  |  |  | 6.00 |  |  |  |  |
TOTAL |  |  | 1,871,417 |  |  | $ | 4.35 |  |  |  | 46,140 |

(1) Includes an issuance during 2010 related to employee inducement stock option grants in the amount of 100,000 stock options to Leonard Keen which subsequently due to Mr. Keen’s termination, 85,714 forfeited. In addition , during 2010 30,000 stock options were issued to Jeff Rencher related to employee inducement as terms of his employment. An additional 20,000 restricted stock options granted to Howard Stallard pursuant to an employment agreement dated October 1, 2006 and related to the Lican Development asset purchase agreement are also in this total.
Dividend Policy
We have never declared or paid any cash dividends on our common stock and we do not intend to pay cash dividends in the foreseeable future. We currently expect to retain any future earnings to fund the operation and expansion of our business.

ITEM 6. | Selected Financial Data

The following selected consolidated financial data (presented in thousands, except per share amounts and employee data) are derived from our consolidated financial statements. This data should be read in conjunction with the consolidated financial statements and notes thereto, and with Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations.
18

Table of Contents
Year Ended December 31,
(in thousands, except per share amounts)

|  | 2011 |  |  | 2010 |  |  | 2009 |  |  | 2008 |  |  | 2007 |
|  |  |  |  |  |  |  |  |  |  |  |  |  | (As restated) |
Sales, net |  | $ | 25,411 |  |  | $ | 24,230 |  |  | $ | 26,953 |  |  | $ | 28,097 |  |  | $ | 28,779 |
Cost of sales |  |  | 14,680 |  |  |  | 14,242 |  |  |  | 15,098 |  |  |  | 16,248 |  |  |  | 17,464 |
Gross Profit |  |  | 10,731 |  |  |  | 9,988 |  |  |  | 11,855 |  |  |  | 11,849 |  |  |  | 11,315 |
Gain on legal settlement and cancellation of agreement |  |  | 750 |  |  |  | -- |  |  |  | -- |  |  |  | 1,496 |  |  |  | -- |
Other costs: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  | 1,197 |  |  |  | 1,854 |  |  |  | 2,083 |  |  |  | 2,061 |  |  |  | 1,643 |
Professional services |  |  | 1,250 |  |  |  | 1,556 |  |  |  | 1,398 |  |  |  | 991 |  |  |  | 738 |
Salaries and related costs |  |  | 3,114 |  |  |  | 3,155 |  |  |  | 3,003 |  |  |  | 3,017 |  |  |  | 2,805 |
Selling, general and administration |  |  | 4,347 |  |  |  | 4,889 |  |  |  | 4,656 |  |  |  | 4,489 |  |  |  | 4,023 |
Legal settlement |  |  | 1,591 |  |  |  | -- |  |  |  | -- |  |  |  | -- |  |  |  | -- |
Asset impairment |  |  | -- |  |  |  | 1,286 |  |  |  | -- |  |  |  | -- |  |  |  | -- |
Total other costs |  |  | 11,499 |  |  |  | 12,740 |  |  |  | 11,140 |  |  |  | 10,558 |  |  |  | 9,209 |
Income (loss) from operations |  |  | (18 | ) |  |  | (2,752 | ) |  |  | 715 |  |  |  | 2,787 |  |  |  | 2,106 |
Other income and (expense): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest (expense) income |  |  | (237 | ) |  |  | (223 | ) |  |  | (52 | ) |  |  | (10 | ) |  |  | 140 |
Minority interest |  |  | -- |  |  |  | -- |  |  |  | -- |  |  |  | -- |  |  |  | 5 |
Change in fair value of liabilities, net |  |  | 287 |  |  |  | 513 |  |  |  | -- |  |  |  | -- |  |  |  | -- |
Total other income (expense) net |  |  | 50 |  |  |  | 290 |  |  |  | (52 | ) |  |  | (10 | ) |  |  | 145 |
Income (loss) before income taxes |  |  | 32 |  |  |  | (2,462 | ) |  |  | 663 |  |  |  | 2,777 |  |  |  | 2,251 |
Benefit (provision) for income taxes |  |  | 77 |  |  |  | 927 |  |  |  | (67 | ) |  |  | (945 | ) |  |  | 1,550 |
Net income (loss) |  | $ | 109 |  |  | $ | (1,535 | ) |  | $ | 596 |  |  | $ | 1,832 |  |  | $ | 3,801 |
Earnings (loss) per common share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | .01 |  |  | $ | (0.09 | ) |  | $ | 0.04 |  |  | $ | 0.11 |  |  | $ | 0.25 |
Diluted |  | $ | .01 |  |  | $ | (0.09 | ) |  | $ | 0.03 |  |  | $ | 0.11 |  |  | $ | 0.22 |
Balance Sheet Information: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 4,880 |  |  | $ | 3,827 |  |  | $ | 2,155 |  |  | $ | 2,565 |  |  | $ | 3,535 |
Working capital |  | $ | 14,095 |  |  | $ | 13,107 |  |  | $ | 10,741 |  |  | $ | 9,943 |  |  | $ | 10,071 |
Total assets |  | $ | 28,240 |  |  | $ | 27,786 |  |  | $ | 27,462 |  |  | $ | 26,725 |  |  | $ | 20,213 |
Long-term liabilities |  | $ | 3,734 |  |  | $ | 4,216 |  |  | $ | 3,958 |  |  | $ | 4,143 |  |  | $ | 318 |
Stockholders’ equity |  | $ | 22,117 |  |  | $ | 21,765 |  |  | $ | 21,031 |  |  | $ | 20,128 |  |  | $ | 18,192 |

ITEM 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis in conjunction with our financial statements and related notes contained elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors discussed in this report and those discussed in other documents we file with the SEC. In light of these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements represent beliefs and assumptions on as of the date of this report. While we may elect to update forward-looking statements and at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.
19

Table of Contents
Executive Level Overview
We are a medical device company engaged in manufacturing and marketing of electrosurgical devices. Our medical products include a wide range of devices including electrosurgical generators and accessories, cauteries, medical lighting, nerve locators and other products.
We internally divide our operations into three product lines. Electrosurgical products, battery-operated cauteries and other products. The electrosurgical line sells electrosurgical products which include desiccators, generators, electrodes, electrosurgical pencils and various ancillary disposable products. These products are used in surgery for the cutting and coagulation of tissue. Battery-operated cauteries are used for precise hemostasis (to stop bleeding) in ophthalmology and in other fields. Our other revenues are derived from nerve locators, disposable and reusable penlights, medical lighting, license fees, development fees and other miscellaneous income.
Most of our products currently are marketed through medical distributors, which distribute to more than 6,000 hospitals, and to doctors and other health-care facilities. New distributors are contacted through responses to our advertising in international and domestic medical journals and domestic or international trade shows. International sales represented 21% of total revenues in 2011 and in 2010 and 16% in 2009. Our products are sold in more than 150 countries through local dealers which are coordinated by sales and marketing personnel at the Clearwater, Florida facility. As mentioned previously for the launch of our new surgical suite product lines, we have established the use of a network of approximately 50 commission-based independent direct sales contractors to market these products. Our business is generally not seasonal in nature.
We strongly encourage investors to visit our website: www.boviemedical.com to view the most current news and to review our filings with the Securities and Exchange Commission.
Results of Operations –
Sales

|  | 2011 vs. 2010 |  |  | 2010 vs. 2009 |
Sales by Product Line (in thousands) |  | 2011 |  |  | 2010 |  |  | Percent change |  |  | 2010 |  |  | 2009 |  |  | Percent change |
Electrosurgical |  | $ | 16,896 |  |  |  | 15,956 |  |  |  | 5.9 | % |  | $ | 15,956 |  |  |  | 18,576 |  |  |  | (14.1 | )%
Cauteries |  |  | 6,268 |  |  |  | 6,383 |  |  |  | (1.8 | )% |  |  | 6,383 |  |  |  | 6,252 |  |  |  | 2.1 | %
Other |  |  | 2,247 |  |  |  | 1,891 |  |  |  | 18.8 | % |  |  | 1,891 |  |  |  | 2,125 |  |  |  | (11.0 | )%
Total |  | $ | 25,411 |  |  |  | 24,230 |  |  |  | 4.9 | % |  | $ | 24,230 |  |  |  | 26,953 |  |  |  | (10.1 | )%
Sales by Domestic and International (in thousands) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Domestic |  | $ | 19,972 |  |  |  | 19,174 |  |  |  | 4.2 | % |  | $ | 19,174 |  |  |  | 22,506 |  |  |  | (14.8 | )%
International |  |  | 5,439 |  |  |  | 5,056 |  |  |  | 7.6 | % |  |  | 5,056 |  |  |  | 4,447 |  |  |  | 13.7 | %
Total |  | $ | 25,411 |  |  |  | 24,230 |  |  |  | 4.9 | % |  | $ | 24,230 |  |  |  | 26,953 |  |  |  | (10.1 | )%

Our sales for the twelve months ended December 31, 2011 outpaced sales for the same period in 2010 by approximately $1.2 million, or 4.9%. The increase in sales has been driven mainly by increased demand for our electrosurgical generators both domestically and internationally which amounted to an approximate increase of $690,000 for the year ended December 31, 2011 compared to the same period in 2010. Sales of our new distribution products released this year, coated blades which are categorized as electrosurgical and medical lighting systems which are categorized as other products, amounted to increases of approximately $675,000 and $356,000 respectively for the year ended December 31, 2011 compared to the same period in 2010. However, increases in electrosurgical sales were offset by an approximate decrease of $425,000 related to discontinued sales of an OEM disposable electrosurgical device for the twelve month period compared to the same period in 2010. In addition cautery sales were down by approximately $115,000 for the current year ended compared to the same period in 2010. We continue to see increased demand for our third party medical lighting products and as part of our ongoing business strategy we will be bringing on more third party medical products to offer through our distribution channel.
20

Table of Contents
Sales for the year ended December 31, 2010 decreased approximately $2.7 million or 10.1% compared to the same period in 2009. This overall decrease was mainly the result of the reduction in electrosurgical disposables sales of Arthrex ablators which decreased approximately $3.6 million or 14.1% from the previous year. Sales of other products were down approximately $234,000 or 11.0% mainly due to a reduction in the sale of penlights. 2010 over 2009 did show some significant offsetting increases however, with approximately $1.0 million of increased demand and sales of electrosurgical generators or 8.7% and an approximate increase of $131,000 in cautery sales.
Our ten largest customers accounted for approximately 65.5%, 66.5%, and 71.5% of net revenues for 2011, 2010, and 2009 respectively. In 2011, no one customer accounted for over 10% of our sales. In 2010 and 2009, Arthrex accounted for over 10% of total revenues (11% and 22% of our revenues for each such year). In 2010, National Distribution & Contracting Inc. also accounted for 11% of the sales. Sales of generators and accessories to Arthrex decreased by approximately $3.2 million or 53.3% to approximately $2.8 million for the year ended December 31, 2010 from approximately $6.0 million for the year ended December 31, 2009.
Gross Profit

|  | Years ended December 31, |
(in thousands) |  | 2011 |  |  | 2010 |  |  | Percent change ’10 vs ’11 |  |  | 2009 |  |  | Percent change ’09 vs ’10 |
Cost of sales |  | $ | 14,680 |  |  | $ | 14,242 |  |  |  | 3.1 | % |  | $ | 15,099 |  |  |  | (5.7 | %)
Cost of sales as a percentage of revenue |  |  | 57.8 | % |  |  | 58.8 | % |  |  |  |  |  |  | 56.0 | % |  |  |  |
Gross profit |  | $ | 10,731 |  |  | $ | 9,988 |  |  |  | 7.4 | % |  | $ | 11,855 |  |  |  | (15.7 | %)
Gross profit as a percentage of revenue |  |  | 42.2 | % |  |  | 41.2 | % |  |  | 1.0 | % |  |  | 44.0 | % |  |  | (2.8 | %)

We improved our gross profit margin on a dollar basis by 7.4% or approximately $742,000 during the year ended December 31, 2011, compared to the same period in 2010 as a result of a combination of increased sales mentioned above and a net reduction in some of our costs attributed to those sales. Our cost of sales as a percentage of sales decreased by 1.0% mainly as a result of reductions approximating $216,000 in direct and indirect labor costs and $141,000 eliminated from our consolidating the Canadian facility. The total of these cost savings was offset by approximately $103,000 due to higher material cost related to our third party medical lighting sales when compared to our manufactured product lines.
In contrast, in the year ended December 31, 2010 compared to the same period for 2009, our overall gross profit dollars declined by approximately $1.9 million, or a decrease of 15.7%. This decline was primarily the result of losing gross margin dollars associated with the $3.2 million reduction in sales of ablators which were a higher profit margin product offset by an approximate $365,000 decrease in direct and indirect labor costs for the Florida and Canadian operations.
We do not anticipate any material impact to our gross profit, material costs, or other costs as a result of the effect of inflation or changing prices on net revenue.
Other Gain (Loss)
Salient/Medtronic Settlement
On March 3, 2011, we entered into a settlement agreement related to the legal action with Salient Surgical Technologies, Inc. and Medtronic, Inc. The settlement called for us and related parties to immediately exit and not enter into the monopolar and bipolar saline-enhanced RF device business (including SEER™ and BOSS™) worldwide through February 2015. In exchange, Salient made a one-time payment to us of $750,000. As a condition, we will not be able to sell certain finished products, which as of the settlement date amounted to approximately $100,000 of our inventory. We reserved for approximately $87,000 of our inventory related to the products in this settlement in the first quarter of 2011. The terms also include a provision outlining a possible OEM contract manufacturing relationship between Salient and our Company. We currently have a longstanding OEM contract manufacturing agreement with Medtronic for advanced electrosurgical generators. We have given Medtronic notice that the agreement will terminate as of December 31, 2011, with final deliveries occurring in 2012. We will continue to service the generators sold during this contract for the next five years. We anticipate sales of accessories and spare parts to continue into the future.
21

Table of Contents
Research and development

|  | Year ended December 31, |
(in thousands) |  | 2011 |  |  | 2010 |  |  | Percent change ’10 vs ’11 |  |  | 2009 |  |  | Percent change ’09 vs ’10 |
Research and Development expense |  | $ | 1,197 |  |  | $ | 1,854 |  |  |  | (35.4 | %) |  | $ | 2,083 |  |  |  | (11.0 | %)
R&D expense as a percentage of revenue |  |  | 4.7 | % |  |  | 7.7 | % |  |  |  |  |  |  | 7.7 | % |  |  |  |

We experienced a 35.4% decrease in research and development expense or approximately $657,000 for the year ended 2011 compared to the same period in 2010. This 3% decrease as a percentage of sales, was primarily related to the saline-enhanced RF device business product line and reductions in development costs of approximately $300,000 in engineering costs and approximately $118,000 in product design, testing labs, and material related costs. In March of this year as part of our legal settlement with Salient Surgical Technologies, Inc. we agreed to exit and not enter into the monopolar and bipolar saline-enhanced RF device business (SEER™ and BOSS™) worldwide through February 2015. We also had reductions of approximately $239,000 in consulting fees associated with the development of our vessel sealing product as a result of our consolidating the Canadian operations to Florida.
Our R&D expense decreased by approximately $229,000 or 11% in the year ended December 31, 2010 as compared to the same period for 2009, but as a percentage of sales it remained the same year over year. The decrease in dollars was primarily the result of reduced labor and overhead costs associated with the development of our vessel sealing product as a result of our consolidating the Canadian operations to Florida amounting to approximately $379,000. These reductions were offset by increases in other new product, including our plasma product line, engineering and development costs of approximately $150,000.
Professional services

|  | Year ended December 31, |
(in thousands) |  | 2011 |  |  | 2010 |  |  | Percent change ’10 vs ’11 |  |  | 2009 |  |  | Percent change ’09 vs ’10 |
Professional services expense |  | $ | 1,250 |  |  | $ | 1,556 |  |  |  | (19.7 | %) |  | $ | 1,398 |  |  |  | 11.3 | %
Professional services as a percentage of revenue |  |  | 4.9 | % |  |  | 6.4 | % |  |  |  |  |  |  | 5.2 | % |  |  |  |

Our professional costs decreased by 19.7% or approximately $306,000 for the year ended December 31, 2011 compared to the same period in 2010, due mainly to a reductions in legal fees of approximately $70,000 related to settled cases and $99,000 in tax consulting fees due to the closing of our IRS audit earlier this year. In addition, we had savings of approximately $69,000 in other consulting costs from our nonrenewal of a consulting firm to support marketing of new products which we used in 2010. Various smaller savings were approximately $25,000 in internal control testing costs, $28,000 in patent related costs, and $15,000 in stock based compensation costs.
22

Table of Contents
We experienced an 11.3% increase or approximately $158,000 in professional services costs in the year ended December 31, 2010 compared to the same period for 2009 which was primarily the result of increased legal fees related to the Salient/Medtronics and Livneh lawsuits compared to the fees incurred for the Erbe lawsuit in 2009 by approximately $80,000. For this period we also incurred increased tax consulting costs of $65,000 which were related to an IRS audit being conducted during the latter half of 2010 and increased consulting fees related to engaging a consulting firm to support marketing of new products of approximately $49,000. These increased costs were partially offset by savings of approximately $36,000 in patent related legal fees.
Salaries and related costs

|  | Year ended December 31, |
(in thousands) |  | 2011 |  |  | 2010 |  |  | Percent change ’10 vs ’11 |  |  | 2009 |  |  | Percent change ’09 vs ’10 |
Salaries and related expenses |  | $ | 3,114 |  |  | $ | 3,155 |  |  |  | (1.3 | %) |  | $ | 3,003 |  |  |  | 5.1 | %
Salaries & related expenses as a percentage of revenue |  |  | 12.3 | % |  |  | 13.0 | % |  |  |  |  |  |  | 11.1 | % |  |  |  |

Our salaries and related costs decreased overall by approximately $41,000, or 1.3% for the year ended December 31, 2011 when compared to the same period in 2010. Although we experienced an increase in our health insurance premiums of approximately $52,000, this increase was offset by a reduction in salaries related to the elimination of a marketing position for the sintered steel product line that we agreed to exit out of as part of the Salient Surgical Technologies, Inc. settlement.
Our salaries and related cost dollars increased by approximately $152,000, or 5.1% for the year ended December 31, 2010 when compared to the same period in 2009, which as a percentage of sales was an increase of approximately 1.9%. The increase was primarily the result of a $230,000 from a new legal counsel position salary, which included a onetime $80,000 payment to cover relocation and housing costs. Other increases for this period were approximately $51,000 in health insurance and other benefits and approximately $36,000 in stock based compensation. Some offsetting decreases we experienced during this period were approximately $145,000 in eliminated marketing position salaries and approximately $20,000 in eliminated salaries in the Canadian facility.
Selling, general and administrative expenses

|  | Year ended December 31, |
(in thousands) |  | 2011 |  |  | 2010 |  |  | Percent change ’10 vs 11’ |  |  | 2009 |  |  | Percent change 09’ vs 10’ |
SG&A expense |  | $ | 4,347 |  |  | $ | 4,889 |  |  |  | (11.1 | %) |  | $ | 4,656 |  |  |  | 5.0 | %
SG&A expense as a percentage of revenue |  |  | 17.1 | % |  |  | 20.2 | % |  |  |  |  |  |  | 17.3 | % |  |  |  |
Loss on impairment of IP |  |  | -- |  |  | $ | 1,286 |  |  |  |  |  |  |  | -- |  |  |  |  |
|  |  |  |  |  |  | 5.3 | % |  |  |  |  |  |  |  |  |  |  |  |

Our selling, general and administrative costs decreased by 11.1% overall or approximately $542,000 for the year ended December 31, 2011 compared to the same period in 2010. A large portion of our cost savings were from decreases related to the suspension of the sintered steel product line as part of the Salient Surgical Technologies, Inc. settlement for approximate amounts of $131,000 in reduction in travel costs, $95,000 decrease in amortization expense, and a $54,000 reduction in sintered steel marketing costs. Other large cost saving components included in the 11.1% overall reduction mentioned above were related to general overhead costs which included approximate amounts of $240,000 related to reductions from consolidating the Canadian operation to Florida, a $326,000 decrease in loss on disposition of assets incurred on the sale of our old building in late 2010, and $86,000 decrease in utilities and facility maintenance costs. We also experienced some decreases in our manufacturing rep training and other various selling expenses amounting to approximately $71,000.
23

Table of Contents
We continue to increase sales of our new distribution product lines, coated electrodes and medical lighting systems, and to introduce other new products under development and as a result we incurred approximate increases in selling costs of $41,000 for advertising, $99,000 for commission expense, and $21,000 for show and other marketing costs. In addition, during 2011, as our new products approached the completion phase we experienced an increase of approximately $68,000 in regulatory testing costs compared to the prior year. We also saw an increase in our general insurance costs of approximately $71,000 due to increases related to our directors and officer’s coverage and we expect this trend to continue in 2012 as we re-evaluate our coverage in other areas. As a result of settling one of our lawsuits we incurred an approximate increase of $83,000 in settlement expense. Other various increases in cost in our year ended December 31, 2011 over the same period in 2010 include approximate amounts of $25,000 in shareholder and stock exchange related costs, $32,000 in our provision for obsolete inventory, and $21,000 inventory storage costs.
For the year ended December 31, 2010 as compared to the same period in 2009 we experienced a 5.0% increase in selling, general and administrative costs which amounted to approximately $233,000. A large portion of this overall increase in costs was primarily the result of the condition in the commercial real estate market during the time period that we sold our St. Petersburg facility, which coupled with the disposition of some Canadian assets, resulted in an approximate $327,000 loss on disposition of assets. We also experienced increased costs related to our new distribution and other products for this same comparative period which included approximate increases of $85,000 in regulatory costs, $95,000 in show costs, $78,000 in advertising and marketing costs, and $30,000 in travel costs. Other various areas we had incurred increased costs during the year ended December 31, 2010 over 2009 included approximate amounts of $52,000 in building infrastructure and maintenance costs, $83,000 in bank fees and other general administration costs, and $33,000 in foreign currency loss.
While the overall trend in selling, general, and administrative costs was a 5.0% increase, we also experienced several areas where we reduced costs. Reductions in costs related to the consolidating of our Canadian facility amounted to approximately $194,000. During this 2010 time period by our non-renewal of a contract we reduced our European selling costs by approximately $98,000. Other reduction in costs we experienced in the year ended December 31, 2010 over 2009 include approximate amounts of $160,000 related to a 2009 lawsuit settlement, $77,000 in general insurance from an insurance audit credit, and $21,000 in our provision for obsolete inventory.
Legal Settlement
In December 2011, a settlement related to the Livneh litigation was structured and subsequently signed on February 22, 2012 (the “Settlement Agreement”). Under the terms of the Settlement Agreement, the Company will, among other things, perform the following: (i) make a $250,000 lump sum payment to Livneh ($50,000 of which was previously recorded and expensed), (ii) make 18 installment payments to Livneh in the amount of $23,222.22 per month, (iii) reimburse Livneh for all unpaid expenses that Livneh incurred on behalf of the Company during the period of his employment and/or consultancy (from October 1, 2006 through August 11, 2010), (iv) pay Livneh $14,700, which represents the balance of the amounts due to Henvil Corp. Ltd. under a certain bill of sale, dated April 12, 2010, (v) transfer to Livneh the title of a certain automobile, (vi) transfer to Livneh all of our rights and interest in certain Intellectual Property (as defined in the Settlement Agreement) pertaining to the Modular Ergonomic Grip (“MEG”), Modullion, RF Skin Resurfacing, Scannula, Double Jaw Forceps and Tip-On-Tube designs and trade name (collectively, the “Assigned Patents”), (vi) transfer to Livneh certain parts for the MEG device, (vii) grant Livneh an exclusive license to produce, market and sell the Seal-N-Cut device in the People’s Republic of China, (viii) pay to Livneh royalty payments of 3% on our net sales (as defined in the Settlement Agreement) of the Seal-N-Cut device outside the People’s Republic of China, and (ix) pay to Livneh a one-time royalty payment of 5% upon the closing of any sale by the Company of its right or interest in any Intellectual Property pertaining to the Seal-N-Cut device. To secure our obligations, we granted Livneh a security interest in all of its rights and interest of the Company in the Seal-N-Cut device, including all Intellectual Property pertaining thereto. Since the loss was quantifiable and known in December 2011, we recognized this settlement loss in 2011 in accordance with GAAP and all payments hereunder were accrued during the fourth quarter.
24

Table of Contents
In addition, as a result of the Settlement Agreement, the Company has taken a write down in the fourth quarter of 2011 of approximately $737,000 off its balance sheets for the transfer of the MEG and the Modullion intellectual property. We have also accrued expenses in approximate amounts for the transfer of related inventory and molds of $194,000 and an additional $27,000 for other various expenses.
The total financial impact of this settlement agreement to our consolidated financial statements for the year ended December 31, 2011 was approximately $1.6 million.
Asset Impairment
In December 2010, after evaluating the future outlook of our patent related to our SEER™ product line, we determined that the asset value was impaired and further calculated the impairment loss to be approximately $1.3 million. Subsequent to our assessment that the patent was impaired, as a condition of the March 3, 2011 settlement with Salient Surgical Technologies, Inc. and Medtronic, Inc., we are required to immediately exit and not enter into the monopolar and bipolar saline-enhanced RF device business (including SEER™ and BOSS™) worldwide through February 2015 (see Item 3. Legal Proceedings). As a condition we will not be able to sell certain finished products, which as of the settlement date amounted to approximately $87,000 of our inventory.
Other Income

|  | Year ended December 31, |
(in thousands) |  | 2011 |  |  | 2010 |  |  | Percent change ’10 vs ’11 |  |  | 2009 |  |  | Percent change ’09 vs ’10 |
Interest income |  | $ | 12 |  |  | $ | 15 |  |  |  | (20.0 | %) |  | $ | 24 |  |  |  | (37.5 | %)
Interest expense |  | $ | (249 | ) |  | $ | (238 | ) |  |  | 4.6 | % |  | $ | (76 | ) |  |  | 213 | %
Total other income (expense) |  | $ | (237 | ) |  | $ | (223 | ) |  |  | 6.3 | % |  | $ | (52 | ) |  |  | 329 | %
Other income (expense) as a percentage of revenue |  |  | (0.9 | %) |  |  | (0.9 | %) |  |  |  |  |  |  | (0.2 | )% |  |  |  |
Change in fair value of liabilities, net |  | $ | 287 |  |  | $ | 513 |  |  |  | (44.1 | %) |  |  | -- |  |  |  |  |
Other Gain as a percentage of sales |  |  | 1.1 | % |  |  | 2.1 | % |  |  |  |  |  |  |  |  |  |  |  |

Net interest expense increased by approximately $14,000 or 6.3% for the year ended December 31, 2011 as compared to the same period in 2010 primarily due to the refinancing of the Industrial Revenue Bonds in late 2011.
Net interest expense increased by approximately $171,000 or 329% for the year ended December 31, 2010 as compared to the same period in 2009 primarily due to the capitalization in 2009 of certain interest expenses related to the industrial revenue bonds used to finance our new facility.
The change in fair value of liabilities was related to the warrants associated with our equity issuance in April of 2010 and adjustment for the fair value of the Lican liability. The derivative warrant liability was valued at approximately $799,000 at the issuance date and was valued at approximately $105,000 and $332,000 at December 31, 2011 and December 31, 2010 respectively. This resulted in a year-to-date gain of approximately $227,000 and 467,000 for the years ended December 31, 2011 and 2010 respectively. The Lican liability fair value as of December 31, 2009 was $218,150 and was valued at approximately $111,300 and $172,200 at December 31, 2011 and 2010. This resulted in a gain of $61,000 and $46,000 for the years ended December 31, 2011 and 2010 respectively.
Interest income decreased by approximately $9,000 during the year ended December 31, 2010 when compared with 2009. This was due to lower interest rates on our sweep account coupled with lower cash balances year over year.
Interest expense increased progressively from 2009 through 2011 mainly as a direct result of interest incurred on debt originated in 2008. This debt was used to primarily to acquire and renovate our new facility and for working capital purposes. We expect that our interest expense for 2012 should be similar to the amount incurred in 2011.
25

Table of Contents
Income Taxes
During 2010, our 2008 and 2009 federal tax returns were selected for examination by the United States Internal Revenue Service (“the IRS”). The exam was concluded in March, 2011. As a result of the IRS exam, our federal net operating loss carryforward was reduced by approximately $350,000 and R&D credits were reduced by approximately $55,000.
Deferred income taxes reflect the impact of temporary differences between the amount of assets and liabilities recognized for financial reporting purposes and such amounts recognized for income tax purposes. The tax effects of these temporary differences representing the components of deferred tax assets (liabilities) at December 31 were approximately as follows (in thousands):

|  | 2011 |  |  | 2010 |
Deferred tax assets, current: |  |  |  |  |  |
U.S. net operating loss carryforwards |  | $ | 980 |  |  | $ | 1,011 |
State net operating loss carryforwards |  |  | 176 |  |  |  | 189 |
Research and development credits |  |  | 774 |  |  |  | 743 |
AMT credits |  |  | 73 |  |  |  | 73 |
Asset impairment |  |  | -- |  |  |  | 486 |
Accounts receivable |  |  | 16 |  |  |  | 5 |
Inventory |  |  | 1 |  |  |  | 2 |
Charitable |  |  | 9 |  |  |  | 4 |
Accrued expenses |  |  | 56 |  |  |  | 72 |
Unrecognized tax benefit liability for current temporary differences |  |  | -- |  |  |  | -- |
Accrued Settlement |  |  | 593 |  |  |  | -- |
Non-current estimate of loss and credit carryforwards |  |  | (2,178 | ) |  |  | (2,185 | )
Total deferred tax assets, current |  |  | 500 |  |  |  | 400 |
Deferred tax assets, non-current: |  |  |  |  |  |  |  |
Loss and credit carryforwards |  |  | 2,178 |  |  |  | 2,185 |
Stock based compensation |  |  | 70 |  |  |  | 49 |
Total deferred tax assets, non- current |  |  | 2,248 |  |  |  | 2,234 |
Deferred tax liabilities, non-current: |  |  |  |  |  |  |  |
Property and equipment |  |  | (422 | ) |  |  | (410 | )
Intangibles |  |  | (254 | ) |  |  | (217 | )
Unrecognized tax benefit liability for non-current temporary differences |  |  | (63 | ) |  |  | (74 | )
Total deferred tax liabilities, non- current |  |  | (739 | ) |  |  | (701 | )
Net non-current deferred income tax asset |  | $ | 1,509 |  |  | $ | 1,533 |

Pursuant to ASC 740, we must consider all positive and negative evidence regarding the realization of deferred tax assets, including past operating results and future sources of taxable income. U.S. net operating losses will begin to expire in years beginning in 2019.
We have adopted the provisions of FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes, now under ASC 740. Under ASC 740, the impact of an uncertain tax position taken or expected to be taken on an income tax return must be recognized in the financial statements at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained. All of our positions arise from taxable temporary differences and, as such, the liability has been recognized in the net deferred tax asset, current and non-current items to which they relate. The calculated amount of penalties and interest related to these timing differences were immaterial at December 31, 2011 and 2010. In addition, because the amounts are related to temporary timing differences, there would be no material impact on our effective tax rate if recognized.
26

Table of Contents
Below is a reconciliation of the statutory federal income tax rate to our effective tax rate for the fiscal years ended December 31, 2010 and 2011:

|  | 2011 |  |  | 2010 |  |  | 2009 |
Federal Tax Provision |  |  | 34.0 | % |  |  | 34.0 | % |  |  | 34.0 | %
State taxes (net of federal benefit) |  |  | (32.0 | %) |  |  | 4.3 | % |  |  | 2.6 | %
Stock based compensation* |  |  | (27.8 | %) |  |  | 0.5 | % |  |  | (15.9 | %)
Research and development credits* |  |  | (78.0 | %) |  |  | 5.0 | % |  |  | (12.8 | %)
Warrant Gains |  |  | (372.4 | %) |  |  | - |  |  |  | - |
Meals and Entertainment |  |  | 39.1 | % |  |  | - |  |  |  | - |
Other |  |  | - |  |  |  | (6.1 | %) |  |  | 2.3 | %
|  |  | (437.1 | %) |  |  | 37.7 | % |  |  | 10.2 | %

* Net of IRS Exam adjustments for 2010
Liquidity and Capital Resources
Our working capital at December 31, 2011 was $14.1 million compared with $13.1 million at December 31, 2010. Accounts receivable days sales outstanding were 36 days and 42 days at December 31, 2011 and 2010, respectively. The number of days worth of sales in inventory, which is the total inventory available for production divided by the 12-month average cost of materials, decreased 19 days to 237 days equating to an inventory turn ratio of 1.32 at December 31, 2011 from 256 days and an inventory turn ratio of 1.3 at December 31, 2010. The lower number of days worth of sales in inventory which translated into a higher inventory turnover rate is mainly due to the increase in sales related to our generator product lines which contain a greater number of component parts compared to all our other products.
For the year ended December 31, 2011, net cash provided by operating activities was $1.9 million used compared with net cash used of approximately $566,000 from operations in 2010.
Net cash used in investing activities was approximately $542,000 for the year ended December 31, 2011 compared to net cash provided by investing activities of approximately $432,000 during 2010. The change was due mainly to increased purchases of equipment, molds and test fixtures to support our new products and because we received approximately $633,000 from the sale of our St. Petersburg, Florida facility.
We used cash from financing activities of approximately $302,000 during year ended December 31, 2011 compared to cash provided of approximately $1.7 million in 2010. The change primarily resulted from the following:

| ● | proceeds of approximately $2,767,000 from sale of stock in 2010;

| ● | a repayment of our line of credit balance of approximately $1,000,000 in 2010; and

| ● | a net repayment on our bond refinancing and repayment of our equipment credit facility, which totalled approximately $300,000 in 2011.

We currently have approximately $3.5 million outstanding under industrial revenue bonds which we previously used for the purchase and renovation of our Clearwater, Florida facility. During 2011 these bonds were refinanced through PNC Bank, N.A. The bonds, which are being amortized over a 20-year term, balloon in November 2018 and bear interest at a fixed interest rate of 5.6%. Scheduled maturities of this indebtedness are $129,800, $137,300, $145,000, $153,100 and $161,700 for 2012, 2013, 2014, 2015 and 2016, respectively and approximately $2.8 million thereafter.
27

Table of Contents
We had approximately $4.9 million in cash and cash equivalents at December 31, 2011. We believe our cash on hand, as well as anticipated cash flows from operations, will be sufficient to meet our operating cash commitments for the next year. Should additional funds be required, we have secured additional borrowing capacity with PNC Bank. (See below)
We have a $6 million secured revolving line of credit facility with PNC Bank, which at December 31, 2011 had a zero balance. Advances under the $6 million line of credit are due on demand and bear interest at a rate of daily LIBOR plus 1.75% and are secured by a perfected first security interest in our inventory and accounts receivable.
In addition we have a separate additional credit facility with PNC Bank for up to $1 million specific to financing new equipment purchases. This credit facility provides for a 1 year draw up to the conversion date of October 31, 2012. Prior to the conversion dates amounts outstanding will bear an interest rate of daily LIBOR plus 2.25%. Once the note is converted the term will be 5 years and will bear an interest rate of daily LIBOR plus 2.50%. The note would be secured by a perfected first security interest in the new equipment purchased.
Subsequent available borrowings for both these credit facilities are subject to a borrowing base utilizing a percentage of eligible receivables, inventories, and any assigned cash along with certain financial ratios, specifically maintaining: a ratio of total funded debt to EBITDA of less than 3.25 to 1.0 and a ratio of minimum Fixed Charge of 1.5 to 1.0 measured on a rolling four quarter basis.
At December 31, 2011, we were in full compliance with the loan covenants and ratios of both the credit facilities. According to our most recent borrowing base calculation, we had approximately $3.0 million total availability under the $6 million credit line, of which we currently have a zero balance. We also have available approximately $1.0 million under the equipment line of credit.
Our future contractual obligations for agreements with initial terms greater than one year and agreements to purchase materials in the normal course of business are summarized as follows (in thousands):

Description |  | Years Ending December 31, |
|  | 2012 |  |  | 2013 |  |  | 2014 |  |  | 2015 |  |  | 2016 |  |  | 2017 |
Operating leases |  | $ | 256 |  |  | $ | 228 |  |  | $ | 12 |  |  |  | - |  |  |  | - |  |  |  | - |
Employment agreements |  |  | 611 |  |  |  | 591 |  |  |  | 46 |  |  |  | - |  |  |  | - |  |  |  | - |
Purchase Commitments |  |  | 3,838 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |

Critical Accounting Estimates
In preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), we have adopted various accounting policies. Our most significant accounting policies are disclosed in Note 2 to the consolidated financial statements.
The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to inventories, intangible assets, property, plant and equipment, legal proceedings, research and development, warranty obligations, product liability, fair valued liabilities, sales returns and discounts, and income taxes are updated as appropriate, which in most cases is at least quarterly. We base our estimates on historical experience, or various assumptions that are believed to be reasonable under the circumstances and the results form the basis for making judgments about the reported values of assets, liabilities, revenues and expenses. Actual results may materially differ from these estimates.
28

Table of Contents
Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that are uncertain at the time the accounting estimates are made, and (2) other materially different estimates could have been reasonably made or material changes in the estimates are reasonably likely to occur from period to period. Our critical accounting estimates include the following:
Inventory reserves
When necessary we maintain reserves for excess and obsolete inventory resulting from the potential inability to sell our products at prices in excess of current carrying costs. The markets in which we operate are highly competitive, with new products and surgical procedures introduced on an ongoing basis. Such marketplace changes may cause our products to become obsolete. We make estimates regarding the future recoverability of the costs of these products and record a provision for excess and obsolete inventories based on historical experience, and expected future trends. If actual product life cycles, product demand or acceptance of new product introductions are less favorable than projected by management, additional inventory write-downs may be required, which would unfavorably affect future operating results.
Long-lived assets
We review long-lived assets which are held and used, including property and equipment and intangible assets, for impairment whenever changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Such evaluations compare the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset over its expected useful life and are significantly impacted by estimates of future prices and volumes for our products, capital needs, economic trends and other factors that are inherently difficult to forecast. If the asset is considered to be impaired, we record an impairment charge equal to the amount by which the carrying value of the asset exceeds its fair value determined by either a quoted market price, if any, or a value determined by utilizing a discounted cash flow technique.
Liabilities valued at fair value
We generally do not use derivative financial instruments to hedge exposures to cash-flow risks or market-risks. However, certain financial instruments, such as warrants, which are indexed to our common stock, are classified as liabilities when either (a) the holder possesses rights to net-cash settlement or (b) physical or net-share settlement is not within our control. In such instances, net-cash settlement is assumed for financial accounting and reporting purposes, even when the terms of the underlying contracts do not provide for net-cash settlement. Such financial instruments are initially recorded, and continuously carried, at fair value.
Determining the fair value of these instruments involves judgment and the use of certain relevant assumptions including, but not limited to, interest rate risk, historical volatility and stock price, estimated life of the derivative, antidilution provisions, and conversion/redemption privileges. The use of different assumptions or changes in those assumptions could have a material effect on the estimated fair value amounts.
Share-based Compensation
Under our stock option plan, options to purchase common shares of the Company may be granted to key employees, officers and directors of the Company by the Board of Directors. The Company accounts for stock options in accordance with FASB ASC Topic 718-10-10, Share-Based Payment, with option expense amortized over the vesting period based on the binomial lattice option-pricing model fair value on the grant date, which includes a number of estimates that affect the amount of our expense.
Income Taxes
The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between the financial statement and tax bases of assets and liabilities. Deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax bases of assets and liabilities using enacted marginal tax rates. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Deferred income tax expenses or credits are based on the changes in the asset or liability from period to period.
29

Table of Contents
We have net operating loss and tax credit carry forwards available in certain jurisdictions to reduce future taxable income. Future tax benefits for net operating loss and tax credit carry forwards are recognized to the extent that realization of these benefits is considered more likely than not. This determination is based on the expectation that related operations will be sufficiently profitable or various tax, business and other planning strategies will enable us to utilize the operating loss and tax credit carry forwards. We cannot be assured that we will be able to realize these future tax benefits or that future valuation allowances will not be required. To the extent that available evidence raises doubt about the realization of a deferred income tax asset, a valuation allowance is established.
It is our policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. To the extent that the probable tax outcome of these uncertain tax positions changes, such changes in estimate will impact the income tax provision in the period in which such determination is made. At December 31, 2011, we believe we have appropriately accounted for any unrecognized tax positions. To the extent we prevail in matters for which a liability for an unrecognized tax benefit is established or we are required to pay amounts in excess of the liability, our effective tax rate in a given financial statement period may be affected.
Since inception, we have been subject to tax by both federal and state taxing authorities. Until the respective statutes of limitations expire (which may be as much as 20 years while we have unused NOL’s), we are subject to income tax audits in the jurisdictions in which we operate.
Inflation
Inflation has not materially impacted the operations of our Company.
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements at this time.
Recent Accounting Pronouncements
See Note 7 of the Notes to Consolidated Financial Statements.

ITEM 7A. | Quantitative and Qualitative Disclosures about Market Risk

Our short-term investments consist of cash, cash equivalents and overnight investments. As such we do not believe we are exposed to significant interest rate risk. The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest in highly liquid overnight money market investments. If a 10% change in interest rates were to have occurred on December 31, 2011, this change would not have had a material effect on the fair value of our investment portfolio as of that date.

ITEM 8. | Financial Statements and Supplementary Data

The information required by this item may be found beginning on page F-1 of this Annual Report On Form 10-K.

ITEM 9. | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

There were no disagreements with our current accountants on accounting and financial disclosures.
30

Table of Contents

ITEM 9A. | Disclosure Controls and Procedures

Controls and Procedures
We have carried out an evaluation, under the supervision of and with the participation of our management, including our Chief Executive Officer (CEO) and Chief Financial Officer (CFO), of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of December 31, 2011. Based upon that evaluation, our CEO and CFO concluded that, as of the end of that period, our disclosure controls and procedures are effective in providing reasonable assurance that (a) the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (b) such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Changes in Internal Control over Financial Reporting
Section 404 of the Sarbanes-Oxley Act of 2002 requires us to evaluate annually the effectiveness of our internal controls over financial reporting as of the end of each fiscal year, and to include a management report assessing the effectiveness of our internal control over financial reporting in all annual reports. There were no changes in our internal control over financial reporting during the year ended December 31, 2011 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Management’s Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act as a process designed by, or under the supervision of, a company’s principal executive and principal financial officers and effected by a company’s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that:

| ● | pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;

| ● | provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and

| ● | provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
31

Table of Contents
Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2011. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control — Integrated Framework. Based on our assessment, our management has concluded that, as of December 31, 2011, our internal control over financial reporting is effective based on those criteria.

ITEM 9B. | Other Information

None.
Part III

ITEM 10. | Directors, Executive Officers, and Corporate Governance

BACKGROUND AND EXPERIENCE OF DIRECTORS
When considering whether directors and nominees have the experience, qualifications, attributes or skills, taken as a whole, to enable the Board of Directors (“Board”) to satisfy its oversight responsibilities effectively in light of the Company’s business and structure, the Governance and Nominating Committee focused primarily on each person’s background and experience as reflected in the information discussed in each of the directors’ individual biographies set forth immediately above. We believe that our directors provide an appropriate mix of experience and skills relevant to the size and nature of our business. As more specifically described in such person’s individual biographies set forth below, our directors possess relevant and industry-specific experience and knowledge in the medical, engineering and business fields, as the case may be, which we believe enhances the Board’s ability to oversee, evaluate and direct our overall corporate strategy. The Governance and Nominating Committee annually reviews and makes recommendations to the Board regarding the composition and size of the Board so that the Board consists of members with the proper expertise, skills, attributes, and personal and professional backgrounds needed by the Board, consistent with applicable regulatory requirements.
The Governance and Nominating Committee believes that all directors, including nominees, should possess the highest personal and professional ethics, integrity, and values, and be committed to representing the long-term interests of our stockholders. The Governance and Nominating Committee will consider criteria including the nominee’s current or recent experience as a senior executive officer, whether the nominee is independent, as that term is defined in existing independence requirements of the NYSE Amex Market and the Securities and Exchange Commission, the business, scientific or engineering experience currently desired on the Board, geography, the nominee’s industry experience, and the nominee’s general ability to enhance the overall composition of the Board.
The Governance and Nominating Committee does not have a formal policy on diversity; however, in recommending directors, the Board and the Committee consider the specific background and experience of the Board members and other personal attributes in an effort to provide a diverse mix of capabilities, contributions and viewpoints which the Board believes enables it to function effectively as the Board of Directors of a company with our size and nature of business.
Our Board had consisted of nine (9) directors, however, on March 22, 2012, it was determined by our Board to reduce the number of directors to seven (7), and as a result, Gregory Konesky and Steven MacLaren voluntarily resigned from the Board.
Set forth below is information regarding the executive officers and directors of Bovie Medical Corporation as of March 28, 2012

Name |  | Position |  | Director Since
Andrew Makrides |  | Chairman of the Board and CEO |  | December 1982
J. Robert Saron |  | President Chief Sales and Marketing Officer and Director |  | August 1988
George Kromer, Jr. |  | Research Analyst and Director |  | October 1995
Michael Norman |  | Director |  | September 2004
August Lentricchia |  | Director |  | October 2007
Moshe Citronowicz |  | Sr. Vice President |  |
Gary D. Pickett |  | Chief Financial Officer, Treasurer, and Secretary |  |
Michael Geraghty |  | Director |  | March 2011
Lawrence J. Waldman |  | Director |  | March 2011

32

Table of Contents
Directors serve for one-year terms and are elected at the annual stockholders’ meeting.
Andrew Makrides, Esq. age 70, Chairman of the Board and CEO and member of the Board of Directors, received a Bachelor of Arts degree in Psychology from Hofstra University and a Juris Doctor Degree from Brooklyn Law School. He is a member of the Bar of the State of New York and practiced law from 1968 until joining Bovie Medical Corporation as a co-founder and Executive Vice President and director, in 1982. Mr. Makrides became President of the Company in 1985 and the CEO in December 1998 and has served as such until March 18, 2011 at which point he relinquished his position as President, but remained CEO. Mr. Makrides employment contract extends to January 31, 2014. Mr. Makrides has over 29 years of executive experience in the medical industry.
J. Robert Saron, age 59, President, Chief Sales and Marketing Officer and Director, holds a Bachelor degree in Social and Behavioral Science from the University of South Florida. From 1988 to present Mr. Saron has served as a director of the Company. Mr. Saron has previously served on two industry boards. He served as both director and president of the Health Care Manufacturing Management Council. In 2011 Mr. Saron received the Leonard Berke Achievement award for ethics, mentoring, marketing skill, industry knowledge, contributions to the industry and contributions to HMMC. He also served as a director of the Health Industry Distributors Association Education Foundation. Mr. Saron also received the Health Industry Distributors Association’s highest award in 2008, the Industry Award of Distinction. Mr. Saron’s employment contract extends to January 31, 2014. Mr. Saron brings over 23 years of executive marketing and distribution experience in the medical industry.
George Kromer, Jr., age 71, became a director on October 1, 1995. On January 1, 2006, Mr. Kromer accepted an employment position with Bovie Medical Corporation as research analyst for the company in which he still maintains his capacity as a director. Mr. Kromer had been writing for business publications since 1980. In 1976, he received a Master’s Degree in health administration from Long Island University. He was engaged as a Senior Hospital Care Investigator for the City of New York Health & Hospital Corporation from 1966 to 1986. He also holds a Bachelor of Science Degree from Long Island University’s Brooklyn Campus and an Associate in Applied Science Degree from New York City Community College, Brooklyn, New York. Mr. Kromer has over 30 years of business analyst experience with a specialty in the medical industry.
Moshe Citronowicz, age 59, Sr. Vice President, came to the United States in 1978, and has worked in a variety of manufacturing and high technology industries. In October 1993, Mr. Citronowicz joined the Company as Vice President of Operations and served as our Chief Operating Officer until November 2011. Currently, he is serving as the Director of Strategic Development.
Gary D. Pickett, CPA, age 60, holds an MBA from the University of Tampa, a BS degree in Accounting from Florida State University, and served five years as a field artillery officer in the United States Army. Mr. Pickett joined as controller of Bovie in March 2006 and became Chief Financial Officer in October 2006. During the five years prior to joining Bovie, Mr. Pickett held positions of Director of Financial Systems with Progress Energy Services of Raleigh, NC, Vice President and Controller of Progress Rail Services, a subsidiary of Progress Energy Services in Albertville, AL, each of which were non-affiliated with Bovie. He has had extensive experience in Sarbanes-Oxley implementation as well as GAAP accounting and SEC Reporting. Mr. Pickett’s employment contract extends to June 2013.
33

Table of Contents
Michael Norman, CPA age 54, joined Bovie in 2004. He manages the CPA firm, Michael Norman, CPA, PC since 1994 specializing in business financial planning as well as governmental and financial auditing. Mr. Norman is a member of the Nassau County Board of Assessors, Treasurer of the Don Monti Memorial Research Foundation and a Glen Cove City Councilman, all located on Long Island, New York. Mr. Norman provides the board with over 20 years of experience as a CPA and also serves as a member of our Audit Committee.
August Lentricchia, age 57, is presently employed by Freedom Tax and Financial Services Bohemia as a Registered Representative since 2001. He is also licensed as a Registered Representative and investment consultant of HD Vest Investment Services, a non-bank subsidiary of Wells Fargo and Company. He has also served as an investment consultant for Citibank. He received a BA degree from the University of Arizona in 1977 and has received a Masters degree in Education from Dowling College in 2004. Mr. Lentricchia has over 25 years of financial and investment experience and also serves on our Audit Committee.
Lawrence J. Waldman, age 65, has served as a director since March 2011 and is certified public accountant. Mr. Waldman is currently the Partner-in-Charge of the Commercial Audit Practice Development of the accounting firm Eisner-Amper, LLC. He has over thirty-five years of experience in public accounting, including twenty-five years experience as an audit partner serving a wide range of clients. Prior to joining Eisner-Amper, LLC, Mr. Waldman was the Partner-in-Charge of Commercial Audit Practice Development for Holtz Rubenstein Reminick, LLP. Mr. Waldman was the Managing Partner of the Long Island office of KPMG LLP from 1994 through 2006, the accounting firm where he started at in 1972. Mr. Waldman is also a member of the Board of Trustees of the Long Island Power Authority and serves on the Finance and Audit Committee of the Board of Trustees. He is currently the Treasurer of the Long Island Association as well as a member of its Board of Directors and Chairman of the Finance Committee. In addition, Mr. Waldman is a member of the Board of Directors and Treasurer of each of the Long Island Angel Network and the Advanced Energy research Center at Stony Brook University and a member of the Dean’s Advisory Board of the Hofstra University Frank G. Zarb School of Business. Mr. Waldman received his bachelor’s degree and MBA from Hofstra University where he is also an adjunct professor. Mr. Waldman also serves on our Audit Committee as its financial expert.
Michael Geraghty, age 64, has served as a director since March 2011and is the Executive Vice President of Global Sales at Optos, Inc., a developer and manufacturer of retinal imaging devices for screening, detection and diagnosis of eye related conditions. From 2005 through 2008, he was the President of International Sales at Gyrus Acmi where he first started in 2000 as Senior Vice President of Sales for Gyrus Medical. Prior to this, Mr. Geraghty was the Vice President of Sales and Marketing for Everest Medical, Inc. and before that was the Director of Marketing for Advanced Products at Arthrocare Corporation. Mr. Geraghty specializes in building independent direct sales teams in the medical device industry and has extensive domestic and international sales and marketing experience. He received his bachelor’s degree from St. Mary’s University and graduate degree in Executive Sales Management from the University of Minnesota.
34

Table of Contents
Independent Board Members
The Board currently has four independent members, Michael Norman, August Lentricchia, Michael Geraghty, and Lawrence Waldman, that meet the existing independence requirements of the NYSE Amex Market and the Securities and Exchange Commission. On March 22, 2012 it was determined by the Board that Gregory Konesky and Steven MacLaren, did not satisfy the independence criteria and therefore are no longer deemed independent board members. The Board also voted to reduce the number of directors constituting the full Board to seven (7) as a result, Mr. Konesky and Mr. MacLaren voluntarily resigned from the Board.
Board Leadership
The Board has no formal policy with respect to separation of the positions of Chairman and CEO or with respect to whether the Chairman should be a member of management or an independent director, and believes that these are matters that should be discussed and determined by the Board from time to time. Currently, Andrew Makrides serves as our Chairman and CEO. Given the fact that Mr. Makrides, in his capacity as our CEO is tasked with the responsibility of implementing our corporate strategy, we believe he is best suited for leading discussions, at the Board level, regarding performance relative to our corporate strategy, and this discussion accounts for a significant portion of the time devoted at our Board meetings.
Risk Management
The Board believes that risk management is an important component of the Company’s corporate strategy. While we assess specific risks at our committee levels, the Board, as a whole, oversees our risk management process, and discusses and reviews with management major policies with respect to risk assessment and risk management. The Board is regularly informed through its interactions with management and committee reports about risks we face in the course of our business. Finally, the Board believes the combined Chairman and CEO role assists us in our implementation of major policies addressing our risks. Our Audit Committee also takes an active role in risk assessment and risk management.
Audit Committee
The Audit Committee assists the Board in its general oversight of our financial reporting, internal controls, and audit functions, and is directly responsible for the appointment, compensation and oversight of the work of our independent registered public accounting firm. The Audit Committee reviews and discusses with management and our independent accountants the annual audited and quarterly financial statements (including the disclosures under “Management’s Discussion and Analysis of Financial Condition and Results of Operations”), reviews the integrity of the financial reporting processes, both internal and external, reviews the qualifications, performance and independence of our independent accountants, and prepares the Audit Committee Report included in this Annual Report on Form 10-K in accordance with rules and regulations of the Securities and Exchange Commission. The Audit Committee has the power to investigate any matter brought to its attention within the scope of its duties. It also has the authority to retain counsel and advisors to fulfill its responsibilities and duties. The Audit Committee also acts as a qualified legal compliance committee.
Our Audit Committee consists of three independent members of the Board of Directors, Michael Norman CPA, August Lentricchia, and Lawrence Waldman, CPA. As a smaller reporting company, we are required to have at least two independent members comprising our Audit Committee in accordance with Rule 10A-3 of the Securities Exchange Act of 1934 and the rules of the NYSE Amex Exchange. During 2011 Michael Norman served as Chairman of the Audit Committee and Lawrence Waldman served as the Audit Committee financial expert.
35

Table of Contents
Effective March 22, 2012, Lawrence Waldman, CPA will serve as Chairman and as the Audit Committee financial expert. The Audit Committee meets as often as it determines necessary but not less frequently than once every fiscal quarter.
AUDIT COMMITTEE REPORT
Our Audit Committee is composed of “independent” directors, as determined in accordance with Rule 10A-3 of the Securities Exchange Act of 1934. The Audit Committee operates pursuant to a written charter adopted by the Board of Directors.
As described more fully in its charter, the purpose of the Audit Committee is to assist the Board of Directors with its oversight responsibilities regarding the integrity of our financial statements, our compliance with legal and regulatory requirements, assessing the independent registered public accounting firm’s qualifications, independence and performance for us. Management is responsible for preparation, presentation and integrity of our financial statements as well as our financial reporting process, accounting policies, internal audit function, internal accounting controls and disclosure controls and procedures. The independent registered public accounting firm is responsible for performing an independent audit of our consolidated financial statements in accordance with generally accepted auditing standards and to issue a report thereon. The Audit Committee’s responsibility is to monitor and oversee these processes. The following is the Audit Committee’s report submitted to the Board of Directors for 2011.
The Audit Committee has:

| ● | reviewed and discussed our audited financial statements with management and Kingery & Crouse, P. A., the independent public accountants

| ● | discussed with Kingery & Crouse, P.A. matters required to be discussed by SEC and PCAOB requirements, as may be modified or supplemented; and

| ● | received from Kingery & Crouse, P. A. the written disclosures and the letter regarding their independence as required by PCAOB Rule 3526, Communication with Audit Committees Concerning Independence, as may be modified or supplemented, and discussed the auditors’ independence with them.

In addition, the Audit Committee has met separately with management and with Kingery & Crouse, P. A.
Based on the review and discussions referred to above, the Audit Committee recommended to the Board of Directors that the audited financial statements be included in our Annual Report on Form 10-K for the year ended December 31, 2011 for filing with the Securities and Exchange Commission.
The foregoing Audit Committee Report shall not be deemed incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, and shall not otherwise be deemed filed under these acts, except to the extent we specifically incorporate by reference into such filings.
Governance and Nominating Committee
The Governance and Nominating Committee is responsible for matters relating to the corporate governance of our company and the nomination of members of the board and committees thereof. During 2011, our Governance and Nominating Committee consisted of four independent members of the Board of Directors, Michael Norman CPA, August Lentricchia, Steven MacLaren who served as Chairman, and Lawrence Waldman.
Effective March 22, 2012, our Governance and Nominating Committee will consist of three independent members of the Board of Directors, Michael Norman CPA who serves as Chairman, August Lentricchia, and Michael Geraghty. The Governance and Nominating Committee meets as often as it determines necessary, but not less than once a year.
36

Table of Contents
Compensation Committee
The Compensation Committee is responsible for overseeing our compensation and employee benefit plans (including those involving the issuance of our equity securities) and practices, including formulating, evaluating, and approving the compensation of our executive officers and reviewing and recommending to the full Board of Directors the compensation of our Chief Executive Officer. During 2011, our Compensation Committee consisted of four independent members of the Board of Directors, Michael Norman CPA, August Lentricchia, Steven MacLaren who served as Chairman, and Michael Geraghty.
Effective March 22, 2012, our Compensation Committee consists of three independent members of the Board of Directors, Michael Norman CPA, August Lentricchia who serves as Chairman, and Lawrence Waldman. The Compensation Committee meets as often as it determines necessary, but not less than once a year.
In 2011, the Compensation Committee did not engage any independent consultants.
Code of Ethics
On March 30, 2004 Bovie adopted a Code of Ethics for executive employees.
A copy of the code of ethics which expressly includes the CEO and CFO, will be provided without charge to any person upon request to Bovie Medical Corporation, 734 Walt Whitman Road, Melville, NY 11747, Attn: Andrew Makrides.

ITEM 11. | Executive Compensation Discussion and Analysis

General Compensation Philosophy
The primary objective of our compensation program for employees, including our compensation program for executive officers, is to attract, retain, and motivate qualified individuals and reward them in a manner that is fair to all stockholders. We strive to provide incentives for every employee that rewards them for their contribution to the Company.
Our compensation program is designed to be competitive with other employment opportunities and to align the interests of all employees, including executive officers, with the long-term interests of our stockholders. Historically, for our executive officers, we link a much higher percentage of total compensation to incentive compensation such as stock based compensation than we do for other employees.
With these objectives in mind, our Board has built executive and non-executive compensation programs that consist of two principal elements - base salary and grants of stock options and/or shares of restricted stock.
Compensation Program
Base Salary
Bovie pays base salaries to its Named Executive Officers (as defined below) in order to provide a consistent, minimum level of pay that sustained individual performance warrants. We also believe that a competitive annual base salary is important to attract and retain an appropriate caliber of talent for each position over time.
The annual base salaries of our Named Executive Officers are determined by our Compensation Committee and approved by the Board of Directors. All salary decisions are based on each Named Executive Officer's level of responsibility, experience and recent and past performance, as determined by the Compensation Committee. The Compensation Committee does not benchmark its base salaries in any way, nor do they presently employ the services of a compensation consultant.
37

Table of Contents
Stock Options
The second component of executive compensation is equity grants which have mainly come in the form of stock options. We believe that equity ownership in our Company is important to provide our Named Executive Officers with long-term incentives to better align interests of executives with the interests of stockholders and build value for Bovie stockholders. In addition, the equity compensation is designed to attract and retain the executive management team. Stock options have value only if the stock price increases over time and, therefore, provide executives with an incentive to build Bovie's value. This characteristic ensures that the Named Executive Officers have a meaningful portion of their compensation tied to future stock price increases and rewards management for long-term strategic planning through the resulting enhancement of the stock price.
Stock option awards to Named Executive Officers are entirely discretionary. The CEO and Director of Strategic Development recommend to the Compensation Committee which individuals should be awarded stock options. The Compensation Committee considers the prior contribution of these individuals and their expected future contributions to the growth of Bovie then formulates and presents the recommended allocation of stock option awards to the Board of Directors for approval. The Board of Directors approves or, if necessary, modifies the Committee’s recommendations.
Perquisites and Other Benefits
Our Named Executive Officers are eligible for the same health and welfare programs and benefits as the rest of its employees in their respective locations. In addition, our CEO and Chief Sales and Marketing Officer each receive an automobile allowance of approximately $6,300 per year.
Our Named Executive Officers are entitled to participate in and receive employer contributions to Bovie's 401(k) Savings Plan. However, during January of 2009 management made the decision to suspend the employer 401(k) match, which as of December 31, 2011 has not been re-instated. For more information on employer contributions to the 401(k) Savings Plan see the Summary Compensation Table and its footnotes.
Tax and Accounting Considerations.
Section 162(m) of the Internal Revenue Code of 1986, as amended (the “Code”), places a limit of $1,000,000 on the amount of compensation that we may deduct as a business expense in any year with respect to each of our most highly paid executives unless, among other things, such compensation is performance-based and has been approved by stockholders. The non-performance-based compensation paid to our executive officers for the 2011 fiscal year did not exceed the $1 million limit per executive officer. Accounting considerations also play an important role in the design of our executive compensation program. Accounting rules, such as FASB ASC Topic 718-10-10, Share-Based Payment, require us to expense the cost of our stock option grants which reduces the amount of our reported profits. Because of option expensing and the impact of dilution on our stockholders, we pay close attention to the number and value of the shares underlying stock options we grant.
38

Table of Contents
Compensation of Named Executive Officers
The following table sets forth the compensation paid to each of Bovie’s Named Executive Officers for the three years ended December 31, 2011 for services to our Company in all capacities:
Summary Compensation Table

Name And Principal Position |  | Year |  |  | Salary ($) |  |  | Bonus ($) |  |  | Stock Awards ($) |  |  | Option Awards ($) * |  |  | Non- Equity Incentive Plan Compensa- tion Earnings ($) |  |  | Change in Pension Value and Nonquali- fied Deferred compen- sation Earnings ($) |  |  | All Other Compen- Sation ($) |  |  | Total ($) |
(a) |  | (b) |  |  | (c) |  |  | (d) |  |  | (e) |  |  | (f) |  |  | (g) |  |  | (h) |  |  | (i) |  |  | (j) |
Andrew Makrides |  |  | 2011 |  |  | $ | 205,252 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  | $ | 18,823 | (9) |  | $ | 224,075 |
CEO, |  |  | 2010 |  |  | $ | 205,252 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 19,542 | (6) |  | $ | 224,794 |
Chairman of the Board |  |  | 2009 |  |  | $ | 205,252 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 18,463 | (1) |  | $ | 223,715 |
Gary D. |  |  | 2011 |  |  | $ | 109,331 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  | $ | 374 | (15) |  | $ | 109,705 |
Pickett |  |  | 2010 |  |  | $ | 101,970 |  |  |  | 0 |  |  |  | 0 |  |  | $ | 9,800 | (7) |  |  | 0 |  |  |  | 0 |  |  | $ | 374 | (10) |  | $ | 112,144 |
CFO, Treasurer, Secretary |  |  | 2009 |  |  | $ | 101,186 |  |  |  | 0 |  |  |  | 0 |  |  | $ | 43,750 | (8 ) |  |  | 0 |  |  |  | 0 |  |  | $ | 483 | (2) |  | $ | 145,419 |
J. Robert |  |  | 2011 |  |  | $ | 290,651 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  | $ | 19,321 | (12) |  | $ | 309,972 |
Saron |  |  | 2010 |  |  | $ | 290,651 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  | $ | 9,159 | (11) |  | $ | 299,810 |
President, Chief Sales and Marketing Officer and Director |  |  | 2 009 |  |  | $ | 290,651 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  | $ | 10,972 | (3) |  | $ | 301,623 |
Moshe |  |  | 2011 |  |  | $ | 212,199 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  | $ | 16,534 | (14) |  | $ | 228,733 |
Citronowicz |  |  | 2010 |  |  | $ | 213,549 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  | $ | 15,327 | (13) |  | $ | 228,876 |
Sr. Vice President |  |  | 2009 |  |  | $ | 213,549 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  | $ | 14,069 | (4) |  | $ | 227,618 |
Leonard Keen |  |  | 2011 |  |  | $ | 188,324 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  | $ | 479 | (17) |  | $ | 188,803 |
V.P.& General Counsel (**) |  |  | 2010 |  |  | $ | 151,442 | (16) |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  | $ | 82,580 | (5) |  | $ | 234,022 |

* These columns represent the grant date fair value of the awards as calculated in accordance with FASB ASC 718 (Stock Compensation). Pursuant to SEC rule changes effective February 28, 2010, we are required to reflect the total grant date fair values of the option grants in the year of grant, rather than the portion of this amount that was recognized for financial statement reporting purposes in a given fiscal year which was required under the prior SEC rules, resulting in a change to the amounts reported in prior Annual Reports.
** Mr. Keen was terminated as of December 9, 2011.
(1) This amount includes: $155 of employer contributions under the Bovie Employee 401(k) savings plan; car allowance of $6,310; life insurance premiums of $431; and health insurance premiums of $11,567.
(2) This amount includes: $118 of employer contributions under the Bovie Employee 401(k) savings plan; and life insurance premiums of $365.
39

Table of Contents
(3) This amount includes: $336 of employer contributions under the Bovie Employee 401(k) savings plan; car allowance of $6,310; life insurance premiums of $470; and health insurance premiums of $3,856.
(4) This amount includes: $242 of employer contributions under the Bovie Employee 401(k) savings plan; car allowance of $6,310; life insurance premiums of $470; and health insurance premiums of $7,047.
(5) This amount includes: life insurance premiums of $280; and relocation and housing expenses of $82,300.
(6) This amount includes: car allowance of $6,310; life insurance premiums of $440; and health insurance premiums of $12,792.
(7) In 2010 a total of 10,000 options were granted to Mr. Pickett on July 8, 2010 with a fair value of $0.98 per option.
(8) On October 26, 2009 a total of 12,500 options were granted to Mr. Pickett with a fair value of $3.50 per option.
(9) This amount includes: car allowance of $6,309; life insurance premiums of $441; and health insurance premiums of $12,073.
(10) This amount includes life insurance premiums of $374.
(11) This amount includes: car allowance of $6,310; life insurance premiums of $479; and health insurance premiums of $2,370.
(12) This amount includes: car allowance of $6,309; life insurance premiums of $479; and health insurance premiums of $12,533.
(13) This amount includes: car allowance of $6,310; life insurance premiums of $479; and health insurance premiums of $8,538.
(14) This amount includes: car allowance of $5,824; life insurance premiums of $479; and health insurance premiums of $10,231.
(15) This amount includes: life insurance premiums of $374.
(16) This amount represents a partial year as Mr. Keen was hired on March 2, 2010.
(17) This amount includes: life insurance premiums of $479.
Employment Agreements and Potential Payments Upon Termination or Change in Control
At December 31, 2011, employment contracts with Mr. Makrides and Mr. Saron, which are set to expire in January 2014, contain an automatic extension for a period of one year unless we provide the executives with appropriate written notice pursuant to the contracts. The employment agreements provide, among other things, that the executive may be terminated as follows:

| (a) | Upon the death of the executive, in which case the executive’s estate shall be paid the basic annual compensation due the employee pro-rated through the date of death.

| (b) | By the resignation of the executive at any time upon at least thirty (30) days prior written notice to Bovie in which case Bovie shall be obligated to pay the employee the basic annual compensation due him pro-rated to the effective date of termination.

| (c) | By Bovie, “for cause” if during the term of the employment agreement the employee violates the non-competition provisions of his employment agreement, or is found guilty in a court of law of any crime of moral turpitude in which case the contract would be terminated and provisions for future compensation forfeited.

40

Table of Contents

| (d) | By Bovie, without cause, with the majority approval of the Board of Directors, for Mr. Makrides and Mr. Saron at any time upon at least thirty (30) days prior written notice to the executive. In this case Bovie shall be obligated to pay the executive compensation in effect at such time, including all bonuses, accrued or prorated, and expenses up to the date of termination. Thereafter for Messrs Makrides, and Saron, for the period remaining under the contract, Bovie shall pay the executive the salary in effect at the time of termination payable weekly until the end of their contract.

| (e) | If Bovie fails to meet its obligations to the executive on a timely basis, or if there is a change in the control of Bovie, the executive may elect to terminate his employment agreement. Upon any such termination or breach of any of its obligations under the employment agreement, Bovie shall pay the executive a lump sum severance equal to three times the annual salary and bonus in effect the month preceding such termination or breach as well as any other sums which may be due under the terms of the employment agreement up to the date of termination.

We have an employment contract with Mr. Pickett to serve as Chief Financial Officer which has a current expiration date of June 2013. In the event of a change of control, the contract provides that Mr. Pickett will receive salary and bonus in effect up to the date of the remaining portion of the contract.
There are no other employment contracts that have non-cancelable terms in excess of one year.
Grants of Plan-Based Awards
There were no incentive awards granted to Named Executive Officers during 2011.
Options Exercises During Fiscal 2011
There were no options exercised during the year ended December 31, 2011 by the Named Executive Officers.
Outstanding Equity Awards
The following table presents information with respect to each unexercised stock option held by Bovie's Named Executive Officers as of December 31, 2011:

|  | Outstanding Equity Awards at 12/31/11
Name |  | # of Securities Underlying Unexercised Options (# Exercisable) |  |  | # of Securities Underlying Unexercised Options (# Unexercisable) |  |  | Option Exercise Price ($/sh) |  | Option Expiration Date 10 Years After Grant Date
Andrew Makrides |  |  | 25,000 |  |  |  | -- |  |  |  | 3.25 |  | 9/29/2013
|  |  | 25,000 |  |  |  | -- |  |  |  | 2.13 |  | 9/23/2014
|  |  | 25,000 |  |  |  | -- |  |  |  | 2.25 |  | 5/5/2015
J. Robert Saron |  |  | 12,500 |  |  |  | -- |  |  |  | 3.25 |  | 9/29/2013
|  |  | 12,500 |  |  |  | -- |  |  |  | 2.13 |  | 9/23/2014
|  |  | 12,500 |  |  |  | -- |  |  |  | 2.25 |  | 5/5/2015
Gary Pickett |  |  | 20,000 |  |  |  | 11,429 |  |  |  | 8.66 |  | 1/12/2017
|  |  | 5,000 |  |  |  | 2,857 |  |  |  | 7.10 |  | 3/29/2017
|  |  | 12,500 |  |  |  | 10,714 |  |  |  | 8.32 |  | 10/26/2019
|  |  | 10,000 |  |  |  | 10,000 |  |  |  | 2.46 |  | 7/12/2020
Leonard Keen | (1) |  | 14,286 |  |  |  | 14,286 |  |  |  | 7.45 |  | 3/2/2020

(1) On December 9, 2011 Mr. Keen was terminated which included forfeiture of stock options. Mr. Keen has commenced litigation against the Company claiming among other things, that he is entitled to retain his stock options and, that the vesting of such stock options should have been accelerated upon his termination. The Company disputes Mr. Keen’s claims.
41

Table of Contents
Compensation of Non-Employee Directors
The following is a table showing the director compensation for the year ended December 31, 2011:

Name |  | Fees Earned Or Paid In Cash ($) |  |  | Stock Awards ($) |  |  | Option Awards ($) *** |  |  | Non-Equity Incentive Plan Compensa- tion ($) |  |  | Change in Pension Value and Nonqualified Deferred Compensation Earnings ($) |  |  | All Other Compensa- tion ($) |  |  | Total ($) |
(a) |  | (b) |  |  | (c) |  |  | (d) |  |  | (e) |  |  | (f) |  |  | (g) |  |  | (h) |
Lawrence Waldman |  | $ | 3,500 |  |  |  | 0 |  |  | $ | 10,125 | (1) |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  | $ | 13,625 |
Michael Norman |  | $ | 3,500 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  | $ | 3,500 |
August Lentricchia |  | $ | 3,500 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  | $ | 3,500 |
Steven MacLaren |  | $ | 3,500 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  | $ | 3,500 |
Michael Geraghty |  | $ | 2,500 |  |  |  | 0 |  |  | $ | 10,125 | (1) |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  | $ | 12,625 |
Gregory Konesky |  | $ | 3,500 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  |  | 0 |  |  | $ | 3,500 |

*** These columns represent the grant date fair value of the awards as calculated in accordance with FASB ASC 718 (Stock Compensation). Pursuant to SEC rule changes effective February 28, 2010, we are required to reflect the total grant date fair values of the option grants in the year of grant, rather than the portion of this amount that was recognized for financial statement reporting purposes in a given fiscal year which was required under the prior SEC rules, resulting in a change to the amounts reported in prior Annual Reports.
(1) 7,500 ten year stock options with an exercise price of $2.81 and calculated option fair value of $1.35 were granted to these new board members upon them joining the Board.
Directors' compensation is determined by the Board of Directors based upon recommendations from the Compensation Committee. The Board periodically grants directors stock options in order to assure that they have proper incentives and an opportunity for an ownership interest in common with other stockholders. During 2011, since there were limited stock options available, the Board decided to add cash payments as a compensation method. Independent board members receive $500 per month for attendance in any and all telephonic meetings for that month and $1,000 per month for attendance at any in person board meetings for that month.
Our Board of Directors presently consists of J. Robert Saron, Andrew Makrides, George Kromer, Jr., Michael Norman, August Lentricchia, Lawrence Waldman and Michael Geraghty.
In 2003, the Board of Directors adopted and stockholders approved Bovie’s 2003 Executive and Employee Stock Option Plan covering a total of 1,200,000 shares of common stock issuable upon exercise of options to be granted under the Plan. In 2001, the Board of Directors adopted the 2001 Executive and Employee Stock Option Plan which reserved for issuance 1,200,000 stock options.
42

Table of Contents
On October 30, 2007, stockholders approved and the Board of Directors adopted an amendment to the 2003 Executive and Employee Stock Option Plan to increase the maximum aggregate number of shares of common stock reserved for issuance under the 2003 Plan from 1.2 million shares (already reserved against outstanding options) to 1.7 million shares, or an increase of 500,000 shares of common stock for future issuance pursuant to the terms of the plan. Except for the increase in the number of shares covered by the plan, the plan remains otherwise unchanged from its present status. In 2011, the Board of Directors granted 25,000 options to purchase a like number of shares of common stock.
There have been no changes in the pricing of any options previously or currently awarded.
COMPENSATION COMMITTEE REPORT
Our Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis contained in this Annual Report on Form 10-K with management. Based on our Compensation Committee’s review of and the discussions with management with respect to the Compensation Discussion and Analysis, our Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in our Proxy Statement and in this Annual Report on Form 10-K for the fiscal year ended December 31, 2011 for filing with the SEC. The members of our Compensation Committee are Steven MacLaren, Michael Norman (CPA), Michael Geraghty and August Lentricchia.

ITEM 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Equity Compensation Plan Information
See “ITEM 5. Market for Registrant’s Common Equity and Related Stockholder Matters”.
Security Ownership of Certain Beneficial Owners
The following table sets forth certain information as of March 28, 2012, with respect to the beneficial ownership of the Company’s common stock by its executive officers, directors, all persons known by the Company to be the beneficial owners of more than 5% of its outstanding shares and by all officers and directors as a group.

| Number of Shares |  |
|  |  | Nature of | Percentage of
Name and Address | Title | Owned (i) | Ownership | Ownership (i)
RENN Universal Growth Investment Trust | Common | 1,925,342(xvi) | Beneficial | 10.8%
Frost National Bank 8201 Preston Road, Ste 540 Dallas, Texas 75206 |  |  |  |
Andrew Makrides 734 Walt Whitman Road Melville, NY 11746 | Common | 674,213(ii) | Beneficial | 3.8%
George Kromer P.O. Box 188 Farmingville, NY 11738 | Common | 336,508(iii) | Beneficial | 1.9%

43

Table of Contents

J. Robert Saron 5115 Ulmerton Rd. Clearwater, FL 33760 | Common | 424,819(iv) | Beneficial | 2.4%
Mike Norman 734 Walt Whitman Road Melville, NY 11746 | Common | 78,572(vii) | Beneficial | 0.4%
Moshe Citronowicz 5115 Ulmerton Rd. Clearwater, FL 33760 | Common | 406,504 (v) | Beneficial | 2.3%
Gary Pickett 5115 Ulmerton Rd. Clearwater, FL 33760 | Common | 22,857 (ix) | Beneficial | 0.1%
August Lentricchia 734 Walt Whitman Road Melville, NY 11746 | Common | 10,172 (xi) | Beneficial | 0.1%
Lawrence Waldman 734 Walt Whitman Road Melville, NY 11746 | Common | 1,071 (xiv) | Beneficial | 0.0%
Michael E. Geraghty 734 Walt Whitman Road Melville, NY 11746 | Common | 1,071 (xv) | Beneficial | 0.0%
Officers and Directors as a group (9 Persons) |  | 1,955,787(xiii) |  | 9.9%

(i) Based on 17,768,198 outstanding shares of Common Stock and 1,526,346 outstanding options to acquire a like number of shares of Common Stock as of March 28, 2012, of which officers and directors owned a total of 382,500 options and 1,656,144 shares at December 31, 2011. We have calculated the percentages on the basis of the amount of outstanding securities plus, for each person or group, any securities that person or group has current or future right to acquire pursuant to options, warrants, conversion privileges or other rights.
(ii) Includes 599,213 shares and 75,000 ten year options owned by Mr. Makrides to purchase shares of Common Stock of the Company. Exercise prices for his options range from $2.13 for 25,000 shares to $3.25 for 25,000 shares.
(iii) Includes 261,508 shares and 75,000 ten year options owned by Mr. Kromer, exercisable at prices ranging from $2.13 per share for 25,000 shares, and $3.25 per share for 25,000 shares.
(iv) Includes 387,319 shares and 37,500 ten year options owned by Mr. Saron, exercisable at prices ranging from $2.13 per share for 12,500 shares, and $3.25 per share for 12,500 shares.
(v) Includes 406,504 shares owned by Mr. Citronowicz.
44

Table of Contents
(vii) Includes 78,572 vested ten year options out of a total 105,000 ten year options owned by Mr. Norman exercisable at prices ranging from $2.13 for 25,000 shares to $8.66 for 12,500 shares.
(ix) Includes 22,857 vested ten year options out of a total 47,500 ten year options owned by Mr. Pickett exercisable at prices ranging from $2.46 for 10,000 shares to $8.66 for 20,000 shares. These options vest over a 7 year period.
(xi) Includes 1,600 Shares owned by Mr. Lentricchia and 8,572 vested ten year options out of a total 27,500 ten year options issued to Mr. Lentricchia exercisable at prices ranging from $2.46 for 10,000 shares to $8.32 for 10,000 shares. These options vest over a period of 7 years.
(xiii) Includes 299,643 vested ten year options out of a total of 382,500 ten year outstanding options and 1,656,144 shares owned by all Executive Officers and directors as a group. The last date options can be exercised is March 28, 2021.
(xiv) Includes 1,071 vested ten year options out of a total of 7,500 options issued March 18, 2011 exercisable at a price of $2.81. These options vest over a period of 7 years.
(xv) Includes 1,071 vested ten year options out of a total of 7,500 options issued March 18, 2011 exercisable at a price of $2.81. These options vest over a period of 7 years.
(xvi) RENN Capital Group, Inc. ("RENN") is an investment advisor to RENN Universal Growth Investment Trust ("RUGIT"), RENN Global Entrepreneurs Fund Inc. ("RENN Global") and RENN Entrepreneurial Fund Ltd. ("RENN Entrepreneurial") and has shared voting power over these shares. The shares of common stock are owned of record as follows: RUGIT - 1,400,000; RENN Global - 402,500; RENN Entrepreneurial - 122,842. Russell Cleveland is the President of each of RENN, RUGIT, RENN Global and RENN Entrepreneurial and may be deemed to be the beneficial owner of the shares of common stock. Mr. Cleveland disclaims any such beneficial ownership.
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Securities Exchange Act of 1934 requires our officers and directors, and persons who own more than ten percent of a registered class of our equity securities, to file reports of ownership and changes in ownership with the Securities and Exchange Commission. Officers, directors and greater than ten-percent shareholders are required by SEC regulation to furnish us with copies of all Section 16(a) forms they file.
Based solely on a review of the copies of such forms furnished to us, we believe that during the year ended December 31, 2011 all officers, directors and ten percent beneficial owners who were subject to the provisions of Section 16(a) complied with all of the filing requirements during the year.

ITEM 13. | Certain Relationships and Related Transactions, and Director Independence

Certain Relationships and Related Transactions
Our policy is that employees, non-employees, and third parties must obtain authorization from the appropriate department executive manager, for any business relationship or proposed business transaction in which they or an immediate family member has a direct or indirect interest, or from which they or an immediate family member may derive a personal benefit (a “related party transaction”). The maximum dollar amount of related party transactions that may be approved as described above in this paragraph in any calendar year is $120,000. Any related party transactions that would bring the total value of such transactions to greater than $120,000 must be referred to the Audit Committee to determine the procedure for approval, and then have the recommendations presented to the Board of Directors for approval.
45

Table of Contents
Steven MacLaren, a director of Bovie, is president and a shareholder of Ronin Consulting Group, Inc., a company which provides various financial and analytical project consulting services to Bovie. Ronin Consulting Group, Inc. was paid consulting fees approximating $80,000, $80,000 and $99,800 during 2011, 2010 and 2009, respectively. On March 27, 2012, Mr. MacLaren resigned from the Board.
Greg Konesky a director of Bovie provided consulting services related to research and development of certain products and was paid consulting fees approximating $30,000 during 2011, 2010, and 2009, respectively. On March 23, 2012 Mr. Konesky resigned from the board.
A relative of Bovie’s Director of Strategic Development is considered a related party. Arik Zoran, is a consultant of the Company doing business as AR Logic, Inc., which is a consulting firm owned by Arik Zoran, Mr. Citronowicz’s brother. During January 2011, we entered into a three year consulting services agreement with AR Logic that provides for a monthly retainer for engineering support for our existing generator product line and a separate hourly based fee structure for additional consulting related to new product lines. The consulting rates are consistent with rates of an arms length transaction. AR Logic was paid consulting fees of approximately $171,700 during 2011. Previous to 2011, Mr. Zoran was an employee in charge of the engineering department and was paid inclusive of benefits $192,014, and $188,363 for 2010 and 2009, respectively.
A second relative of Bovie’s Director of Strategic Development is considered a related party. Yechiel Tsitrinovich is also a brother of Mr. Citronowicz, and acts as a consultant to the Company related to research and development of certain products. Mr. Tsitrinovich has a royalty contract with us related to the creation and design of a proprietary technology that is used in some of our generators. Mr. Tsitrinovich was paid a combination of consulting fees and royalties on previous product designs approximating $85,310, $65,654, and $82,558 for 2011, 2010, and 2009, respectively.
Related party transactions and contracts are reviewed by our independent audit committee.
Independent Board Members
The Board currently has four independent members, Michael Norman, August Lentricchia, Michael Geraghty, and Lawrence Waldman, that meet the existing independence requirements of the NYSE Amex Market and the Securities and Exchange Commission. On March 22, 2012 it was determined by the Board that Gregory Konesky and Steven MacLaren, did not satisfy the independence criteria for board membership and therefore are no longer deemed independent board members. On the same date, the Board also voted to reduce the number of directors constituting the full Board from nine (9) to seven (7) effective on the date of our next annual meeting of stockholders. As a result, Mr. Konesky and Mr. MacLaren voluntarily resigned from the Board.

ITEM 14. | Principal Accountant Fees and Services

The following table sets forth the aggregate fees billed to us for fiscal years ended December 31, 2011 and 2010 by our current accountants, Kingery & Crouse P.A. (in thousands) :

|  | 2011 |  |  | 2010 |
Audit Fees (1) |  | $ | 135 |  |  | $ | 165 |
Non-Audit Fees: |  |  |  |  |  |  |  |
Related Fees(2) |  |  | 11 |  |  |  | 11 |
Tax Fees(3) |  |  |  |  |  |  | - |
All other Fees(4) |  |  | - |  |  |  | 3 |
Total Fees billed |  | $ | 146 |  |  | $ | 179 |

46

Table of Contents
(1) Audit fees consist of fees billed for professional services rendered for the audit of Bovie’s annual financial statements and reviews of its interim consolidated financial statements included in quarterly reports and other services related to statutory and regulatory filings or engagements.
(2) Related fees consist of fees billed for assurance and related services that are reasonably related to the performance of the audit or reviews of Bovie’s consolidated financial statements and are not reported under “Audit Fees”.
(3) Tax fees consist of fees billed for professional services rendered for tax compliance and tax advice (domestic and international). These services include assistance regarding federal, state and international tax compliance, acquisitions and international tax planning.
(4) All other fees consist of fees for products and services other than the services reported above.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in Melville, New York on March 29, 2012.

| Bovie Medical Corporation
| By: /s/ ANDREW MAKRIDES
| Andrew Makrides
| President
| Chairman of the Board

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Name |  | Title |  | Date
Principal Executive Officer: |  |  |  |
/s/ ANDREW MAKRIDES Andrew Makrides |  | Chief Executive Officer and Chairman of the Board |  | March 29, 2012
Principal Financial Officer: |  |  |  |
/s/ GARY D. PICKETT Gary D. Pickett |  | Chief Financial Officer, Treasurer, and Secretary |  | March 29, 2012
Directors: |  |  |  |
/s/ J. ROBERT SARON J. Robert Saron |  | President, Chief Sales and Marketing Officer and Director |  | March 29, 2012

47

Table of Contents

/s/ GEORGE KROMER George Kromer |  | Director |  | March 29, 2012
/s/ MICHAEL NORMAN Michael Norman |  | Director |  | March 29, 2012
/s/ AUGUST LENTRICCHIA August Lentricchia |  | Director |  | March 29, 2012
/s/ LAWRENCE J. WALDMAN Lawrence J. Waldman |  | Director |  | March 29, 2012
/s/ MICHAEL GERAGHTY Michael Geraghty |  | Director |  | March 29, 2012

PART IV

ITEM 15. | Exhibits and Financial Statement Schedules

The financial statements and exhibits filed as part of this annual report on Form 10-K are provided below:

ITEM 15A. | Financial Statements

BOVIE MEDICAL CORPORATION INDEX TO FINANCIAL STATEMENTS | Page
Report of Independent Registered Certified Public Accounting Firm | F-1
Consolidated Balance Sheets at December 31, 2011 and 2010 | F-2
Consolidated Statements of Operations for the years ended December 31, 2011, 2010 and 2009 | F-4
Consolidated Statements of Stockholders' Equity and Comprehensive Income (Loss) for the years ended December 31, 2011, 2010 and 2009 | F-5
Consolidated Statements of Cash Flows for the years ended December 31, 2011, 2010 and 2009 | F-6
Notes to Consolidated Financial Statements | F-7

48

Table of Contents
[LETTERHEAD OF KINGERY & CROUSE, P.A.]
REPORT OF INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of Bovie Medical Corporation:
We have audited the accompanying consolidated balance sheets of Bovie Medical Corporation (the “Company”), as of December 31, 2011 and 2010, and the related consolidated statements of operations, stockholders’ equity and comprehensive income (loss), and of cash flows for the years ended December 31, 2011, 2010 and 2009. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financials based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States of America). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no opinion. Our audits included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2011 and 2010, and the results of its operations and its cash flows for the years ended December 31, 2011, 2010 and 2009 in conformity with accounting principles generally accepted in the United States of America.
Kingery & Crouse, P.A s/s
Tampa, FL
March 29, 2012
F-1

Table of Contents
BOVIE MEDICAL CORPORATION
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2011 AND 2010
(in thousands)

|  | 2011 |  |  | 2010 |
ASSETS |  |  |  |  |  |
Current assets: |  |  |  |  |  |
Cash and cash equivalents |  | $ | 4,880 |  |  | $ | 3,827 |
Trade accounts receivable, net |  |  | 2,216 |  |  |  | 2,114 |
Inventories, net |  |  | 8,178 |  |  |  | 7,605 |
Prepaid expenses and other current assets |  |  | 710 |  |  |  | 966 |
Deferred income tax assets, net |  |  | 500 |  |  |  | 400 |
Total current assets |  |  | 16,484 |  |  |  | 14,912 |
Property and equipment, net |  |  | 7,176 |  |  |  | 7,432 |
Brand name and trademark |  |  | 1,510 |  |  |  | 1,510 |
Purchased technology, net |  |  | 752 |  |  |  | 1,598 |
License rights, net |  |  | 26 |  |  |  | 90 |
Deferred income tax assets, net |  |  | 1,509 |  |  |  | 1,533 |
Other assets |  |  | 783 |  |  |  | 711 |
Total Assets |  | $ | 28,240 |  |  | $ | 27,786 |

The accompanying notes are an integral part of the consolidated financial statements.
F-2

Table of Contents
BOVIE MEDICAL CORPORATION
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2011 AND 2010
(Continued) (in thousands)
LIABILITIES AND STOCKHOLDERS' EQUITY

LIABILITIES |  | 2011 |  |  | 2010 |
Current liabilities: |  |  |  |  |  |
Accounts payable |  | $ | 1,085 |  |  | $ | 951 |
Accrued payroll |  |  | 88 |  |  |  | 101 |
Accrued vacation |  |  | 149 |  |  |  | 169 |
Current portion of bonds payable to bank |  |  | 130 |  |  |  | 140 |
Current portion of settlement |  |  | 587 |  |  |  | -- |
Accrued and other liabilities |  |  | 350 |  |  |  | 444 |
Total current liabilities |  |  | 2,389 |  |  |  | 1,805 |
Bonds payable, net of current portion |  |  | 3,420 |  |  |  | 3,600 |
Settlement liability, net of current portion |  |  | 209 |  |  |  | -- |
Capital lease payable, net of current portion |  |  | -- |  |  |  | 112 |
Derivative liabilities |  |  | 105 |  |  |  | 504 |
Total liabilities |  |  | 6,123 |  |  |  | 6,021 |
Commitments and Contingencies (see Note 12) |  |  |  |  |  |  |  |
Stockholders' equity: |  |  |  |  |  |  |  |
Preferred stock, par value $.001; 10,000,000 shares authorized; none issued or outstanding |  |  | -- |  |  |  | -- |
Common stock, par value $.001 par value; 40,000,000 shares authorized; 17,760,724 and 17,705,980 issued and 17,617,645 and 17,562,901 outstanding on December 31, 2011 and December 31, 2010, respectively |  |  | 18 |  |  |  | 18 |
Additional paid-in capital |  |  | 25,356 |  |  |  | 25,113 |
Deficit |  |  | (3,257 | ) |  |  | (3,366 | )
Total stockholders' equity |  |  | 22,117 |  |  |  | 21,765 |
Total Liabilities and Stockholders' Equity |  | $ | 28,240 |  |  | $ | 27,786 |

The accompanying notes are an integral part of the consolidated financial statements.
F-3

Table of Contents
BOVIE MEDICAL CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE YEARS ENDED DECEMBER 31, 2011, 2010 AND 2009
(in thousands)

|  | 2011 |  |  | 2010 |  |  | 2009 |
Sales, net |  | $ | 25,411 |  |  | $ | 24,230 |  |  | $ | 26,953 |
Cost of sales |  |  | 14,680 |  |  |  | 14,242 |  |  |  | 15,098 |
Gross Profit |  |  | 10,731 |  |  |  | 9,988 |  |  |  | 11,855 |
Gain on legal settlement |  |  | 750 |  |  |  | -- |  |  |  | -- |
Other costs: |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  | 1,197 |  |  |  | 1,854 |  |  |  | 2,083 |
Professional services |  |  | 1,250 |  |  |  | 1,556 |  |  |  | 1,398 |
Salaries and related costs |  |  | 3,114 |  |  |  | 3,155 |  |  |  | 3,003 |
Selling, general and administration |  |  | 4,347 |  |  |  | 4,889 |  |  |  | 4,656 |
Legal settlement |  |  | 1,591 |  |  |  | -- |  |  |  | -- |
Asset impairment |  |  | -- |  |  |  | 1,286 |  |  |  | -- |
Total other costs |  |  | 11,499 |  |  |  | 12,740 |  |  |  | 11,140 |
Income (loss) from operations |  |  | (18 | ) |  |  | (2,752 | ) |  |  | 715 |
Other income (expense): |  |  |  |  |  |  |  |  |  |  |  |
Interest (expense) income |  |  | (237 | ) |  |  | (223 | ) |  |  | (52 | )
Change in fair value of liabilities, net |  |  | 287 |  |  |  | 513 |  |  |  | -- |
Total other income (expense), net |  |  | 50 |  |  |  | 290 |  |  |  | (52 | )
Income (loss) before income taxes |  |  | 32 |  |  |  | (2,462 | ) |  |  | 663 |
Provision for current income taxes |  |  | -- |  |  |  | (7 | ) |  |  | (7 | )
Benefit (provision) for deferred income taxes |  |  | 77 |  |  |  | 934 |  |  |  | (60 | )
Total benefit (provision) for income taxes - net |  |  | 77 |  |  |  | 927 |  |  |  | (67 | )
Net income (loss) |  | $ | 109 |  |  | $ | (1,535 | ) |  | $ | 596 |
Earnings (loss) per common share: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.01 |  |  | $ | (0.09 | ) |  | $ | 0.04 |
Diluted |  | $ | 0.01 |  |  | $ | (0.09 | ) |  | $ | 0.03 |
Weighted average number of common shares Outstanding - Basic |  |  | 17,597 |  |  |  | 17,367 |  |  |  | 16,899 |
Weighted average number of common shares outstanding adjusted for dilutive securities |  |  | 17,669 |  |  |  | 17,367 |  |  |  | 17,836 |

The accompanying notes are an integral part of the consolidated financial statements.
F-4

Table of Contents
BOVIE MEDICAL CORPORATION
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY AND COMPREHENSIVE INCOME
(LOSS)
FOR THE YEARS ENDED DECEMBER 31, 2011, 2010 AND 2009
(in thousands)

|  | Common |  |  | Additional Paid-in |  |  | Accumulated Other Comprehensive |  |  |  |  |  |  |
|  | Shares |  |  | Par Value |  |  | Capital |  |  | Income (Loss) |  |  | Deficit |  |  | Total |
January 1, 2009 |  |  | 16,795 |  |  | $ | 17 |  |  | $ | 22,719 |  |  | $ | (88 | ) |  | $ | (2,427 | ) |  | $ | 20,221 |
Options exercised |  |  | 183 |  |  |  | - |  |  |  | 286 |  |  |  | - |  |  |  | - |  |  |  | 286 |
Stock based compensation |  |  | - |  |  |  | - |  |  |  | 136 |  |  |  | - |  |  |  | - |  |  |  | 136 |
Stock swap to acquire options |  |  | (26 | ) |  |  | - |  |  |  | (207 | ) |  |  | - |  |  |  | - |  |  |  | (207 | )
Net income |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 596 |  |  |  | 596 |
Foreign currency remeasurement |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (1 | ) |  |  | - |  |  |  | (1 | )
Comprehensive income |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 595 |
December 31, 2009 |  |  | 16,952 |  |  |  | 17 |  |  |  | 22,934 |  |  |  | (89 | ) |  |  | (1,831 | ) |  |  | 21,031 |
Options exercised |  |  | 46 |  |  |  | - |  |  |  | 39 |  |  |  | - |  |  |  | - |  |  |  | 39 |
Stock based compensation |  |  | - |  |  |  | - |  |  |  | 163 |  |  |  | - |  |  |  | - |  |  |  | 163 |
Stock swap to acquire options |  |  | (6 | ) |  |  | - |  |  |  | (30 | ) |  |  | - |  |  |  | - |  |  |  | (30 | )
Equity Issuance |  |  | 572 |  |  |  | 1 |  |  |  | 2,766 |  |  |  | - |  |  |  | - |  |  |  | 2,767 |
Fair value of warrants issued in connection with equity raise |  |  | - |  |  |  | - |  |  |  | (799 | ) |  |  | - |  |  |  | - |  |  |  | (799 | )
Tax benefit from share based payments |  |  | - |  |  |  | - |  |  |  | 40 |  |  |  | - |  |  |  | - |  |  |  | 40 |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (1,535 | ) |  |  | (1,535 | )
Foreign currency remeasurement |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 89 |  |  |  | - |  |  |  | 89 |
Comprehensive loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (1,446 | )
December 31, 2010 |  |  | 17,564 |  |  |  | 18 |  |  |  | 25,113 |  |  |  | - |  |  |  | (3,366 | ) |  |  | 21,765 |
Options exercised |  |  | 69 |  |  |  | - |  |  |  | 39 |  |  |  | - |  |  |  | - |  |  |  | 39 |
Stock based compensation |  |  | - |  |  |  | - |  |  |  | 132 |  |  |  | - |  |  |  | - |  |  |  | 132 |
Stock swap to acquire options |  |  | (14 | ) |  |  | - |  |  |  | (39 | ) |  |  | - |  |  |  | - |  |  |  | (39 | )
Non Cash elimination of Lican Restricted Stock Liability |  |  |  |  |  |  |  |  |  |  | 111 |  |  |  |  |  |  |  |  |  |  |  | 111 |
Net Income |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 109 |  |  |  | 109 |
December 31, 2011 |  |  | 17,619 |  |  | $ | 18 |  |  | $ | 25,356 |  |  | $ | - |  |  | $ | (3,257 | ) |  | $ | 22,117 |

The accompanying notes are an integral part of the consolidated financial statements.
F-5

Table of Contents

BOVIE MEDICAL CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2011, 2010 AND 2009
(in thousands)

|  | 2011 |  |  | 2010 |  |  | 2009 |
Cash flows from operating activities: |  |  |  |  |  |  |  |  |
Net income (loss) |  | $ | 109 |  |  | $ | (1,535 | ) |  | $ | 596 |
Adjustments to reconcile net income to net cash provided by (used in) operating activities: |  |  |  |  |  |  |  |  |  |  |  |
Depreciation and amortization of property and equipment |  |  | 753 |  |  |  | 734 |  |  |  | 777 |
Amortization of intangible assets |  |  | 172 |  |  |  | 273 |  |  |  | 273 |
Provision for (recovery of) inventory obsolescence |  |  | 37 |  |  |  | (8 | ) |  |  | 27 |
Loss (gain) on disposal of fixed assets |  |  | -- |  |  |  | 326 |  |  |  | (1 | )
Loss on Goodwill Impairment Bovie Canada |  |  | -- |  |  |  | 54 |  |  |  | -- |
Loss on impairment of intangible assets (Note 5) |  |  | -- |  |  |  | 1,286 |  |  |  | -- |
Stock-based compensation |  |  | 132 |  |  |  | 163 |  |  |  | 136 |
Non cash Other Income – Warrants |  |  | (227 | ) |  |  | (513 | ) |  |  | -- |
Non cash Other Income – Lican derivatives |  |  | (61 | ) |  |  | -- |  |  |  | -- |
Non cash legal settlement |  |  | 954 |  |  |  | -- |  |  |  | -- |
Provision (benefit) for deferred income taxes |  |  | (76 | ) |  |  | (934 | ) |  |  | 60 |
Provision for (recovery of) bad debts |  |  | -- |  |  |  | -- |  |  |  | (7 | )
Gain on cancellation of agreement |  |  | -- |  |  |  | -- |  |  |  | -- |
Change in assets and liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Trade receivables |  |  | (126 | ) |  |  | 451 |  |  |  | 440 |
Prepaid expenses and other current assets |  |  | 257 |  |  |  | (47 | ) |  |  | 150 |
Inventories |  |  | (719 | ) |  |  | (822 | ) |  |  | (1,462 | )
Deposits |  |  | (111 | ) |  |  | (281 | ) |  |  | (305 | )
Accounts payable |  |  | 134 |  |  |  | 362 |  |  |  | (728 | )
Settlement Liability |  |  | 731 |  |  |  | -- |  |  |  | -- |
Accrued and other liabilities |  |  | (30 | ) |  |  | (56 | ) |  |  | (3 | )
Accrued payroll |  |  | (12 | ) |  |  | 23 |  |  |  | 17 |
Accrued vacation |  |  | (20 | ) |  |  | (2 | ) |  |  | (67 | )
Net cash provided by (used in) operating activities |  |  | 1,897 |  |  |  | (526 | ) |  |  | (97 | )
Cash flows from investing activities: |  |  |  |  |  |  |  |  |  |  |  |
Purchases of property and equipment |  |  | (542 | ) |  |  | (201 | ) |  |  | (2,465 | )
Proceeds from sale of property and equipment |  |  | -- |  |  |  | 633 |  |  |  | 1 |
Increase in purchased technology |  |  | -- |  |  |  | -- |  |  |  | -- |
Net cash provided by (used in) investing activities |  |  | (542 | ) |  |  | 432 |  |  |  | (2,464 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from mortgage note payable to bank (net of amounts in escrow) |  |  | -- |  |  |  | 36 |  |  |  | 1,249 |
Proceeds from private placement (net of costs of $233,014) |  |  | -- |  |  |  | 2,767 |  |  |  | -- |
Net change in line of credit |  |  | -- |  |  |  | (1,000 | ) |  |  | 1,000 |
Repayments of capital lease payable |  |  | (111 | ) |  |  | -- |  |  |  | -- |
Proceeds from sales of common stock |  |  | -- |  |  |  | 9 |  |  |  | 79 |
Proceeds from long-term debt |  |  | 3,549 |  |  |  | -- |  |  |  | -- |
Repayments of long-term debt |  |  | (3,740 | ) |  |  | (135 | ) |  |  | (175 | )
Net cash provided by (used in) financing activities |  |  | (302 | ) |  |  | 1,677 |  |  |  | 2,153 |
Effect of exchange rate changes on cash and cash equivalents |  |  | -- |  |  |  | 89 |  |  |  | (1 | )
Net change in cash and cash equivalents |  |  | 1,053 |  |  |  | 1,672 |  |  |  | (409 | )
Cash and cash equivalents at beginning of year |  |  | 3,827 |  |  |  | 2,155 |  |  |  | 2,564 |
Cash and cash equivalents at end of year |  | $ | 4,880 |  |  | $ | 3,827 |  |  | $ | 2,155 |
Cash paid for: |  |  |  |  |  |  |  |  |  |  |  |
Interest paid, net of amounts capitalized of $119,000 in 2009 |  | $ | 237 |  |  | $ | 223 |  |  | $ | 128 |
Income taxes |  | $ | -- |  |  | $ | -- |  |  | $ | 245 |
Noncash financing activities during year ended December 31, 2011, 2010, and 2009: |  |  |  |  |  |  |  |  |  |  |  |
Equipment financed with loan |  | $ | -- |  |  | $ | 111 |  |  | $ | -- |

The accompanying notes are an integral part of the consolidated financial statements.
F-6

Table of Contents
BOVIE MEDICAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1. DESCRIPTION OF BUSINESS
Bovie Medical Corporation (“Bovie”) was incorporated in 1982, under the laws of the State of Delaware and is a medical device company engaged in the manufacturing and marketing of electrosurgical devices. Our medical products include a wide range of devices including electrosurgical generators and accessories, cauteries, medical lighting, nerve locators and other products.
NOTE 2. SIGNIFICANT ACCOUNTING POLICIES
Consolidated Financial Statements
The accompanying consolidated financial statements include the accounts of Bovie and its wholly owned subsidiaries, Aaron Medical Industries, Inc., Bovie Holdings, Inc. (which in turn prior to June 30, 2010 owned 100% of Bovie Canada ulc) and Jump Agentur Fur Electrotechnik Gmbh (“JAG”) (collectively, the “Company” or “we”, “our” or “us”). All intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates in the Preparation of Financial Statements
The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. The reported amounts of revenues and expenses during the reporting period may be affected by the estimates and assumptions we are required to make. Estimates that are critical to the accompanying consolidated financial statements relate principally to the adequacy of our inventory allowances and the recoverability of certain intangibles and our deferred income tax assets. In addition, stock-based compensation and the fair value of certain warrants represent significant estimates as such expense is derived from a formula that uses various assumptions to estimate the future but unknown value of our common stock. The markets for the Company’s products are characterized by intense price competition, rapid technological development, evolving standards and short product life cycles, all of which could impact the future realization of its assets. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the period that they are determined to be necessary. It is at least reasonably possible that the Company’s estimates could change in the near term with respect to these matters.
Cash and Cash Equivalents
Holdings of highly liquid investments with original maturities of three months or less are considered to be cash equivalents.
Fair Values of Financial Instruments and Concentration of Credit Risk
The carrying amount of our financial instruments included in current assets and liabilities approximates fair value due to their short term nature. In addition, we believe the book values of our bonds payable and capital lease payable approximates their fair values as the terms of such obligation approximates the terms at which similar types of borrowing arrangements could be currently obtained.
Financial instruments, which potentially subject us to significant concentrations of credit risk, consist primarily of cash and cash equivalents, and trade accounts receivable. With respect to cash, we frequently maintain cash and cash equivalent balances in excess of federally insured limits. We have not experienced any losses in such accounts.
F-7

Table of Contents
See Note 6 for discussion of fair market value measurements of other liabilities.
With respect to receivables, our ten largest customers accounted for approximately 62%, 61% and 65% of trade receivables as of December 31, 2011, 2010 and 2009, respectively, and 64.6%, 66.5% and 71.5% of net revenues for the respective years then ended. In 2011, no customer accounted for over 10% of total revenues. In 2010 Arthrex and National Distribution and Contracting, Inc. amounted to 11.4% and 11.2%, respectively and in 2009, Arthrex was our only customer that accounted for over 10% of total revenues, accounting for 22% of such revenues. All of these entities are customers of our U.S. operations. We perform ongoing credit evaluations of our customers and generally do not require collateral because we believe we have procedures in place to limit potential for significant losses, and because of the nature of our customer base.
Accounts Receivable and Allowance for Doubtful Accounts
Our credit terms for our billings range from net 10 days to net 30 days, depending on the customer agreement. Accounts receivable are determined to be past due if payments are not made in accordance with such agreements and a reserve is created for them when they become three months past due or sooner if there are other indicators that the receivables may not be recovered. Customary collection efforts are initiated and receivables are written off when we determine they are not collectible and abandon these collection efforts. We gave negotiated sales volume discounts, which amounted to approximately $520,000, $522,000 and $534,000 for 2011, 2010 and 2009, respectively. Sales are reported net of all discounts.
We evaluate the allowance for doubtful accounts on a regular basis for adequacy based upon our periodic review of the collectability of the receivables in light of historical experience, adverse situations that may affect our customers’ ability to pay, estimated value of any underlying collateral and prevailing economic conditions. This evaluation is inherently subjective, as it requires estimates that are susceptible to significant revision as more information becomes available. Substantially all of the receivables included in the accompanying balance sheets were recovered subsequent to the respective year ends. Because of this, and because historical losses on accounts receivable have not been material, management believes that the allowances for doubtful accounts of approximately $20,000 and $14,600 at December 31, 2011 and 2010, respectively, are, or were, adequate to provide for possible bad debts.
Inventories and Repair Parts
Inventories are stated at the lower of average cost or market. Finished goods and work-in-process inventories include material, labor, and overhead costs. Factory overhead costs are allocated to inventory manufactured in-house based upon cost of materials.
We monitor usage reports to determine if the carrying value of any items should be adjusted due to lack of demand for the item and adjust the inventory for estimated obsolescence or unusable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required.
Inventories at December 31, 2011 and 2010 were as follows (in thousands):

|  | 2011 |  |  | 2010 |
Raw materials |  | $ | 5,043 |  |  | $ | 4,586 |
Work in process |  |  | 1,865 |  |  |  | 2,315 |
Finished goods |  |  | 1,822 |  |  |  | 1,218 |
Gross inventories |  |  | 8,730 |  |  |  | 8,119 |
Less: reserve for obsolescence |  |  | (552 | ) |  |  | (514 | )
Net inventories |  | $ | 8,178 |  |  | $ | 7,605 |

F-8

Table of Contents
During 2011, the reserves and related costs of sales increased by approximately $37,000. In 2010 and 2009 the reserves and related cost of sales were reduced by approximately $8,400 and $27,000 respectively as a result of changes in estimates regarding the recoverability of certain types of our inventory. There are no reserves for finished goods or work in progress as of December 31, 2011 and 2010.
Property and Equipment
These assets are recorded at cost. Depreciation and amortization are provided for using the straight-line method over the estimated useful lives of the assets. The amortization of leasehold improvements is based on the shorter of the lease term or the life of the improvement. Betterments and large improvements, which extend the life of the asset, are capitalized, whereas maintenance and repairs and small improvements are expensed as incurred. The estimated useful lives are: machinery and equipment, 3-10 years; buildings, 39 years; molds, 7-15 years and furniture and fixtures, 5-10 years.
Intangible Assets
These assets consist of licenses, purchased technology and brand name and trademarks. The licenses and purchased technology (other intangibles) are being amortized by the straight-line method over a 5-17 year period commencing with the date they were placed in service. Estimated aggregate amortization expense for the five years ending December 31, 2016 is expected to approximate $725,000.
Brand name and trademark qualifies as an indefinite-lived intangible asset and is not subject to amortization. Intangibles with indefinite lives are analyzed for impairment annually, or more frequently if events and circumstances indicate that the asset may be impaired. If impaired, an impairment loss is recognized in an amount equal to the excess of the asset's carrying value over its fair value.
Other Long-Lived Assets
We review other long-lived assets for recoverability if events or changes in circumstances indicate that the assets may have been impaired. This circumstance exists when the carrying amount of the asset exceeds the sum of the undiscounted cash flows expected to result from its use and eventual disposition. In those cases an impairment loss is recognized to the extent that the assets’ carrying amount exceeds its fair value. Any impairment losses are not restored in the future if the fair value increases. At December 31, 2011, we believe the remaining carrying values of our long-lived assets are recoverable.
Revenue Recognition
Revenue is recognized when title has been transferred to the customer, which is generally at the time of shipment. The following policies apply to our major categories of revenue transactions:

| ● | Sales to customers are evidenced by firm purchase orders. Title and the risks and rewards of ownership are transferred to the customer when the product is shipped. Payment by the customer is due under fixed payment terms.

| ● | Product returns are only accepted at our discretion and in accordance with our “Returned Goods Policy.” Historically, the level of product returns has not been significant. We accrue for sales returns, rebates and allowances based upon an analysis of historical customer returns and credits, rebates, discounts and current market conditions.

| ● | Our terms of sale to customers generally do not include any obligations to perform future services. Limited warranties are generally provided for sales and provisions for warranty are provided at the time of product sale based upon an analysis of historical data.

| ● | Amounts billed to customers related to shipping and handling are included in net sales. Shipping and handling costs included in cost of sales were approximately $129,000, $121,000 and $106,000 in 2011, 2010 and 2009, respectively.

F-9

Table of Contents
We have no consignment inventory with customers but we do have inventory of approximately $800,000 and $1.0 million, respectively located at contract manufacturers that produce components for us.
Advertising Costs
All advertising costs are expensed as incurred. The amounts of advertising costs were approximately $305,000, $276,000, and $216,000 for 2011, 2010 and 2009, respectively.
Stock-Based Compensation
We account for stock-based compensation in accordance with FASB ASC Topic 718, Compensation-Stock Compensation. ASC 718 requires recognizing compensation costs for all share-based payment awards made to employees and directors based upon the awards’ grant date fair value. The standard covers employee stock options, restricted stock, and other equity awards. For stock options, we use a binomial lattice option-pricing model to estimate the grant date fair value of stock option awards, and recognize compensation cost on a straight-line basis over the awards’ vesting periods.
Tax Effects of Stock-Based Compensation
We will only recognize a tax benefit from windfall tax deductions for stock-based awards in additional paid-in capital if an incremental tax benefit is realized after all other tax attributes currently available have been utilized.
Net Earnings (Loss) Per Common Share
We compute basic earnings (loss) per share by dividing net income (loss) by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share gives effect to all potential dilutive shares outstanding (in our case, stock options that are in the money) during the period. The number of dilutive shares is calculated using the treasury method which reduces the effective number of shares by the amount of shares we could purchase with the proceeds of assumed exercises. During the year ended December 31, 2011, we reported net income per share and, accordingly, common equivalent shares outstanding as of December 31, 2011, which consisted of employee stock options and warrants issued in connection with our private placement. During periods of net loss per share these employee stock options and warrants are excluded from diluted net loss per common share calculations as of such dates because they are anti-dilutive and results in basic and diluted loss per share to be equivalent.
Research and Development Costs
With the exception of development costs that are purchased from another enterprise and have alternative future use, research and development expenses are charged to operations as incurred.
Research and Development Costs for Others
For research and development activities that are partially or completely funded by other parties, and when the obligation is incurred solely to perform contractual services, expenses are charged to cost of sales and all revenues are shown as sales.
Income Taxes
The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between the financial statement and tax bases of assets and liabilities. Deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax bases of assets and liabilities using enacted marginal tax rates. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Deferred income tax expenses or credits are based on the changes in the asset or liability from period to period.
F-10

Table of Contents
We have net operating loss and tax credit carryforwards available in certain jurisdictions to reduce future taxable income. Future tax benefits for net operating loss and tax credit carry forwards are recognized to the extent that realization of these benefits is considered more likely than not. This determination is based on the expectation that related operations will be sufficiently profitable or that various tax, business and other planning strategies will enable us to utilize the operating loss and tax credit carry forwards. We cannot be assured that we will be able to realize these future tax benefits or that future valuation allowances will not be required. To the extent that available evidence raises doubt about the realization of a deferred income tax asset, a valuation allowance is established.
It is our policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. To the extent that the probable tax outcome of these uncertain tax positions changes, such changes in estimate will impact the income tax provision in the period in which such determination is made. At December 31, 2011, we believe we have appropriately accounted for any unrecognized tax benefits. To the extent we prevail in matters for which a liability for an unrecognized tax benefit is established or we are required to pay amounts in excess of the liability, our effective tax rate in a given financial statement period may be affected.
Since inception, we have been subject to tax by both federal and state taxing authorities. Until the respective statutes of limitations expire (which may be as much as 20 years while we have unused NOL’s), we are subject to income tax audits in the jurisdictions in which we operate.
In 2010, we were notified that our 2008 tax year was selected for examination by the Internal Revenue Service. Subsequently, in March 2011, we received the final adjustments from the examination which resulted in a partial disallowance of approximately $350,000 of our net operating loss carryforwards. The adjustments related mainly to certain stock option expense amounts from 2004 that, according to the IRS, were not able to be substantiated due to the inability to recover pertinent records, and to our R&D credit carryforward and attributable expenses. We have agreed to the adjustments and, because the reductions are limited to our net operating loss carryforwards, no cash tax payment was needed as a result of the IRS examination.
Foreign Currency Transactions
The United States dollar is the functional currency of the Company’s operations in the United States and in line with determining guidance outlined in FASB ASC Topic 830, has also been determined to be the functional currency for the Company’s Canadian subsidiary, which was closed and consolidated to the Clearwater, Florida facility in 2010. FASB ASC Topic 830 provides for using the remeasurement method in converting the foreign subsidiary’s financial statements into U.S. dollars. Monetary assets and liabilities denominated in foreign currency are converted at the current rate, while nonmonetary assets, liabilities, and shareholder equity accounts are converted at the appropriate historical rate. Revenue and expenses are converted at the weighted-average exchange rate for the period. FASB ASC Topic 830 requires any gain or loss as a result of remeasurement to be included in current period income unless the investment in the subsidiary is not expected to be recovered in the foreseeable future. As our investment in the Canadian subsidiary was not expected to be recovered in the near future, we reflected the net gains and losses from the remeasurement as other accumulated comprehensive loss in the accompanying 2010 and 2009 statements of stockholders’ equity and comprehensive income. For the year ended December 31, 2011 we had no comprehensive income or loss.
Reclassifications
Certain amounts in our prior years’ financial statements have been reclassified to conform to the current year presentation.
F-11

Table of Contents
NOTE 3. TRADE ACCOUNTS RECEIVABLE
As of December 31, 2011 and 2010, trade accounts receivable were as follows (in thousands):

|  | 2011 |  |  | 2010 |
Trade accounts receivable |  | $ | 2,236 |  |  | $ | 2,129 |
Less: allowance for doubtful accounts |  |  | (20 | ) |  |  | (15 | )
Trade accounts receivable, net |  | $ | 2,216 |  |  | $ | 2,114 |

NOTE 4. PROPERTY, PLANT AND EQUIPMENT
As of December 31, 2011 and 2010, property, plant and equipment consisted of the following (in thousands):

|  | 2011 |  |  | 2010 |
Land |  | $ | 1,600 |  |  | $ | 1,600 |
Machinery and equipment |  |  | 3,601 |  |  |  | 3,311 |
Building and improvements |  |  | 3,733 |  |  |  | 3,684 |
Furniture and fixtures |  |  | 1,770 |  |  |  | 1,645 |
Leasehold improvements |  |  | 384 |  |  |  | 384 |
Molds |  |  | 1,088 |  |  |  | 1,118 |
|  |  | 12,176 |  |  |  | 11,742 |
Less: accumulated depreciation |  |  | (5,000 | ) |  |  | (4,310 | )
Net property, plant, and equipment |  | $ | 7,176 |  |  | $ | 7,432 |

NOTE 5. INTANGIBLE ASSETS
At December 31, 2011 and 2010, intangible assets consisted of the following (in thousands):

|  | 2011 |  |  | 2010 |
Brand name and trademark (life indefinite) |  | $ | 1,510 |  |  | $ | 1,510 |
Purchased technology (9-17 year lives) |  | $ | 1,441 |  |  | $ | 2,251 |
Less: accumulated amortization |  |  | (689 | ) |  |  | (653 | )
Purchased technology, net |  | $ | 752 |  |  | $ | 1,598 |
License rights (5 year life) |  | $ | 316 |  |  | $ | 316 |
Less: accumulated amortization |  |  | (290 | ) |  |  | (226 | )
License rights, net |  | $ | 26 |  |  | $ | 90 |

With respect to our trademark and brand name, we continue to market products, release new products and product extensions and maintain and promote these trademarks and brand name in the marketplace through legal registration and such methods as advertising, medical education and trade shows. It is our belief that these trademarks and brand names will generate cash flow for an indefinite period of time. Therefore, we believe our trademarks and brand name intangible assets are recoverable.
During 2011, certain intangible assets were transferred in conjunction with our settlement agreement with Mr. Livneh (See Note 12).
F-12

Table of Contents
NOTE 6. FAIR VALUE MEASUREMENTS
Certain assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2011 are measured in accordance with FASB ASC Topic 820-10-05, Fair Value Measurements. FASB ASC Topic 820-10-05 defines fair value, establishes a framework for measuring fair value and expands the disclosure requirements regarding fair value measurements for financial assets and liabilities as well as for non-financial assets and liabilities that are recognized or disclosed at fair value on a recurring basis in the financial statements.
The statement requires fair value measurement be classified and disclosed in one of the following three categories:
Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
The following table summarizes our financial instruments measured at fair value as of December 31, 2011 (in thousands):

|  | December 31, 2011 Fair Value Measurements |
|  | Total |  |  | Level 1 |  |  | Level 2 |  |  | Level 3 |
Assets: |  |  |  |  |  |  |  |  |  |  |  |
Cash and equivalents – United States |  | $ | 4,870 |  |  | $ | 4,870 |  |  | $ | – |  |  | $ | – |
Cash and equivalents - Foreign currency |  |  | 10 |  |  |  | 10 |  |  |  | – |  |  |  | – |
Total assets |  | $ | 4,880 |  |  | $ | 4,880 |  |  | $ | – |  |  | $ | – |
Derivative Liabilities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant liability (2) |  | $ | 105 |  |  | $ | – |  |  |  | – |  |  | $ | 105 |
Due to Lican (1) |  |  | -- |  |  |  | – |  |  | $ | – |  |  |  | -- |
Total liabilities |  | $ | 105 |  |  | $ | – |  |  | $ | – |  |  | $ | 105 |

The following table summarizes our financial instruments measured at fair value as of December 31, 2010 (in thousands):

|  | December 31, 2010 Fair Value Measurements |
|  | Total |  |  | Level 1 |  |  | Level 2 |  |  | Level 3 |
Assets: |  |  |  |  |  |  |  |  |  |  |  |
Cash and equivalents – United States |  | $ | 3,788 |  |  | $ | 3,788 |  |  | $ | – |  |  | $ | – |
Cash and equivalents - Foreign currency |  |  | 39 |  |  |  | 39 |  |  |  | – |  |  |  | – |
Total assets |  | $ | 3,827 |  |  | $ | 3,827 |  |  | $ | – |  |  | $ | – |
Derivative Liabilities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant liability (2) |  | $ | 332 |  |  | $ | – |  |  |  | – |  |  | $ | 332 |
Due to Lican (1) |  |  | 172 |  |  |  | – |  |  | $ | – |  |  |  | 172 |
Total liabilities |  | $ | 504 |  |  | $ | – |  |  | $ | – |  |  | $ | 504 |

F-13

Table of Contents

(1) | Thisamount has been reduced to zero in 2011 as a result of the Steve Livneh settlement (See Note 12). At December 31, 2010 this amount was based upon the probable realization of 75,000 out of a possible 150,000 contingent shares related to the Lican Developments Ltd. Asset Purchase Agreement, which was valued at the adjusted current fair value market share price.

(2) | On April 18, 2010, we entered into a securities purchase agreement with purchasers named therein to raise in the aggregate of approximately $3 million in a private placement of common stock and warrants pursuant to Section 4(2) of the Securities Act of 1933, as amended, and/or Regulation D promulgated thereunder. Upon closing of the transaction, we entered into a registration rights agreement with the buyers and issued to the buyers an aggregate of 571,429 shares of common stock at a per share price of $5.25, and warrants to acquire additional shares of common stock of up to fifty (50%) percent of the common shares acquired by each respective buyer at an exercise price of $6.00 per share.

The warrants are immediately exercisable and will terminate on the fifth anniversary of the issuance date. The exercise price of the warrants is subject to adjustment so that, among other things, if we issue any shares of common stock (including options and warrants, with standard exceptions), at a price that is lower than the exercise price then in effect, the exercise price then in effect will be reduced to such lower price.
In connection with the private placement, we paid certain cash fees and issued a warrant to the placement agent, Rodman & Renshaw, LLC, for the purchase of 42,857 shares of Common Stock at an exercise price of $6.00 per share for its activity engaged on behalf of the Company. In addition, the Company paid certain cash fees and issued a warrant to Gilford Securities Incorporated for the purchase of 10,000 shares of Common Stock at an exercise price of $6.00 per share for its activity engaged on behalf of the Company.
The warrants issued contained provisions for a net cash settlement in the event that there is a fundamental transaction (contractually defined as a merger, sale of substantially all assets, tender offer or share exchange). Due to this contingent redemption provision, the warrants require liability classification according to FASB ASC 480-10, “Distinguishing Liabilities from Equity" and must be recorded at fair value each reporting period. These warrants required classification as liabilities at inception and ongoing measurement at fair value each reporting period thereafter.
The warrants are valued using a binomial lattice valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments. Significant assumptions used in this model at inception and as of December 31, 2011 included an expected life of 4 years, an expected dividend yield of zero, estimated volatility of 47%, and risk-free rates of return of 0.2%. For the risk-free rates of return, we use the published yields on zero-coupon Treasury Securities with maturities consistent with the remaining term of the warrants and volatility is based on a weighted average of the historical volatility of our stock price and peer company stock price volatility. We also take into consideration a probability assumption for anti-dilution.
F-14

Table of Contents
Changes in Fair Value Measurements Using Significant Unobservable Inputs (Level 3) (in thousands):

Description |  | Year Ended December 31, 2011 |  |  | Year Ended December 31, 2010 |
Beginning balance |  | $ | 504 |  |  | $ | 218 |
Purchases, issuances, and settlements |  |  | -- |  |  |  | 799 |
Reduced Lican liability from settlement |  |  | (111) |  |  |  | -- |
Total gain included in earnings (3) |  |  | (288) |  |  |  | (513 | )
Ending Balance |  | $ | 105 |  |  | $ | 504 |

(3) | Gains for the period ended December 31, 2011 related to the revaluation of equity based liabilities. The gains related to the warrant liability portion were calculated from the date of the warrant issuance (April 18, 2010) through December 31, 2011. These gains and losses are reflected in our consolidated statements of operations as a component of other income (expense).

NOTE 7. RECENT ACCOUNTING PRONOUNCEMENTS
In June 2011, the FASB issued Accounting Standards Update (“ASU”) No. 2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income which requires an entity to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In both choices, an entity is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income. ASU 2011-05 eliminates the option to present the components of other comprehensive income as part of the statement of stockholders’ equity. The amendments in ASU 2011-05 do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. ASU 2011-05 is effective for our fiscal years beginning January 1, 2012. Early adoption is permitted. We are currently assessing the implementation of this new guidance, however these changes will only affect our presentation and will not have an impact on our consolidated financial statements.
In May 2011, the FASB issued ASU No. 2011-04, Fair Value Measurements and Disclosures (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and International Financial Reporting Standards to provide a consistent definition of fair value and ensure that the fair value measurement and disclosure requirements are similar between U.S. GAAP and International Financial Reporting Standards. ASU 2011-04 changes certain fair value measurement principles and enhances the disclosure requirements, mainly for level 3 fair value measurements. ASU 2011-04 is effective for our fiscal years beginning January 1, 2012. Early adoption is not permitted. We are currently evaluating the impact of this new guidance, but we do not expect it to have a material impact on our consolidated financial statements.
In September 2011, the FASB issued ASU No. 2011-08, Intangibles-Goodwill and Other an update that amends the accounting guidance on goodwill impairment testing. The amendments in this accounting standard update are intended to reduce complexity and costs by allowing an entity the option to first assess qualitative factors in its evaluation about the likelihood of goodwill impairment to determine whether it is necessary to perform the two-step quantitative goodwill impairment test of a reporting unit. In addition the amendments include a number of events and circumstances for an entity to consider in conducting the qualitative assessment. ASU No. 2011-08 is effective for our fiscal years beginning after January 1, 2012 with early adoption permitted. We do not expect it to have a material impact on our consolidated financial statements.
We have reviewed all other recently issued standards and have determined they will not have a material impact on our consolidated financial statements, or do not apply to our operations.
NOTE 8. LINE OF CREDIT
Line of Credit
We have an $6 million secured revolving line of credit facility with PNC Bank N.A., which at December 31, 2011 had a zero balance. Advances under the $6 million line of credit are due on demand and bear interest at a rate of daily LIBOR plus 1.75% and are secured by a perfected first security interest in our inventory and accounts receivable.
F-15

Table of Contents
In addition we have a separate additional credit facility with PNC Bank N.A. for up to $1 million specific to financing new equipment purchases. This credit facility provides for a 1 year draw up to the conversion date of October 31, 2012. Prior to the conversion date amounts outstanding will bear an interest rate of daily LIBOR plus 2.25%. Once the note is converted the term will be 5 years and will bear an interest rate of daily LIBOR plus 2.50%. The note would be secured by a perfected first security interest in the new equipment purchased.
Subsequent available borrowings for both these credit facilities is subject to a borrowing base utilizing a percentage of eligible receivables, inventories, and any assigned cash along with certain financial ratios, specifically maintaining: a ratio of total funded debt to EBITDA of less than 3.25 to 1.0 and a ratio of minimum Fixed Charge of 1.5 to 1.0 measured on a rolling four quarter basis.
At December 31, 2011 we were in compliance with the loan covenants and ratios of both the credit facilities. According to our most recent borrowing base calculation, we had approximately $3.0 million total availability under the $6 million credit line, of which we currently have a zero balance. We also have available approximately $1.0 million under the equipment line of credit.
Mortgage Note Payable
We currently have approximately $3.5 million borrowed under industrial revenue bonds which we previously used for the purchase and renovation of our Clearwater, Florida facility. During 2011 these bonds were refinanced through PNC Bank N.A. The bonds, which are being amortized over a 20-year term, balloon in November 2018 and bear interest at a fixed interest rate of 5.6%. Scheduled maturities of this indebtedness are shown below:

|  | Years Ending December 31, |
|  | 2012 |  |  | 2013 |  |  | 2014 |  |  | 2015 |  |  | 2016 |  |  | Thereafter |
Mortgage scheduled maturities |  | $ | 130 |  |  | $ | 137 |  |  | $ | 145 |  |  | $ | 153 |  |  | $ | 162 |  |  | $ | 2,823 |

NOTE 9. TAXES AND NET OPERATING LOSS CARRYFORWARDS
During 2010, our 2008 and 2009 federal tax returns were selected for examination by the United States Internal Revenue Service (“the IRS”). The exam was concluded in March, 2011. As a result of the IRS exam, our federal net operating loss carryforwards were reduced by approximately $350,000 and R&D credits were reduced by approximately $55,000.
Deferred income taxes reflect the impact of temporary differences between the amount of assets and liabilities recognized for financial reporting purposes and such amounts recognized for income tax purposes. The tax effects of these temporary differences representing the components of deferred tax assets (liabilities) at December 31 were approximately as follows (in thousands):
F-16

Table of Contents

|  | 2011 |  |  | 2010 |
Deferred tax assets, current: |  |  |  |  |  |
U.S. net operating loss carryforwards |  | $ | 980 |  |  | $ | 1,011 |
State net operating loss carryforwards |  |  | 176 |  |  |  | 189 |
Research and development credits |  |  | 774 |  |  |  | 743 |
AMT credits |  |  | 73 |  |  |  | 73 |
Asset impairment |  |  | -- |  |  |  | 486 |
Accounts receivable |  |  | 16 |  |  |  | 5 |
Inventory |  |  | 1 |  |  |  | 2 |
Charitable |  |  | 9 |  |  |  | 4 |
Accrued expenses |  |  | 56 |  |  |  | 72 |
Unrecognized tax benefit liability for current temporary differences |  |  | -- |  |  |  | -- |
Accrued Settlement |  |  | 593 |  |  |  | -- |
Non-current estimate of loss and credit carryforwards |  |  | (2,178 | ) |  |  | (2,185 | )
Total deferred tax assets, current |  |  | 500 |  |  |  | 400 |
Deferred tax assets, non-current: |  |  |  |  |  |  |  |
Loss and credit carryforwards |  |  | 2,178 |  |  |  | 2,185 |
Stock based compensation |  |  | 70 |  |  |  | 49 |
Total deferred tax assets, non- current |  |  | 2,248 |  |  |  | 2,234 |
Deferred tax liabilities, non-current: |  |  |  |  |  |  |  |
Property and equipment |  |  | (422 | ) |  |  | (410 | )
Intangibles |  |  | (254 | ) |  |  | (217 | )
Unrecognized tax benefit liability for non-current temporary differences |  |  | (63 | ) |  |  | (74 | )
Total deferred tax liabilities, non- current |  |  | (739 | ) |  |  | (701 | )
Net non-current deferred income tax asset |  | $ | 1,509 |  |  | $ | 1,533 |

Pursuant to ASC 740, we must consider all positive and negative evidence regarding the realization of deferred tax assets, including past operating results and future sources of taxable income. U.S. net operating losses will begin to expire in years beginning in 2019.
We have adopted the provisions of FIN48, now under ASC 740. Under ASC 740, the impact of an uncertain tax position taken or expected to be taken on an income tax return must be recognized in the financial statements at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained. All of our positions arise from taxable temporary differences and, as such, the liability has been recognized in the net deferred tax asset, current and non-current items to which they relate. The calculated amount of penalties and interest related to these timing differences were immaterial at December 31, 2011 and 2010. In addition, because the amounts are related to temporary timing differences, there would be no material impact on our effective tax rate if recognized.
Below is a reconciliation of the statutory federal income tax rate to our effective tax rate for the fiscal years ended December 31, 2011, 2010 and 2009:

|  | 2011 |  |  | 2010 |  |  | 2009 |
Federal Tax Provision |  |  | 34.0 | % |  |  | 34.0 | % |  |  | 34.0 | %
State taxes (net of federal benefit) |  |  | (32.0 | %) |  |  | 4.3 | % |  |  | 2.6 | %
Stock based compensation* |  |  | (27.8 | %) |  |  | 0.5 | % |  |  | (15.9 | %)
Research and development credits* |  |  | (78.0 | %) |  |  | 5.0 | % |  |  | (12.8 | %)
Warrant Gains |  |  | (372.4 | %) |  |  | - |  |  |  | - |
Meals and Entertainment |  |  | 39.1 | % |  |  | - |  |  |  | - |
Other |  |  | - |  |  |  | (6.1 | %) |  |  | 2.3 | %
|  |  | (437.1 | %) |  |  | 37.7 | % |  |  | 10.2 | %

* Net of IRS Exam adjustments for 2010
F-17

Table of Contents
NOTE 10. RETIREMENT PLAN
The Company provides a tax-qualified profit-sharing retirement plan under section 401k of the Internal Revenue Code for the benefit of eligible employees with an accumulation of funds for retirement on a tax-deferred basis and provides for annual discretionary contribution to individual trust funds.
All employees are eligible to participate. The employees may make voluntary contributions to the plan up to the maximum percentage allowed by the Internal Revenue Code. Vesting in employee matching contributions is graded and depends on the years of service. After three years from their date of hire, the employees are 100% vested. The Company makes matching contributions of 50% of the employee contributions up to a total of 3% of participant payroll. During 2009 and throughout 2011 the Company’s management suspended the matching contribution as a cost cutting measure.
The Company’s contributions and expense during 2011, 2010 and 2009 approximated zero, zero and $6,960, respectively.
NOTE 11. OTHER RELATED PARTY TRANSACTIONS
Compensation of Non-Employee Directors
We compensate our board members with a combination of both stock options and cash payments. During the year ended December 31, 2011, we granted 15,000 stock options to new board members having a fair value of approximately $20,250 and we paid $20,000 in cash amounts to our independent directors as consideration for their service on our Board of Directors. We pay $1,000 cash for in person board meetings and $500 cash payments for telephonic board meetings. Prior to 2011, we compensated our board members with stock options only. For the years ended December 31, 2010 and 2009, we granted 64,160 and 37,500 stock options with a fair value of approximately $62,900 and $131,200, respectively.
Research and Development Consulting Services
A relative of Bovie’s Director of Strategic Development is considered a related party. Arik Zoran, is a consultant of the Company doing business as AR Logic, Inc., which is a consulting firm owned by Arik Zoran, Mr. Citronowicz’s brother. During January 2011, we entered into a three year consulting services agreement with AR Logic that provides for a monthly retainer for engineering support for our existing generator product line and a separate hourly based fee structure for additional consulting related to new product lines. The consulting rates are consistent with rates of an arms length transaction. AR Logic was paid consulting fees of approximately $171,700 during 2011. Previous to 2011, Mr. Zoran was an employee in charge of the engineering department and was paid inclusive of benefits $192,014, and $188,363 for 2010 and 2009, respectively.
A second relative of Bovie’s Director of Strategic Development is considered a related party. Yechiel Tsitrinovich is also a brother of Mr. Citronowicz, and acts as a consultant to the Company related to research and development of certain products. Mr. Tsitrinovich has a royalty contract with us related to the creation and design of a proprietary technology that is used in some of our generators. Mr. Tsitrinovich was paid a combination of consulting fees and royalties on previous product designs approximating $85,310, $65,654, and $82,558 for 2011, 2010, and 2009, respectively.
F-18

Table of Contents
Professional Services
A director of Bovie is president and a shareholder of Ronin Consulting Group, Inc., a company which provides various financial and analytical project consulting services to Bovie. Ronin Consulting Group, Inc. was paid fees approximating $80,000, $80,000 and $99,800 during 2011, 2010 and 2009, respectively.
A second director of Bovie provides consulting services related to research and development of certain products and was paid fees approximating $30,000 during 2011, 2010, and 2009, respectively.
Related party transactions and contracts are reviewed by our independent audit committee.
NOTE 12. OTHER COMMITMENTS AND CONTINGENCIES
Property and Rental Agreements
We are obligated under an operating lease for a manufacturing and warehouse facility in St. Petersburg, Florida which lease requires monthly payments of approximately $14,000, and expires on October 31, 2013. We also lease a separate warehouse facility in Clearwater (under a month-to-month arrangement requiring monthly payments of approximately $1,600), and our executive offices in New York (under a month-to-month arrangement requiring monthly payments of approximately $1,500).
The following is a schedule of approximate future minimum lease payments under operating leases as of December 31, 2011 (in thousands):

2012 |  | $ | 256 |
2013 |  |  | 228 |
2014 |  |  | 12 |
Total |  | $ | 496 |

Rent expense for the years ended December 31, 2011, 2010 and 2009 approximated $256,000, $281,000 and $283,000, respectively.
Purchase Commitments
At December 31, 2011, we had non-cancelable purchase commitments for inventories totaling approximately $3.8 million, substantially all of which is expected to be purchased by the end of 2012.
Employment Agreements
At December 31, 2011, we were obligated under three employment agreements which have expiration dates between June 2013 and March 2014. Approximate future minimum payments under these agreements are as follows as of December 31, 2011 (in thousands):

2012 |  |  | 611 |
2013 |  |  | 591 |
2014 |  |  | 46 |
Total |  | $ | 1,248 |

F-19

Table of Contents
During 2011 we terminated Leonard Keen as our V.P. and General Counsel. The termination of Mr. Keen’s employment is presently the subject of litigation (See “Litigation” below). The agreements with our Chief Executive Officer, as well as our President and Chief Sales and Marketing Officer contain the following provisions:

| ● | Clauses that allow for continuous automatic extensions of one year unless timely written notice terminating the contract is provided to such officers (as defined in the agreements).

| ● | Clauses which require the Company to make lump sum payments to such officers equal to three times their salary and bonus in effect at the time of any change in control and/or breach of the agreements by the Company. The 2012 base salaries for these two officers are expected to approximate $496,000, and such amounts may increase by 7.5% per year.

Litigation
Medtronic Settlement
On March 3, 2011, we entered into a settlement agreement related to the legal action with Salient Surgical Technologies, Inc. and Medtronic, Inc (the “Plaintiffs”). The settlement called for us and related parties to immediately exit and not enter into the monopolar and bipolar saline-enhanced RF device business (including SEER™ and BOSS™) worldwide through February 2015. In exchange, Salient made a one-time payment to us of $750,000. As a condition, we will not be able to sell certain finished products, which as of the settlement date amounted to approximately $100,000 of our inventory. We reserved for approximately $87,000 of our inventory related to the products in this settlement in the first quarter of 2011. The terms also include a provision outlining a possible OEM contract manufacturing relationship between Salient and our Company. We currently have a longstanding OEM contract manufacturing agreement with Medtronic for advanced electrosurgical generators. We have given Medtronic notice that the agreement terminated as of December 31, 2011, with final deliveries occurring in 2012. We will continue to service the generators sold during this contract for the next five years. We anticipate sales of accessories and spare parts to continue into the future.
Livneh/Lican Development Settlement
On July 9, 2010, we filed a complaint in the United States District for the Middle District of Florida (Tampa division) naming Steven Livneh, (“Livneh”) who at the time was a director of the Company, and two of his related entities as defendants. In our complaint, we were seeking, among other things, a declaratory judgment from the Court concerning our rights under certain agreements entered into with the defendants in 2006 in connection with our acquisition of certain assets and technology, including intellectual property relating to our Seal-N-Cut™ product. We were also seeking damages for breach of contract, breach of fiduciary duty by Livneh relating to his service as an officer and director of the Company, tortious interference with contractual relations, defamation, slander of title and injunctive relief. Livneh filed a motion seeking to (a) dismiss the complaint or, in the alternative, to (b) transfer venue. On December 20, 2010, the court issued an order dismissing without prejudice five of our fifteen claims, due to New York being defined in the forum selection clauses in two of the underlying contracts with Livneh. The Company re-filed these five claims in federal court in New York. Livneh’s motion to dismiss the remaining claims in Florida was denied and the venue was not transferred.
On January 10, 2011, defendant Livneh filed a counter-complaint/third party complaint against us, our CEO, and our COO, alleging fraud, fraud in the inducement, fraudulent misrepresentation, breach of fiduciary duty, negligent misrepresentation, innocent misrepresentation, breach of contract, tortuous interference, shareholder derivative, defamation, breach of good faith and fair dealing, violation of the Uniform Trade Secrets Act, and violation of the Florida Whistleblower’s Act, and seeking rescission and a declaratory judgment. In addition to the foregoing relief, defendant also sought reinstatement of Mr. Livneh to the Company’s board of directors, issuance of certain shares of unrestricted stock, compensatory, actual and/or special damages, punitive and/or exemplary damages, and attorney’s fees and costs.
In December 2011, a settlement related to the above Livneh litigation was structured and subsequently entered into on February 22, 2012. Under the terms of the Settlement Agreement (the “Settlement Agreement”), the Company will, among other things, perform the following: (i) make a $250,000 lump sum payment to Livneh ($50,000 of which was previously recorded and expensed), (ii) make 18 installment payments to Livneh in the amount of $23,222.22 per month, (iii) reimburse Livneh for all unpaid expenses that Livneh incurred on behalf of the Company during the period of his employment and/or consultancy (from October 1, 2006 through August 11, 2010), (iv) pay Livneh $14,700, which represents the balance of the amounts due to Henvil Corp. Ltd. under a certain bill of sale, dated April 12, 2010, (v) transfer to Livneh the title of a certain automobile, (vi) transfer to Livneh all of the Company’s right and interest in certain Intellectual Property (as defined in the Settlement Agreement) pertaining to the Modular Ergonomic Grip (“MEG”), Modullion, RF Skin Resurfacing, Scannula, Double Jaw Forceps and Tip-On-Tube designs and trade name (collectively, the “Assigned Patents”), (vi) transfer to Livneh certain parts for the MEG device, (vii) grant Livneh an exclusive license to produce, market and sell the Seal-N-Cut device in the People’s Republic of China, (viii) pay to Livneh royalty payments of 3% on the Company’s Net Sales (as defined in the Settlement Agreement) of the Seal-N-Cut device outside the People’s Republic of China, and (ix) pay to Livneh a one-time royalty payment of 5% upon the closing of any sale by the Company of its right or interest in any Intellectual Property pertaining to the Seal-N-Cut device. To secure the Company’s obligations, the Company granted Livneh a security interest in all of its rights and interest of the Company in the Seal-N-Cut device, including all Intellectual Property pertaining thereto. Since the loss was quantifiable and known in December 2011, we recognized this settlement loss in 2011 and all payments hereunder were accrued during the fourth quarter.
F-20

Table of Contents
In exchange, Livneh will, among other things, perform the following: (i) pay to the Company royalty payments of 3% on Livneh’s Net Sales of the Assigned Patents, excluding any Net Sales of the RF Skin Resurfacing or Tip-On-Tube, (ii) pay to the Company a one-time royalty payment of 5% upon the closing of any sale by Livneh, Henvil or Lican Development Ltd. of their right or interest in any Intellectual Property pertaining to the Assigned Patents, and (iii) pay to the Company royalty payments of 3% on Livneh’s Net Sales of the Seal-N-Cut device in the People’s Republic of China.
As a result of the Settlement Agreement, the Company has recorded an expense in the fourth quarter of 2011 of approximately $737,000 for the transfer of the MEG and the Modullion intellectual property. The Company has also accrued expenses in approximate amounts for the transfer of related inventory and molds of $194,000 and an additional $27,000 for other various expenses.
The Settlement Agreement contains no admission of liability or wrongdoing by the Company, Mr. Andrew Makrides, the Company’s Chief Executive Officer, Mr. Moshe Citronowicz, the Company’s Director of Strategic Development, Livneh, Henvil or Lican. Pursuant to the Settlement Agreement, the Company, Mr. Makrides, Mr. Citronowicz, Livneh, Henvil and Lican agreed to dismiss the litigation with prejudice and they fully and finally released all claims known and unknown, foreseen and unforeseen, which they had against each other through the date of the Settlement Agreement.
Eisenstein Settlement
On June 10, 2011, we signed a settlement agreement related to the legal action involving Dr. David Eisenstein, MD under which we paid $53,500 to Dr. Eisenstein and an additional $20,000 directly to his legal counsel for legal fees. In exchange, Dr. Eisenstein surrendered his 5,000 stock options and both parties signed a general release and dismissal.
Stockholder Derivative Action
In September 2011, we were served in a purported stockholder derivative action that was filed in the United State District Court for the Middle District of Florida against the Company and certain of its present and former officers and directors. The complaint asserts, among other things, breach of fiduciary duties and bad faith in relation to the management of the Company. The complaint seeks, among other things, unspecified compensatory damages and various forms of equitable relief. The allegations in the derivative action appear to be based largely on the January 10, 2011 Livneh counterclaim described above. We are reviewing the allegations in the complaint and investigating whether there is a collusive connection between the derivative action and the pending lawsuit with Livneh. We believe the allegations to be frivolous and without merit and we intend to defend the action vigorously. The outcome of this matter is uncertain, no range of potential loss can be estimated and accordingly no effect has been given to any loss that may result from the resolution of this matter in the accompanying consolidated financial statements.
F-21

Table of Contents
Keen Action
In February 2012 we received notice that an action had been commenced against us in United States District Court for the Middle District of Florida, by Leonard Keen our former Vice President and General Counsel, related to his termination on December 9, 2011 and associated employment contract. Mr. Keen is demanding amounts outlined under his employment contract which provided for the payment of a base annual salary of not less than $187,500 as well as certain other payments and benefits. The employment agreement also provided for the payment, under certain circumstances, of a lump sum severance payment equal to three times base compensation plus certain other payments and benefits as set forth in the employment agreement under severance payment. Mr. Keen also asserts a claim concerning an alleged violation of Florida’s “Whistle Blower’s Act” and seeks specific performance of certain indemnification rights under his employment agreement. We believe we have meritorious defenses against Mr. Keen’s claims and will vigorously defend this action. The outcome of this matter is uncertain and accordingly no effect has been given to any loss that may result from the resolution of this matter in the accompanying consolidated financial statements, however the range of potential loss is zero to approximately $600,000 plus possible attorney fees which are not determinable at this time.
In addition to the above, in the normal course of business, we are subject, from time to time, to legal proceedings. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. Consequently, we are unable to ascertain the ultimate aggregate amount of monetary liability or financial impact with respect to these matters as of December 31, 2011. These matters could affect the operating results of any one or more quarters when resolved in future periods.
We expense costs of litigation related to contingencies in the periods in which the costs are incurred.
NOTE 13. GAIN FROM LEGAL SETTLEMENT
On March 3, 2011, we entered into a settlement agreement related to the legal action with Salient Surgical Technologies, Inc. and Medtronic, Inc. The settlement called for us and related parties to immediately exit and not enter into the monopolar and bipolar saline-enhanced RF device business (including SEER™ and BOSS™) worldwide through February 2015. In exchange, Salient made a one-time payment to us of $750,000. As a condition, we will not be able to sell certain finished products, which as of the settlement date amounted to approximately $100,000 of our inventory. We reserved for approximately $87,000 of our inventory related to the products in this settlement in the first quarter of 2011. The terms also include a provision outlining a possible OEM contract manufacturing relationship between Salient and our Company. We currently have a longstanding OEM contract manufacturing agreement with Medtronic for advanced electrosurgical generators. We have given Medtronic notice that the agreement terminated as of December 31, 2011, with final deliveries occurring in 2012. We will continue to service the generators sold during this contract for the next five years. We anticipate sales of accessories and spare parts to continue into the future.
NOTE 14. STOCK OPTIONS
On October 30, 2007, our stockholders approved and the Board of Directors adopted an amendment to the 2003 Executive and Employee Stock Option Plan (the “Plan”) to increase the maximum aggregate number of shares of common stock reserved for issuance under the Plan from 1.2 million shares (already reserved against outstanding options) to 1.7 million shares. Except for the increase in the number of shares covered by the Plan, the Plan remained otherwise unchanged. In 2001, the Board of Directors adopted the 2001 Executive and Employee Stock Option Plan which reserved for issuance 1,200,000 stock options. Stock options typically have a ten-year life and currently vest over a seven year period.
As of December 31, 2011, there was approximately $450,000 of total unrecognized compensation costs related to outstanding stock options, which is expected to be recognized over a period of 5 years.
F-22

Table of Contents
The status of our stock options and stock awards are summarized as follows:

|  | Number Of Options |  |  | Weighted Average Exercise Price |
Outstanding at December 31, 2009 |  |  | 1,741,525 |  |  | $ | 3.61 |
Granted |  |  | 264,160 |  |  | $ | 4.67 |
Exercised |  |  | (46,000 | ) |  | $ | 0.89 |
Cancelled |  |  | (11,425 | ) |  | $ | 7.33 |
Outstanding at December 31, 2010 |  |  | 1,948,260 |  |  | $ | 3.61 |
Granted |  |  | 25,000 |  |  | $ | 2.81 |
Exercised |  |  | (69,000 | ) |  | $ | 0.57 |
Cancelled |  |  | (371,414 | ) |  | $ | 3.52 |
Outstanding at December 31, 2011 |  |  | 1,532,846 |  |  |  |  |
Exercisable at December 31, 2011 |  |  | 1,195,112 |  |  | $ | 3.53 |

F-23

Table of Contents
The following table summarizes information about our options outstanding at December 31, 2011:

Exercise Prices |  |  | Number Outstanding |  | Weighted Average Remaining Contractual Life |  | Options Exercisable |
$ | 0.70 |  |  |  | 35,000 |  | 2 years |  |  | 35,000 |
$ | 0.75 |  |  |  | 21,500 |  | 1 – 2 years |  |  | 21,500 |
$ | 1.30 |  |  |  | 25,000 |  | 2 years |  |  | 25,000 |
$ | 2.13 |  |  |  | 125,000 |  | 3 years |  |  | 125,000 |
$ | 2.25 |  |  |  | 322,500 |  | 4 years |  |  | 322,500 |
$ | 2.41 |  |  |  | 40,000 |  | 3 years |  |  | 40,000 |
$ | 2.93 |  |  |  | 35,000 |  | 4 years |  |  | 35,000 |
$ | 2.95 |  |  |  | 2,500 |  | 3 years |  |  | 2,500 |
$ | 3.25 |  |  |  | 331,700 |  | 2 years |  |  | 331,700 |
$ | 6.93 |  |  |  | 20,000 |  | 5 years |  |  | 20,000 |
$ | 7.10 |  |  |  | 12,125 |  | 7 years |  |  | 9,982 |
$ | 7.18 |  |  |  | 50,000 |  | 8 years |  |  | 50,000 |
$ | 7.33 |  |  |  | 136,075 |  | 8 years |  |  | 59,406 |
$ | 7.68 |  |  |  | 7,500 |  | 7 years |  |  | 4,286 |
$ | 8.66 |  |  |  | 97,857 |  | 7 years |  |  | 57,143 |
$ | 6.60 |  |  |  | 500 |  | 8 years |  |  | 500 |
$ | 8.32 |  |  |  | 68,214 |  | 8 years |  |  | 20,000 |
$ | 7.85 |  |  |  | 7,500 |  | 8 years |  |  | 2,143 |
$ | 6.00 |  |  |  | 30,000 |  | 9 years |  |  | - |
$ | 7.45 |  |  |  | 14,286 |  | 9 years |  |  | 14,286 |
$ | 3.08 |  |  |  | 10,000 |  | 9 years |  |  | 1,429 |
$ | 2.46 |  |  |  | 65,589 |  | 9 years |  |  | 10,594 |
$ | 1.89 |  |  |  | 50,000 |  | 9 years |  |  | 7,143 |
$ | 2.80 |  |  |  | 10,000 |  | 10 years |  |  | - |
$ | 2.81 |  |  |  | 15,000 |  | 10 years |  |  | - |
|  |  |  |  | 1,532,846 |  |  |  |  | 1,195,112 |

The number and weighted average grant-date fair values of options non-vested at the beginning and end of 2011, as well as options granted, vested and forfeited during the year was as follows:

|  | Number Of Options |  |  | Weighted Average Grant Date Fair Value |
Nonvested at January 1, 2011 |  |  | 503,990 |  |  | $ | 2.51 |
Granted in 2011 |  |  | 25,000 |  |  | $ | 1.32 |
Vested in 2011 |  |  | (90,542 | ) |  | $ | 2.74 |
Forfeited in 2011 |  |  | (100,714 | ) |  | $ | 3.33 |
Nonvested at December 31, 2011 |  |  | 337,734 |  |  | $ | 2.12 |

F-24

Table of Contents
Common shares required to be issued upon the exercise of stock options and warrants would be issued from our authorized and unissued shares.
The grant date fair value of options granted in 2011 was estimated on the grant date using a binomial lattice option-pricing model and the following assumptions: expected volatility of 41-42%, expected term of 7 years, risk-free interest rate of 1.8-2.6%, and expected dividend yield of 0%.
The grant date fair value of options granted in 2010 was estimated on the grant date using a binomial lattice option-pricing model and the following assumptions: expected volatility of 42% - 43%, expected term of 7 years, risk-free interest rate of 1.1% - 2.27%, and expected dividend yield of 0%.
The grant date fair value of options granted in 2009 was estimated on the grant date using a binomial lattice option-pricing model and the following assumptions: expected volatility of 40% - 45%, expected term of 7 years, risk-free interest rate of 0% - 2.74%, and expected dividend yield of 0%.
Expected volatility is based on a weighted average of the historical volatility of the Company's stock and peer company volatility. The weighting percentages relative to our stock and the peer group was adjusted in 2010 to a 50%/50% weighting as management determined that sufficient price history reflecting the true volatility existed for our stock. Previous to 2010 we used a weighting of 75% to 25% in favor of the peer group as our price history contained large erratic price swings that were not indicative of our true volatility. Our peer group has remained the same throughout our calculations year over year. The average expected life was calculated using the simplified method as we believe we do not have sufficient history. The risk-free rate is based on the rate of U.S. Treasury zero-coupon issues with a remaining term equal to the expected life of the options. The Company uses historical data to estimate pre-vesting forfeiture rates.
As of December 31, 2011, the aggregate intrinsic value of all stock options outstanding and expected to vest was approximately $111,000 and the aggregate intrinsic value of currently exercisable stock options was approximately $101,000. The intrinsic value of each option share is the difference between the fair market value of BVX common stock and the exercise price of such option share to the extent it is “in-the-money”. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money options had they exercised their options on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation is based on the $2.12 closing stock price of BVX Common Stock on December 31, 2011, the last trading day of 2011. The total number of in-the-money options outstanding and exercisable as of December 31, 2011 was approximately 89,000.
The total intrinsic value of options exercised during the years ended December 31, 2011, 2010 and 2009 was approximately $157,000, $198,000 and $1,097,000, respectively. Intrinsic value of exercised shares is the total value of such shares on the date of exercise less the cash received from the option holder to exercise the options. The total cash proceeds received from the exercise of stock options was approximately zero, $9,000 and $79,000 for the years ended December 31, 2011, 2010 and 2009, respectively.
The total fair value of options granted during the years ended December 31, 2011, 2010 and 2009 was approximately $33,000, $496,000 and $299,000, respectively. The total fair value of option shares vested during the years ended December 31, 2011, 2010, and 2009 was approximately $248,000, $121,000 and $177,000, respectively.
During the year ended December 31, 2011, we issued 54,744 common shares in exchange for 69,000 employee and non-employee stock options and 14,256 common shares (via a stock swap). Net proceeds from the issuance of common shares along with the shares received in the stock swap exercises were zero for the year ended December 31, 2011.
Stock compensation cost recognized for the years ended December 31, 2011, 2010 and 2009 was approximately $132,000, $163,000 and $136,000, respectively. As of December 31, 2011, there was approximately $450,000 of total unrecognized stock-based compensation cost, related to unvested stock options granted under the Amended Plan. This cost is expected to be recognized over a weighted-average period of approximately 4 years.
F-25

Table of Contents
Allocation of stock based compensation expense for the fiscal years ended December 31, 2011, 2010 and 2009 was as follows (in thousands):

|  | 2011 |  |  | 2010 |  |  | 2009 |
Cost of sales |  | $ | 16 |  |  | $ | 16 |  |  | $ | 30 |
Research and development |  |  | 11 |  |  |  | 33 |  |  |  | 32 |
Salaries and related costs |  |  | 105 |  |  |  | 114 |  |  |  | 74 |
Total |  | $ | 132 |  |  | $ | 163 |  |  | $ | 136 |

NOTE 15. GEOGRAPHIC AND SEGMENT INFORMATION
Through 2010, we had two reportable business segments, our main operations, Bovie Medical Corporation located in the United States and Bovie Canada ulc, our Canada operations located in Windsor, Canada. During 2010 we closed the Canadian facility and consolidated the operations to the parent company located in Clearwater, Florida: therefore the 2010 amounts represent only a partial year for Bovie Canada ulc. Because Bovie Canada ulc operations represented a loss greater than 10% of our consolidated net income (on an absolute value basis) we are required to report certain information broken out by segment in the table listed below for the years ended December 31, 2010, and 2009 (in thousands).

|  | Bovie Medical Corp 2010 |  |  | Bovie Canada 2010 |  |  | Bovie Medical Corp 2009 |  |  | Bovie Canada 2009 |
Sales, net |  | $ | 24,189 |  |  | $ | 41 |  |  | $ | 26,768 |  |  | $ | 185 |
Gross profit |  | $ | 10,088 |  |  | $ | (100 | ) |  | $ | 11,713 |  |  | $ | 142 |
Operating expenses |  | $ | 12,499 |  |  | $ | 241 |  |  | $ | 10,298 |  |  | $ | 842 |
Net income (loss) |  | $ | (1,194 | ) |  | $ | (341 | ) |  | $ | 1,295 |  |  | $ | (700 | )

While international sales in 2011, 2010 and 2009 were 21%, 21% and 16.5% of sales, respectively, substantially all of these sales are denominated in U.S. dollars.
NOTE 16. SELECTED QUARTERLY INFORMATION (UNAUDITED)
The following table sets forth certain unaudited quarterly data for each of the four quarters in the years ended December 31, 2011, and 2010, respectively. The data has been derived from the Company's unaudited consolidated financial statements that, in management's opinion, include all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of such information when read in conjunction with the Consolidated Financial Statements and Notes thereto. The results of operations for any quarter are not necessarily indicative of the results of operations for any future period.

|  | First |  |  | Second |  |  | Third |  |  | Fourth |
Year ended December 31, 2011 |  | Quarter |  |  | Quarter |  |  | Quarter |  |  | Quarter |
Total revenue |  | $ | 6,154 |  |  | $ | 6,841 |  |  | $ | 6,256 |  |  | $ | 6,158 |
Gross profit |  | $ | 2,433 |  |  | $ | 3,045 |  |  | $ | 2,606 |  |  | $ | 2,646 |
Net income (3) |  | $ | 492 |  |  | $ | 429 |  |  | $ | 63 |  |  | $ | (875 | )
Diluted earnings (loss) per share (1) |  | $ | 0.03 |  |  | $ | 0.02 |  |  | $ | 0.00 |  |  | $ | (0.05 | )
Year ended December 31, 2010 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  | $ | 5,599 |  |  | $ | 5,897 |  |  | $ | 6,501 |  |  | $ | 6,233 |
Gross profit |  | $ | 2,285 |  |  | $ | 2,316 |  |  | $ | 2,704 |  |  | $ | 2,683 |
Net income (2) |  | $ | (226 | ) |  | $ | 56 |  |  | $ | 4 |  |  | $ | (1,369 | )
Diluted earnings per share (1) |  | $ | (0.01 | ) |  | $ | 0.00 |  |  | $ | 0.00 |  |  | $ | (0.08 | )

(1) | Quarterly income (loss) per share may not equal the annual reported amounts.

(2) | Fourth quarter loss was mainly a result of an asset impairment recognized during the quarter.

(3) | Fourth quarter loss was mainly the result of recognizing a legal settlement loss.

F-26

Table of Contents
NOTE 17. OTHER SUBSEQUENT EVENT
In February 2012 we received 510k clearance from the Food and Drug Administration (FDA) to market our J-Plasma™ handpiece with retractable cutting feature for soft tissue coagulation during surgery. The handpiece will be powered by our GS electrosurgical generator, which has prior 510k market clearance.
EXHIBIT INDEX

3.1 |  | Articles of Incorporation of the Registrant (Incorporated by reference to Registrant's report on Form 10-K/A filed March 31, 2011)
3.2 |  | Bylaws of the Registrant (Incorporated by reference to Registrant's report on Form 10-K/A filed March 31, 2011)
4.1 |  | Specimen Common Stock Certificate (Incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-3 filed November 24, 2004)
10.1 |  | 2001 Statutory and Non-Statutory Stock Option Plan (Incorporated by reference to Registrant’s Registration Statement on Form S-8 filed July 16, 2001)
10.2 |  | 2003 Key Services Stock Option Plan (Incorporated by reference to Registrant’s Registration Statement on Form S-8 filed May 12, 2006)
10.3 |  | Original Equipment Manufacturer Agreement between Arthrex, Inc. and Bovie Medical Corp. dated as of June, 2002
10.4 |  | Distribution Agreement between Bovie Medical Corporation and Boston Scientific dated October 6, 2006 amended and as re-filed, inclusive of Exhibit A
10.5 |  | First Amendment to Distribution Agreement between Boston Scientific Corporation and Bovie Medical Corporation August 23, 2007, as re-filed
10.6 |  | Termination Purchase and License Agreement between Boston Scientific Corporation and Bovie Medical Corporation dated April 29, 2008 as amended and re-filed, inclusive of Exhibit A
10.7 |  | First Amendment to Manufacturing and Development Agreement dated August 24, 2007 between Bovie Medical Corporation and Arthrex, Inc.
10.8 |  | First Amendment to OEM Agreement between Arthrex, Inc. and Bovie Medical Corp. dated as of July, 2007
10.9 |  | Employment Agreement effective January 1, 1998 between Bovie Medical Corporation and Andrew Makrides (Incorporated by reference to Registrant’s report on Form 10KSB/A filed July 15, 2005)
10.10 |  | Amended Employment Agreement dated as of January 6, 2004 by and between Bovie Medical Corporation and Andrew Makrides (Incorporated by reference to Registrant’s report on Form 10KSB/A filed August 25, 2005)
10.11 |  | Amended Employment Agreement dated January 15, 2006 between Bovie Medical Corporation and Andrew Makrides
10.12 |  | Employment Agreement effective January 1, 1998 between Bovie Medical Corporation and J. Robert Saron (Incorporated by reference to Registrant’s report on Form 10KSB/A filed July 15, 2005)
10.13 |  | Amended Employment Agreement dated as of January 6, 2004 by and between Bovie Medical Corporation and J. Robert Saron (Incorporated by reference to Registrant’s report on Form 10KSB/A filed August 25, 2005)

F-27

Table of Contents

10.14 |  | Amended Employment Agreement dated January 15, 2006 between J. Robert Saron and Bovie Medical Corporation
10.15 |  | Employment Agreement dated June 18, 2007 between Bovie Medical Corporation and Gary Pickett
10.16 |  | Modification Agreement by and between Bovie Medical Corporation and RBC Bank (USA) dated December 2, 2009 (Incorporated by reference to the Registrant’s report on Form 8-K filed on March 15, 2010)
10.17 |  | Loan Agreement between Pinellas County Industrial Development Authority and Bovie Medical Corporation dated as of November 1, 2008 (Incorporated by reference to the Registrant’s report on Form 8-K/A filed May 12, 2009)
10.18 |  | Memorandum of Agreement between Pinellas County Industrial Development Authority & Bovie Medical Corporation dated November 13, 2008 (Incorporated by reference to the Registrant’s report on Form 8-K/A filed May 12, 2009)
10.19 |  | Letter of Credit Agreement between Bovie Medical Corporation and RBC Bank (USA) dated as of November 13, 2008 (Incorporated by reference to the Registrant’s report on Form 8-K/A filed May 12, 2009)
10.20 |  | Securities Purchase Agreement, dated April 18, 2010, by and among Bovie Medical Corporation and the investors listed on the Schedule of Buyers attached thereto (Incorporated by reference to the Registrant’s report on Form 8-K filed April 20, 2010)
10.21 |  | Form of Registration Rights Agreement by and among Bovie Medical Corporation and the investors listed on the signature pages thereto (Incorporated by reference to the Registrant’s report on Form 8-K filed April 20, 2010)
10.22 |  | Form of Warrant issued to the Buyers under the Securities Purchase Agreement (Incorporated by reference to the Registrant’s report on Form 8-K filed April 20, 2010)
10.23 |  | Form of Warrant issued to Rodman & Renshaw, LLC and Gilford Securities Inc. (Incorporated by reference to the Registrant’s report on Form 8-K filed April 20, 2010)
10.24 |  | First Amendment to Loan Agreement, dated October 31, 2011, by and between the Company and Pinellas County Industrial Development Authority (filed herewith)
10.25 |  | Credit Agreement dated October 31, 2011, by and between the Company and PNC Bank, National Association (filed herewith)
10.26 |  | Revolving Loan Agreement, dated October 31, 2011, by and between the Company and PNC Bank, National Association (filed herewith)
10.27 |  | Non-Revolving Equipment Line of Credit Note, dated October 31, 2011, by and between the Company and PNC Bank, National Association (filed herewith)
10.28 |  | Revolving Line of Credit Note, dated October 31, 2011, by and between the Company and PNC Bank, National Association (filed herewith)
10.29 |  | Equipment Line Loan Agreement, dated October 31, 2011, by and between the Company and PNC Bank, National Association (filed herewith)
10.30 |  | Security Agreement (Revolving Loan), dated October 31, 2011, by and between the Company and PNC Bank, National Association (filed herewith)
10.31 |  | Security Agreement (Equipment Loan), dated October 31, 2011, by and between the Company and PNC Bank, National Association (filed herewith)
10.32 |  | Security Agreement (Bond Swap), dated October 31, 2011, by and between the Company and PNC Bank, National Association (filed herewith)
10.33 |  | Mortgage and security Agreement, dated October 31, 2011, by and between the Company and New York Mellon Trust Company, N.A. (filed herewith)
10.34 |  | Assignment of Rents, Leases and Profits, dated October 31, 2011, by and between the Company and New York Mellon Trust Company, N.A. (filed herewith)
10.35 |  | Environmental Indemnity Agreement, dated October 31, 2011, by and between the Company and New York Mellon Trust Company, N.A. (filed herewith)
10.36 |  | Settlement Agreement, dated March 3, 2011, by and among Bovie Medical Corporation, Salient Surgical Technologies, Inc. and Medtronic, Inc. (Incorporated by reference to the Registrant’s report on Form 10-Q filed May 12, 2011.
14.1 |  | Bovie Medical Corporation Code of Ethics (Incorporated by reference to Registrants filed herewith)
21.1 |  | List of Subsidiaries (filed herewith)

F-28

Table of Contents

31.1 |  | Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002.
31.2 |  | Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002.
32.1 |  | Certification pursuant to Section 906 of Sarbanes-Oxley Act of 2002.
32.2 |  | Certification pursuant to Section 906 of Sarbanes-Oxley Act of 2002.
101.1 |  | Financial Statements from the Annual Report on Form 10-K of Bovie Medical Corporation as of and for the year ended December 31, 2011, formatted in XBRL.

F-29